5748 lines
569 KiB
Text
5748 lines
569 KiB
Text
|
|
|
|
|
|
|
|
|
|
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" lang="en-us" xml:lang="en-us" >
|
|
|
|
<head>
|
|
|
|
|
|
|
|
<!--
|
|
################################# CRAWLER WARNING #################################
|
|
|
|
- The terms of service and the robots.txt file disallows crawling of this site,
|
|
please see https://omim.org/help/agreement for more information.
|
|
|
|
- A number of data files are available for download at https://omim.org/downloads.
|
|
|
|
- We have an API which you can learn about at https://omim.org/help/api and register
|
|
for at https://omim.org/api, this provides access to the data in JSON & XML formats.
|
|
|
|
- You should feel free to contact us at https://omim.org/contact to figure out the best
|
|
approach to getting the data you need for your work.
|
|
|
|
- WE WILL AUTOMATICALLY BLOCK YOUR IP ADDRESS IF YOU CRAWL THIS SITE.
|
|
|
|
- WE WILL ALSO AUTOMATICALLY BLOCK SUB-DOMAINS AND ADDRESS RANGES IMPLICATED IN
|
|
DISTRIBUTED CRAWLS OF THIS SITE.
|
|
|
|
################################# CRAWLER WARNING #################################
|
|
-->
|
|
|
|
|
|
|
|
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
|
|
<meta http-equiv="cache-control" content="no-cache" />
|
|
<meta http-equiv="pragma" content="no-cache" />
|
|
<meta name="robots" content="index, follow" />
|
|
|
|
|
|
<meta name="viewport" content="width=device-width, initial-scale=1" />
|
|
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
|
|
|
|
|
|
<meta name="title" content="Online Mendelian Inheritance in Man (OMIM)" />
|
|
<meta name="description" content="Online Mendelian Inheritance in Man (OMIM) is a comprehensive, authoritative
|
|
compendium of human genes and genetic phenotypes that is freely available and updated daily. The full-text,
|
|
referenced overviews in OMIM contain information on all known mendelian disorders and over 15,000 genes.
|
|
OMIM focuses on the relationship between phenotype and genotype. It is updated daily, and the entries
|
|
contain copious links to other genetics resources." />
|
|
<meta name="keywords" content="Mendelian Inheritance in Man, OMIM, Mendelian diseases, Mendelian disorders, genetic diseases,
|
|
genetic disorders, genetic disorders in humans, genetic phenotypes, phenotype and genotype, disease models, alleles,
|
|
genes, dna, genetics, dna testing, gene testing, clinical synopsis, medical genetics" />
|
|
<meta name="theme-color" content="#333333" />
|
|
<link rel="icon" href="/static/omim/favicon.png" />
|
|
<link rel="apple-touch-icon" href="/static/omim/favicon.png" />
|
|
<link rel="manifest" href="/static/omim/manifest.json" />
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<script id='mimBrowserCapability'>
|
|
function _0x5069(){const _0x4b1387=['91sZIeLc','mimBrowserCapability','15627zshTnf','710004yxXedd','34LxqNYj','match','disconnect','1755955rnzTod','observe','1206216ZRfBWB','575728fqgsYy','webdriver','documentElement','close','open','3086704utbakv','7984143PpiTpt'];_0x5069=function(){return _0x4b1387;};return _0x5069();}function _0xe429(_0x472ead,_0x43eb70){const _0x506916=_0x5069();return _0xe429=function(_0xe42949,_0x1aaefc){_0xe42949=_0xe42949-0x1a9;let _0xe6add8=_0x506916[_0xe42949];return _0xe6add8;},_0xe429(_0x472ead,_0x43eb70);}(function(_0x337daa,_0x401915){const _0x293f03=_0xe429,_0x5811dd=_0x337daa();while(!![]){try{const _0x3dc3a3=parseInt(_0x293f03(0x1b4))/0x1*(-parseInt(_0x293f03(0x1b6))/0x2)+parseInt(_0x293f03(0x1b5))/0x3+parseInt(_0x293f03(0x1b0))/0x4+-parseInt(_0x293f03(0x1b9))/0x5+parseInt(_0x293f03(0x1aa))/0x6+-parseInt(_0x293f03(0x1b2))/0x7*(parseInt(_0x293f03(0x1ab))/0x8)+parseInt(_0x293f03(0x1b1))/0x9;if(_0x3dc3a3===_0x401915)break;else _0x5811dd['push'](_0x5811dd['shift']());}catch(_0x4dd27b){_0x5811dd['push'](_0x5811dd['shift']());}}}(_0x5069,0x84d63),(function(){const _0x9e4c5f=_0xe429,_0x363a26=new MutationObserver(function(){const _0x458b09=_0xe429;if(document!==null){let _0x2f0621=![];navigator[_0x458b09(0x1ac)]!==![]&&(_0x2f0621=!![]);for(const _0x427dda in window){_0x427dda[_0x458b09(0x1b7)](/cdc_[a-z0-9]/ig)&&(_0x2f0621=!![]);}_0x2f0621===!![]?document[_0x458b09(0x1af)]()[_0x458b09(0x1ae)]():(_0x363a26[_0x458b09(0x1b8)](),document['getElementById'](_0x458b09(0x1b3))['remove']());}});_0x363a26[_0x9e4c5f(0x1a9)](document[_0x9e4c5f(0x1ad)],{'childList':!![]});}()));
|
|
</script>
|
|
|
|
|
|
|
|
<link rel='preconnect' href='https://cdn.jsdelivr.net' />
|
|
<link rel='preconnect' href='https://cdnjs.cloudflare.com' />
|
|
|
|
<link rel="preconnect" href="https://www.googletagmanager.com" />
|
|
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/jquery@3.7.1/dist/jquery.min.js" integrity="sha256-/JqT3SQfawRcv/BIHPThkBvs0OEvtFFmqPF/lYI/Cxo=" crossorigin="anonymous"></script>
|
|
<script src="https://cdn.jsdelivr.net/npm/jquery-migrate@3.5.2/dist/jquery-migrate.js" integrity="sha256-ThFcNr/v1xKVt5cmolJIauUHvtXFOwwqiTP7IbgP8EU=" crossorigin="anonymous"></script>
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/bootstrap@3.4.1/dist/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script>
|
|
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@3.4.1/dist/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
|
|
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@3.4.1/dist/css/bootstrap-theme.min.css" integrity="sha256-8uHMIn1ru0GS5KO+zf7Zccf8Uw12IA5DrdEcmMuWLFM=" crossorigin="anonymous">
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/moment@2.29.4/min/moment.min.js" integrity="sha256-80OqMZoXo/w3LuatWvSCub9qKYyyJlK0qnUCYEghBx8=" crossorigin="anonymous"></script>
|
|
<script src="https://cdn.jsdelivr.net/npm/eonasdan-bootstrap-datetimepicker@4.17.49/build/js/bootstrap-datetimepicker.min.js" integrity="sha256-dYxUtecag9x4IaB2vUNM34sEso6rWTgEche5J6ahwEQ=" crossorigin="anonymous"></script>
|
|
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/eonasdan-bootstrap-datetimepicker@4.17.49/build/css/bootstrap-datetimepicker.min.css" integrity="sha256-9FNpuXEYWYfrusiXLO73oIURKAOVzqzkn69cVqgKMRY=" crossorigin="anonymous">
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/qtip2@3.0.3/dist/jquery.qtip.min.js" integrity="sha256-a+PRq3NbyK3G08Boio9X6+yFiHpTSIrbE7uzZvqmDac=" crossorigin="anonymous"></script>
|
|
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/qtip2@3.0.3/dist/jquery.qtip.min.css" integrity="sha256-JvdVmxv7Q0LsN1EJo2zc1rACwzatOzkyx11YI4aP9PY=" crossorigin="anonymous">
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/devbridge-autocomplete@1.4.11/dist/jquery.autocomplete.min.js" integrity="sha256-BNpu3uLkB3SwY3a2H3Ue7WU69QFdSRlJVBrDTnVKjiA=" crossorigin="anonymous"></script>
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/jquery-validation@1.21.0/dist/jquery.validate.min.js" integrity="sha256-umbTaFxP31Fv6O1itpLS/3+v5fOAWDLOUzlmvOGaKV4=" crossorigin="anonymous"></script>
|
|
|
|
|
|
|
|
|
|
<script src="https://cdn.jsdelivr.net/npm/js-cookie@3.0.5/dist/js.cookie.min.js" integrity="sha256-WCzAhd2P6gRJF9Hv3oOOd+hFJi/QJbv+Azn4CGB8gfY=" crossorigin="anonymous"></script>
|
|
|
|
|
|
|
|
|
|
<script src="https://cdnjs.cloudflare.com/ajax/libs/ScrollToFixed/1.0.8/jquery-scrolltofixed-min.js" integrity="sha512-ohXbv1eFvjIHMXG/jY057oHdBZ/jhthP1U3jES/nYyFdc9g6xBpjDjKIacGoPG6hY//xVQeqpWx8tNjexXWdqA==" crossorigin="anonymous"></script>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<script async src="https://www.googletagmanager.com/gtag/js?id=G-HMPSQC23JJ"></script>
|
|
<script>
|
|
window.dataLayer = window.dataLayer || [];
|
|
function gtag(){window.dataLayer.push(arguments);}
|
|
gtag("js", new Date());
|
|
gtag("config", "G-HMPSQC23JJ");
|
|
</script>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<script src="/static/omim/js/site.js?version=Zmk5Y1" integrity="sha256-fi9cXywxCO5p0mU1OSWcMp0DTQB4s8ncFR8j+IO840s="></script>
|
|
|
|
|
|
<link rel="stylesheet" href="/static/omim/css/site.css?version=VGE4MF" integrity="sha256-Ta80Qpm3w1S8kmnN0ornbsZxdfA32R42R4ncsbos0YU=" />
|
|
|
|
|
|
<script src="/static/omim/js/entry/entry.js?version=anMvRU" integrity="sha256-js/EBOBZzGDctUqr1VhnNPzEiA7w3HM5JbFmOj2CW84="></script>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div id="mimBootstrapDeviceSize">
|
|
<div class="visible-xs" data-mim-bootstrap-device-size="xs"></div>
|
|
<div class="visible-sm" data-mim-bootstrap-device-size="sm"></div>
|
|
<div class="visible-md" data-mim-bootstrap-device-size="md"></div>
|
|
<div class="visible-lg" data-mim-bootstrap-device-size="lg"></div>
|
|
</div>
|
|
|
|
|
|
|
|
<title>
|
|
|
|
Entry
|
|
|
|
- #211980 - LUNG CANCER
|
|
|
|
|
|
- OMIM
|
|
|
|
</title>
|
|
|
|
|
|
|
|
</head>
|
|
|
|
<body>
|
|
<div id="mimBody">
|
|
|
|
|
|
|
|
<div id="mimHeader" class="hidden-print">
|
|
|
|
|
|
|
|
<nav class="navbar navbar-inverse navbar-fixed-top mim-navbar-background">
|
|
<div class="container-fluid">
|
|
|
|
<!-- Brand and toggle get grouped for better mobile display -->
|
|
<div class="navbar-header">
|
|
<button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#mimNavbarCollapse" aria-expanded="false">
|
|
<span class="sr-only"> Toggle navigation </span>
|
|
<span class="icon-bar"></span>
|
|
<span class="icon-bar"></span>
|
|
<span class="icon-bar"></span>
|
|
</button>
|
|
<a class="navbar-brand" href="/"><img alt="OMIM" src="/static/omim/icons/OMIM_davinciman.001.png" height="30" width="30"></a>
|
|
</div>
|
|
|
|
<div id="mimNavbarCollapse" class="collapse navbar-collapse">
|
|
|
|
<ul class="nav navbar-nav">
|
|
|
|
|
|
<li>
|
|
<a href="/help/about"><span class="mim-navbar-menu-font"> About </span></a>
|
|
</li>
|
|
|
|
|
|
|
|
<li class="dropdown">
|
|
<a href="#" id="mimStatisticsDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Statistics <span class="caret"></span></span></a>
|
|
<ul class="dropdown-menu" role="menu" aria-labelledby="statisticsDropdown">
|
|
<li>
|
|
<a href="/statistics/update"> Update List </a>
|
|
</li>
|
|
<li>
|
|
<a href="/statistics/entry"> Entry Statistics </a>
|
|
</li>
|
|
<li>
|
|
<a href="/statistics/geneMap"> Phenotype-Gene Statistics </a>
|
|
</li>
|
|
<li>
|
|
<a href="/statistics/paceGraph"> Pace of Gene Discovery Graph </a>
|
|
</li>
|
|
</ul>
|
|
</li>
|
|
|
|
|
|
|
|
<li class="dropdown">
|
|
<a href="#" id="mimDownloadsDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Downloads <span class="caret"></span></span></a>
|
|
<ul class="dropdown-menu" role="menu" aria-labelledby="downloadsDropdown">
|
|
|
|
<li>
|
|
<a href="/downloads/"> Register for Downloads </a>
|
|
</li>
|
|
<li>
|
|
<a href="/api"> Register for API Access </a>
|
|
</li>
|
|
|
|
</ul>
|
|
</li>
|
|
|
|
|
|
|
|
<li>
|
|
<a href="/contact?mimNumber=211980"><span class="mim-navbar-menu-font"> Contact Us </span></a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<li>
|
|
|
|
<a href="/mimmatch/">
|
|
|
|
<span class="mim-navbar-menu-font">
|
|
<span class="mim-tip-bottom" qtip_title="<strong>MIMmatch</strong>" qtip_text="MIMmatch is a way to follow OMIM entries that interest you and to find other researchers who may share interest in the same entries. <br /><br />A bonus to all MIMmatch users is the option to sign up for updates on new gene-phenotype relationships.">
|
|
MIMmatch
|
|
</span>
|
|
</span>
|
|
</a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
<li class="dropdown">
|
|
<a href="#" id="mimDonateDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Donate <span class="caret"></span></span></a>
|
|
<ul class="dropdown-menu" role="menu" aria-labelledby="donateDropdown">
|
|
<li>
|
|
<a href="https://secure.jhu.edu/form/OMIM" target="_blank" onclick="gtag('event', 'mim_donation', {'destination': 'secure.jhu.edu'})"> Donate! </a>
|
|
</li>
|
|
<li>
|
|
<a href="/donors"> Donors </a>
|
|
</li>
|
|
</ul>
|
|
</li>
|
|
|
|
|
|
|
|
<li class="dropdown">
|
|
<a href="#" id="mimHelpDropdown" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false"><span class="mim-navbar-menu-font"> Help <span class="caret"></span></span></a>
|
|
<ul class="dropdown-menu" role="menu" aria-labelledby="helpDropdown">
|
|
<li>
|
|
<a href="/help/faq"> Frequently Asked Questions (FAQs) </a>
|
|
</li>
|
|
<li role="separator" class="divider"></li>
|
|
<li>
|
|
<a href="/help/search"> Search Help </a>
|
|
</li>
|
|
<li>
|
|
<a href="/help/linking"> Linking Help </a>
|
|
</li>
|
|
<li>
|
|
<a href="/help/api"> API Help </a>
|
|
</li>
|
|
<li role="separator" class="divider"></li>
|
|
<li>
|
|
<a href="/help/external"> External Links </a>
|
|
</li>
|
|
<li role="separator" class="divider"></li>
|
|
<li>
|
|
<a href="/help/agreement"> Use Agreement </a>
|
|
</li>
|
|
<li>
|
|
<a href="/help/copyright"> Copyright </a>
|
|
</li>
|
|
</ul>
|
|
</li>
|
|
|
|
|
|
|
|
<li>
|
|
<a href="#" id="mimShowTips" class="mim-tip-hint" title="Click to reveal all tips on the page. You can also hover over individual elements to reveal the tip."><span class="mim-navbar-menu-font"><span class="glyphicon glyphicon-question-sign" aria-hidden="true"></span></span></a>
|
|
</li>
|
|
|
|
|
|
</ul>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
</div>
|
|
</nav>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div id="mimSearch" class="hidden-print">
|
|
|
|
<div class="container">
|
|
|
|
<form method="get" action="/search" id="mimEntrySearchForm" name="entrySearchForm" class="form-horizontal">
|
|
|
|
<input type="hidden" id="mimSearchIndex" name="index" value="entry" />
|
|
<input type="hidden" id="mimSearchStart" name="start" value="1" />
|
|
<input type="hidden" id="mimSearchLimit" name="limit" value="10" />
|
|
<input type="hidden" id="mimSearchSort" name="sort" value="score desc, prefix_sort desc" />
|
|
|
|
|
|
<div class="row">
|
|
|
|
<div class="col-lg-8 col-md-8 col-sm-8 col-xs-8">
|
|
<div class="form-group">
|
|
<div class="input-group">
|
|
<input type="search" id="mimEntrySearch" name="search" class="form-control" value="" placeholder="Search OMIM..." maxlength="5000" autocomplete="off" autocorrect="off" autocapitalize="none" spellcheck="false" autofocus />
|
|
<div class="input-group-btn">
|
|
<button type="submit" id="mimEntrySearchSubmit" class="btn btn-default" style="width: 5em;"><span class="glyphicon glyphicon-search"></span></button>
|
|
<button type="button" class="btn btn-default dropdown-toggle" data-toggle="dropdown"> Options <span class="caret"></span></button>
|
|
<ul class="dropdown-menu dropdown-menu-right">
|
|
<li class="dropdown-header">
|
|
Advanced Search
|
|
</li>
|
|
<li style="margin-left: 0.5em;">
|
|
<a href="/search/advanced/entry"> OMIM </a>
|
|
</li>
|
|
<li style="margin-left: 0.5em;">
|
|
<a href="/search/advanced/clinicalSynopsis"> Clinical Synopses </a>
|
|
</li>
|
|
<li style="margin-left: 0.5em;">
|
|
<a href="/search/advanced/geneMap"> Gene Map </a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
<li role="separator" class="divider"></li>
|
|
<li>
|
|
<a href="/history"> Search History </a>
|
|
</li>
|
|
|
|
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
<div class="autocomplete" id="mimEntrySearchAutocomplete"></div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
<div class="col-lg-4 col-md-4 col-sm-4 col-xs-4">
|
|
<span class="small">
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</form>
|
|
|
|
<div class="row">
|
|
<p />
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
<!-- <div id="mimSearch"> -->
|
|
|
|
|
|
|
|
|
|
<div id="mimContent">
|
|
|
|
|
|
|
|
<div class="container hidden-print">
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div class="row">
|
|
|
|
<div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
|
|
|
|
<div id="mimAlertBanner">
|
|
|
|
|
|
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<div class="row">
|
|
|
|
|
|
|
|
|
|
<div class="col-lg-2 col-md-2 col-sm-2 hidden-sm hidden-xs">
|
|
|
|
<div id="mimFloatingTocMenu" class="small" role="navigation">
|
|
|
|
<p>
|
|
<span class="h4">#211980</span>
|
|
<br />
|
|
<strong>Table of Contents</strong>
|
|
</p>
|
|
|
|
<nav>
|
|
<ul id="mimFloatingTocMenuItems" class="nav nav-pills nav-stacked mim-floating-toc-padding">
|
|
|
|
<li role="presentation">
|
|
<a href="#title"><strong>Title</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#phenotypeMap"><strong>Phenotype-Gene Relationships</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="/clinicalSynopsis/211980"><strong>Clinical Synopsis</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#text"><strong>Text</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#description">Description</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#clinicalFeatures">Clinical Features</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#inheritance">Inheritance</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#populationGenetics">Population Genetics</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#pathogenesis">Pathogenesis</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#clinicalManagement">Clinical Management</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#mapping">Mapping</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#molecularGenetics">Molecular Genetics</a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation" style="margin-left: 1em">
|
|
<a href="#cytogenetics">Cytogenetics</a>
|
|
</li>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#seeAlso"><strong>See Also</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#references"><strong>References</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#contributors"><strong>Contributors</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#creationDate"><strong>Creation Date</strong></a>
|
|
</li>
|
|
|
|
|
|
|
|
<li role="presentation">
|
|
<a href="#editHistory"><strong>Edit History</strong></a>
|
|
</li>
|
|
|
|
</ul>
|
|
|
|
</nav>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<div class="col-lg-2 col-lg-push-8 col-md-2 col-md-push-8 col-sm-2 col-sm-push-8 col-xs-12">
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div id="mimFloatingLinksMenu">
|
|
|
|
<div class="panel panel-primary" style="margin-bottom: 0px; border-radius: 4px 4px 0px 0px">
|
|
<div class="panel-heading mim-panel-heading" role="tab" id="mimExternalLinks">
|
|
<h4 class="panel-title">
|
|
<a href="#mimExternalLinksFold" id="mimExternalLinksToggle" class="mimTriangleToggle" role="button" data-toggle="collapse">
|
|
<div style="display: table-row">
|
|
<div id="mimExternalLinksToggleTriangle" class="small" style="color: white; display: table-cell;">▼</div>
|
|
|
|
<div style="display: table-cell;">External Links</div>
|
|
</div>
|
|
</a>
|
|
</h4>
|
|
</div>
|
|
</div>
|
|
|
|
<div id="mimExternalLinksFold" class="collapse in">
|
|
|
|
<div class="panel-group" id="mimExternalLinksAccordion" role="tablist" aria-multiselectable="true">
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div class="panel panel-default" style="margin-top: 0px; border-radius: 0px">
|
|
<div class="panel-heading mim-panel-heading" role="tab" id="mimClinicalResources">
|
|
<span class="panel-title">
|
|
<span class="small">
|
|
<a href="#mimClinicalResourcesLinksFold" id="mimClinicalResourcesLinksToggle" class=" mimSingletonTriangleToggle" role="button" data-toggle="collapse" data-parent="#mimExternalLinksAccordion">
|
|
<div style="display: table-row">
|
|
<div id="mimClinicalResourcesLinksToggleTriangle" class="small mimSingletonTriangle" style="color: #337CB5; display: table-cell;">▼</div>
|
|
|
|
<div style="display: table-cell;">Clinical Resources</div>
|
|
</div>
|
|
</a>
|
|
</span>
|
|
</span>
|
|
</div>
|
|
<div id="mimClinicalResourcesLinksFold" class="panel-collapse collapse in mimLinksFold" role="tabpanel" aria-labelledby="clinicalResources">
|
|
<div class="panel-body small mim-panel-body">
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div><a href="https://clinicaltrials.gov/search?cond=(LUNG CANCER) OR (PRKN OR BRAF OR IRF1 OR PPP2R1B OR CASP8 OR ERBB2 OR SLC22A1L OR PIK3CA OR EGFR OR MAP3K8 OR ERCC6 OR FASLG OR CYP2A6 OR KRAS)" class="mim-tip-hint" title="Clinical Trials" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Clinical Trials', 'domain': 'clinicaltrials.gov'})">Clinical Trials</a></div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div><a href="https://www.diseaseinfosearch.org/x/4334" class="mim-tip-hint" title="Network of disease-specific advocacy organizations, universities, private companies, government agencies, and public policy organizations." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Genetic Alliance', 'domain': 'diseaseinfosearch.org'})">Genetic Alliance</a></div>
|
|
|
|
|
|
|
|
|
|
<div><a href="#mimMedlinePlusGeneticsFold" id="mimMedlinePlusGeneticsToggle" data-toggle="collapse" class="mim-tip-hint mimTriangleToggle" title="Consumer-friendly information about the effects of genetic variation on human health."><span id="mimMedlinePlusGeneticsToggleTriangle" class="small" style="margin-left: -0.8em;">►</span>MedlinePlus Genetics</div>
|
|
<div id="mimMedlinePlusGeneticsFold" class="collapse">
|
|
<div style="margin-left: 0.5em;"><a href="https://medlineplus.gov/genetics/condition/lung-cancer" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'MedlinePlus Genetics', 'domain': 'medlineplus.gov'})">Lung cancer </a></div><div style="margin-left: 0.5em;"><a href="https://medlineplus.gov/genetics/gene/alk" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'MedlinePlus Genetics', 'domain': 'medlineplus.gov'})">ALK gene </a></div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div><a href="https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=211980[mim]" class="mim-tip-hint" title="Genetic Testing Registry." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'GTR', 'domain': 'ncbi.nlm.nih.gov'})">GTR</a></div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
<div class="panel panel-default" style="margin-top: 0px; border-radius: 0px">
|
|
<div class="panel-heading mim-panel-heading" role="tab" id="mimAnimalModels">
|
|
<span class="panel-title">
|
|
<span class="small">
|
|
<a href="#mimAnimalModelsLinksFold" id="mimAnimalModelsLinksToggle" class="collapsed mimSingletonTriangleToggle" role="button" data-toggle="collapse" data-parent="#mimExternalLinksAccordion">
|
|
<div style="display: table-row">
|
|
<div id="mimAnimalModelsLinksToggleTriangle" class="small mimSingletonTriangle" style="color: #337CB5; display: table-cell;">►</div>
|
|
|
|
<div style="display: table-cell;">Animal Models</div>
|
|
</div>
|
|
</a>
|
|
</span>
|
|
</span>
|
|
</div>
|
|
<div id="mimAnimalModelsLinksFold" class="panel-collapse collapse mimLinksFold" role="tabpanel">
|
|
<div class="panel-body small mim-panel-body">
|
|
|
|
|
|
|
|
|
|
<div><a href="https://www.alliancegenome.org/disease/DOID:1324" class="mim-tip-hint" title="Search Across Species; explore model organism and human comparative genomics." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Alliance Genome', 'domain': 'alliancegenome.org'})">Alliance Genome</a></div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div><a href="http://www.informatics.jax.org/disease/211980" class="mim-tip-hint" title="Phenotypes, alleles, and disease models from Mouse Genome Informatics." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'MGI Mouse Phenotype', 'domain': 'informatics.jax.org'})">MGI Mouse Phenotype</a></div>
|
|
|
|
|
|
|
|
|
|
|
|
<div><a href="https://omia.org/OMIA001990/" class="mim-tip-hint" title="Online Mendelian Inheritance in Animals (OMIA) is a database of genes, inherited disorders and traits in 191 animal species (other than human and mouse.)" target="_blank">OMIA</a></div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div><a href="https://wormbase.org/resources/disease/DOID:1324" class="mim-tip-hint" title="Database of the biology and genome of Caenorhabditis elegans and related nematodes." target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'Wormbase Disease Ontology', 'domain': 'wormbase.org'})">Wormbase Disease Ontology</a></div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
<span>
|
|
<span class="mim-tip-bottom" qtip_title="<strong>Looking for this gene or this phenotype in other resources?</strong>" qtip_text="Select a related resource from the dropdown menu and click for a targeted link to information directly relevant.">
|
|
|
|
</span>
|
|
</span>
|
|
|
|
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
<div class="col-lg-8 col-lg-pull-2 col-md-8 col-md-pull-2 col-sm-8 col-sm-pull-2 col-xs-12">
|
|
|
|
<div>
|
|
|
|
<a id="title" class="mim-anchor"></a>
|
|
|
|
<div>
|
|
<a id="number" class="mim-anchor"></a>
|
|
<div class="text-right">
|
|
|
|
|
|
|
|
<a href="#" class="mim-tip-icd" qtip_title="<strong>ICD+</strong>" qtip_text="
|
|
|
|
<strong>SNOMEDCT:</strong> 363358000<br />
|
|
|
|
|
|
<strong>ICD10CM:</strong> C34.90<br />
|
|
|
|
|
|
|
|
|
|
<strong>DO:</strong> 1324<br />
|
|
|
|
|
|
">ICD+</a>
|
|
|
|
</div>
|
|
<div>
|
|
<span class="h3">
|
|
<span class="mim-font mim-tip-hint" title="Phenotype description, molecular basis known">
|
|
<span class="text-danger"><strong>#</strong></span>
|
|
211980
|
|
</span>
|
|
</span>
|
|
</div>
|
|
</div>
|
|
|
|
<div>
|
|
<a id="preferredTitle" class="mim-anchor"></a>
|
|
<h3>
|
|
<span class="mim-font">
|
|
|
|
LUNG CANCER
|
|
|
|
</span>
|
|
</h3>
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="includedTitles" class="mim-anchor"></a>
|
|
<div>
|
|
<p>
|
|
<span class="mim-font">
|
|
Other entities represented in this entry:
|
|
</span>
|
|
</p>
|
|
</div>
|
|
<div>
|
|
<span class="h3 mim-font">
|
|
ALVEOLAR CELL CARCINOMA, INCLUDED
|
|
</span>
|
|
</div>
|
|
|
|
<div>
|
|
<span class="h4 mim-font">
|
|
|
|
ADENOCARCINOMA OF LUNG, INCLUDED<br />
|
|
NONSMALL CELL LUNG CANCER, INCLUDED<br />
|
|
LUNG CANCER, PROTECTION AGAINST, INCLUDED
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="phenotypeMap" class="mim-anchor"></a>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Phenotype-Gene Relationships</strong>
|
|
</span>
|
|
</h4>
|
|
<div>
|
|
<table class="table table-bordered table-condensed table-hover small mim-table-padding">
|
|
<thead>
|
|
<tr class="active">
|
|
<th>
|
|
Location
|
|
</th>
|
|
<th>
|
|
Phenotype
|
|
</th>
|
|
<th>
|
|
Phenotype <br /> MIM number
|
|
</th>
|
|
<th>
|
|
Inheritance
|
|
</th>
|
|
<th>
|
|
Phenotype <br /> mapping key
|
|
</th>
|
|
<th>
|
|
Gene/Locus
|
|
</th>
|
|
<th>
|
|
Gene/Locus <br /> MIM number
|
|
</th>
|
|
</tr>
|
|
</thead>
|
|
<tbody>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/1/1427?start=-3&limit=10&highlight=1427">
|
|
1q24.3
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, susceptibility to}
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
FASLG
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/134638"> 134638 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/2/914?start=-3&limit=10&highlight=914">
|
|
2q33.1
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, protection against}
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
CASP8
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/601763"> 601763 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/3/876?start=-3&limit=10&highlight=876">
|
|
3q26.32
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
PIK3CA
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/171834"> 171834 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/5/449?start=-3&limit=10&highlight=449">
|
|
5q31.1
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
IRF1
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/147575"> 147575 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/6/1011?start=-3&limit=10&highlight=1011">
|
|
6q26
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
PRKN
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/602544"> 602544 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/7/271?start=-3&limit=10&highlight=271">
|
|
7p11.2
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
EGFR
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/131550"> 131550 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/7/271?start=-3&limit=10&highlight=271">
|
|
7p11.2
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Nonsmall cell lung cancer, susceptibility to}
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
EGFR
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/131550"> 131550 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/7/271?start=-3&limit=10&highlight=271">
|
|
7p11.2
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, response to tyrosine kinase inhibitor in
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
EGFR
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/131550"> 131550 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/7/742?start=-3&limit=10&highlight=742">
|
|
7q34
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
BRAF
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/164757"> 164757 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/7/742?start=-3&limit=10&highlight=742">
|
|
7q34
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
BRAF
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/164757"> 164757 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/10/132?start=-3&limit=10&highlight=132">
|
|
10p11.23
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
MAP3K8
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/191195"> 191195 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/10/190?start=-3&limit=10&highlight=190">
|
|
10q11.23
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, susceptibility to}
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
ERCC6
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/609413"> 609413 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/11/88?start=-3&limit=10&highlight=88">
|
|
11p15.4
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
SLC22A1L
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/602631"> 602631 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/11/923?start=-3&limit=10&highlight=923">
|
|
11q23.1
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
PPP2R1B
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/603113"> 603113 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/12/240?start=-3&limit=10&highlight=240">
|
|
12p12.1
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
KRAS
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/190070"> 190070 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/17/491?start=-3&limit=10&highlight=491">
|
|
17q12
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, somatic
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
ERBB2
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/164870"> 164870 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/geneMap/19/717?start=-3&limit=10&highlight=717">
|
|
19q13.2
|
|
</a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, resistance to}
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/211980"> 211980 </a>
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="Autosomal dominant">AD</abbr>, <abbr class="mim-tip-hint" title="Somatic mutation">SMu</abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
<abbr class="mim-tip-hint" title="3 - The molecular basis of the disorder is known"> 3 </abbr>
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
CYP2A6
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
<a href="/entry/122720"> 122720 </a>
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
</tbody>
|
|
</table>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
|
|
|
|
<div class="btn-group ">
|
|
<a href="/clinicalSynopsis/211980" class="btn btn-warning" role="button"> Clinical Synopsis </a>
|
|
<button type="button" id="mimPhenotypicSeriesToggle" class="btn btn-warning dropdown-toggle mimSingletonFoldToggle" data-toggle="collapse" href="#mimClinicalSynopsisFold" onclick="ga('send', 'event', 'Unfurl', 'ClinicalSynopsis', 'omim.org')">
|
|
<span class="caret"></span>
|
|
<span class="sr-only">Toggle Dropdown</span>
|
|
</button>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div class="btn-group">
|
|
<button type="button" class="btn btn-success dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
|
|
PheneGene Graphics <span class="caret"></span>
|
|
</button>
|
|
<ul class="dropdown-menu" style="width: 17em;">
|
|
<li><a href="/graph/linear/211980" target="_blank" onclick="gtag('event', 'mim_graph', {'destination': 'Linear'})"> Linear </a></li>
|
|
<li><a href="/graph/radial/211980" target="_blank" onclick="gtag('event', 'mim_graph', {'destination': 'Radial'})"> Radial </a></li>
|
|
</ul>
|
|
</div>
|
|
<span class="glyphicon glyphicon-question-sign mim-tip-hint" title="OMIM PheneGene graphics depict relationships between phenotypes, groups of related phenotypes (Phenotypic Series), and genes.<br /><a href='/static/omim/pdf/OMIM_Graphics.pdf' target='_blank'>A quick reference overview and guide (PDF)</a>"></span>
|
|
|
|
|
|
|
|
<div>
|
|
<p />
|
|
</div>
|
|
|
|
|
|
<div id="mimClinicalSynopsisFold" class="well well-sm collapse mimSingletonToggleFold">
|
|
<div class="small" style="margin: 5px">
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<span class="h5 mim-font">
|
|
<strong> INHERITANCE </strong>
|
|
</span>
|
|
</div>
|
|
<div style="margin-left: 2em;">
|
|
|
|
<div>
|
|
<span class="mim-font">
|
|
|
|
- Somatic mutation <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/124975008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">124975008</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C1866227&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1866227</a>, <a href="https://bioportal.bioontology.org/search?q=C0544886&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0544886</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001442" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001442</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0001442" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0001442</a>]</span><br /> -
|
|
Autosomal dominant <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/263681008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">263681008</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/771269000" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">771269000</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0443147&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0443147</a>, <a href="https://bioportal.bioontology.org/search?q=C1867440&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C1867440</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000006" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000006</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0000006" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0000006</a>]</span><br />
|
|
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<span class="h5 mim-font">
|
|
<strong> RESPIRATORY </strong>
|
|
</span>
|
|
</div>
|
|
<div style="margin-left: 2em;">
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<span class="h5 mim-font">
|
|
<em> Lung </em>
|
|
</span>
|
|
</div>
|
|
<div style="margin-left: 2em;">
|
|
<span class="mim-font">
|
|
|
|
- Alveolar cell carcinoma <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/36310008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">36310008</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/112677002" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">112677002</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0007120&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0007120</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0006519" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0006519</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0006519" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0006519</a>]</span><br /> -
|
|
Nonsmall cell lung cancer <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/254637007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">254637007</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0007131&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0007131</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0030358" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0030358</a>]</span><br /> -
|
|
Adenocarcinoma of lung <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/254626006" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">254626006</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0152013&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0152013</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0030078" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0030078</a>]</span><br />
|
|
|
|
</span>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<span class="h5 mim-font">
|
|
<strong> NEOPLASIA </strong>
|
|
</span>
|
|
</div>
|
|
<div style="margin-left: 2em;">
|
|
|
|
<div>
|
|
<span class="mim-font">
|
|
|
|
- Alveolar cell carcinoma <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/36310008" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">36310008</a>, <a href="https://purl.bioontology.org/ontology/SNOMEDCT/112677002" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">112677002</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0007120&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0007120</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0006519" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0006519</a>]</span> <span class="mim-feature-ids hidden">[HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0006519" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0006519</a>]</span><br /> -
|
|
Nonsmall cell lung cancer <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/254637007" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">254637007</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0007131&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0007131</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0030358" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0030358</a>]</span><br /> -
|
|
Adenocarcinoma of lung <span class="mim-feature-ids hidden">[SNOMEDCT: <a href="https://purl.bioontology.org/ontology/SNOMEDCT/254626006" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'SNOMEDCT\', \'domain\': \'bioontology.org\'})">254626006</a>]</span> <span class="mim-feature-ids hidden">[UMLS: <a href="https://bioportal.bioontology.org/search?q=C0152013&searchproperties=true" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'UMLS\', \'domain\': \'bioontology.org\'})">C0152013</a> HPO: <a href="https://hpo.jax.org/app/browse/term/HP:0030078" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'HPO\', \'domain\': \'hpo.jax.org\'})">HP:0030078</a>]</span><br />
|
|
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<span class="h5 mim-font">
|
|
<strong> MISCELLANEOUS </strong>
|
|
</span>
|
|
</div>
|
|
<div style="margin-left: 2em;">
|
|
|
|
<div>
|
|
<span class="mim-font">
|
|
|
|
- Genes associated with susceptibility to lung cancer, e.g., FASLG (<a href="/entry/134638#0002">134638.0002</a>), FAS (<a href="/entry/134637#0021">134637.0021</a>), CHRNA5 (<a href="/entry/118505#0001">118505.0001</a>), CHRNA3 (<a href="/entry/118503#0001">118503.0001</a>)<br /> -
|
|
Genes associated with a protection against lung cancer, e.g., CASP8 (<a href="/entry/601763#0004">601763.0004</a>), CYP2A6 (<a href="/entry/122720#0002">122720.0002</a>)<br /> -
|
|
Mutations in EGFR (131550) are associated with altered response to treatment with tyrosine kinase inhibitors<br />
|
|
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<span class="h5 mim-font">
|
|
<strong> MOLECULAR BASIS </strong>
|
|
</span>
|
|
</div>
|
|
<div style="margin-left: 2em;">
|
|
|
|
<div>
|
|
<span class="mim-font">
|
|
|
|
- Susceptibility conferred by mutation in the epidermal growth factor receptor gene (EGFR, <a href="/entry/131550#0006">131550.0006</a>)<br />
|
|
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div class="text-right">
|
|
<a href="#mimClinicalSynopsisFold" data-toggle="collapse">▲ Close</a>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</div>
|
|
|
|
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="text" class="mim-anchor"></a>
|
|
|
|
|
|
|
|
<h4 href="#mimTextFold" id="mimTextToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimTextToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
|
|
<span class="mim-font">
|
|
<span class="mim-tip-floating" qtip_title="<strong>Looking For More References?</strong>" qtip_text="Click the 'reference plus' icon <span class='glyphicon glyphicon-plus-sign'></span> at the end of each OMIM text paragraph to see more references related to the content of the preceding paragraph.">
|
|
<strong>TEXT</strong>
|
|
</span>
|
|
</span>
|
|
</h4>
|
|
|
|
|
|
|
|
|
|
|
|
<div id="mimTextFold" class="collapse in ">
|
|
<span class="mim-text-font">
|
|
<p>A number sign (#) is used with this entry because mutations in several genes are associated with lung cancer. Both germline and somatic mutations have been identified in the EGFR (<a href="/entry/131550">131550</a>) and p53 (TP53; <a href="/entry/191170">191170</a>) genes, and somatic mutations have been identified in the KRAS (<a href="/entry/190070">190070</a>), BRAF (<a href="/entry/164757">164757</a>), ERBB2 (<a href="/entry/164870">164870</a>), MET (<a href="/entry/164860">164860</a>), STK11 (<a href="/entry/602216">602216</a>), PIK3CA (<a href="/entry/171834">171834</a>), and PARK2 (<a href="/entry/602544">602544</a>) genes. Amplification of several genes, including EGFR, ERBB2, MET, PIK3CA, and NKX2-1 (<a href="/entry/600635">600635</a>), is also associated with lung cancer. Deletion of several genes, including DOK2 (<a href="/entry/604977">604977</a>), is also associated with lung cancer. An ALK/EML4 fusion gene (see <a href="/entry/105590">105590</a>) has been identified in lung cancer. Several polymorphisms are associated with lung cancer susceptibility, including a 5-prime SNP in the ERCC6 gene (<a href="/entry/609413">609413</a>) and SNPs in the nicotinic acetylcholine receptor gene cluster on chromosome 15q25.1 (see LNCR2; <a href="/entry/612052">612052</a>). Lung cancer susceptibility loci have been mapped to chromosome 6q23-q25 (LNCR1; <a href="/entry/608935">608935</a>), 5p15 (LNCR3; <a href="/entry/612571">612571</a>), 6p21 (LNCR4; <a href="/entry/612593">612593</a>), and 3q28 (LNCR5; <a href="/entry/614210">614210</a>). Deletion alleles in the CYP2A6 (<a href="/entry/122720">122720</a>) and CASP8 (<a href="/entry/601763">601763</a>) genes are associated with a reduced risk of lung cancer in Japanese and Han Chinese individuals, respectively. A SNP in the MPO gene (<a href="/entry/606989">606989</a>) is associated with reduced risk of lung cancer in smokers.</p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="description" class="mim-anchor"></a>
|
|
<h4 href="#mimDescriptionFold" id="mimDescriptionToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimDescriptionToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Description</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimDescriptionFold" class="collapse in ">
|
|
<span class="mim-text-font">
|
|
<p>Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see <a href="/entry/182280">182280</a>), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by <a href="#20" class="mim-tip-reference" title="Herbst, R. S., Heymach, J. V., Lippman, S. M. <strong>Lung cancer.</strong> New Eng. J. Med. 359: 1367-1380, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18815398/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18815398</a>] [<a href="https://doi.org/10.1056/NEJMra0802714" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18815398">Herbst et al., 2008</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18815398" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="clinicalFeatures" class="mim-anchor"></a>
|
|
<h4 href="#mimClinicalFeaturesFold" id="mimClinicalFeaturesToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimClinicalFeaturesToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Clinical Features</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimClinicalFeaturesFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p><a href="#23" class="mim-tip-reference" title="Joishy, S. K., Cooper, R. A., Rowley, P. T. <strong>Alveolar cell carcinoma in identical twins: similarity in time of onset, histochemistry, and site of metastasis.</strong> Ann. Intern. Med. 87: 447-450, 1977.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/199100/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">199100</a>] [<a href="https://doi.org/10.7326/0003-4819-87-4-447" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="199100">Joishy et al. (1977)</a> described identical twins who developed symptoms of alveolar cell carcinoma almost simultaneously. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=199100" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#1" class="mim-tip-reference" title="Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Y., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J., Sidransky, D. <strong>Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.</strong> Cancer 92: 1525-1530, 2001.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/11745231/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">11745231</a>] [<a href="https://doi.org/10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="11745231">Ahrendt et al. (2001)</a> noted that incidence rates for squamous cell and small cell lung carcinoma began falling among males in the mid-1980s, but a decline in the incidence of primary adenocarcinoma of the lung among males was not observed until 5 to 10 years later. Similarly, although the incidence rates of squamous cell, large cell, and small cell lung carcinoma among women leveled off or started to decrease, the incidence of adenocarcinoma continued to increase. With these changes in the incidence among the different histologic types of lung carcinoma over the 1990s, adenocarcinoma of the lung became the most common type of lung carcinoma in the U.S. (<a href="#50" class="mim-tip-reference" title="Wingo, P. A., Ries, L. A. G., Giovino, G. A., Miller, D. S., Rosenberg, H. M., Shopland, D. R., Thun, M. J., Edwards, B. K. <strong>Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking.</strong> J. Nat. Cancer Inst. 91: 675-690, 1999.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10218505/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10218505</a>] [<a href="https://doi.org/10.1093/jnci/91.8.675" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="10218505">Wingo et al., 1999</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?term=10218505+11745231" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="inheritance" class="mim-anchor"></a>
|
|
<h4 href="#mimInheritanceFold" id="mimInheritanceToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimInheritanceToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Inheritance</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimInheritanceFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p><a href="#7" class="mim-tip-reference" title="Braun, M. M., Caporaso, N. E., Page, W. F., Hoover, R. N. <strong>Genetic component of lung cancer: cohort study of twins.</strong> Lancet 344: 440-443, 1994.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/7914565/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">7914565</a>] [<a href="https://doi.org/10.1016/s0140-6736(94)91770-1" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="7914565">Braun et al. (1994)</a> conducted a genetic analysis of lung cancer mortality in the National Academy of Sciences/National Research Council Twin Registry. The registry is composed of 15,924 male twin pairs who were born in the U.S. between 1917 and 1927 and who served in the armed forces during World War II. As evidence for a genetic effect on lung cancer, they required concordance for lung cancer death to be greater among monozygotic than among dizygotic twin pairs. No genetic effect on lung cancer mortality was observed. The ratio of observed to expected concordance among monozygotic twins did not exceed that among dizygotic twins, even though monozygotic twin pairs were more likely to be concordant for smoking than dizygotic twin pairs in this population. A cohort analysis (accounting for age, sex, race, and smoking intensity) of lung cancer mortality found no lung cancer deaths during the 300 person-years of follow-up among 47 monozygotic twins smokers whose smoking twin died of lung cancer, even though smoking histories were very similar within twin pairs. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7914565" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In a multicenter study of lung cancer in lifetime nonsmokers in the United States, 646 female lung cancer patients and 1,252 population controls were interviewed regarding history of cancer in their first-degree relatives. <a href="#52" class="mim-tip-reference" title="Wu, A. H., Fontham, E. T. H., Reynolds, P., Greenberg, R. S., Buffler, P., Liff, J., Boyd, P., Correa, P. <strong>Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States.</strong> Am. J. Epidemiol. 143: 535-542, 1996.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8610670/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8610670</a>] [<a href="https://doi.org/10.1093/oxfordjournals.aje.a008783" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="8610670">Wu et al. (1996)</a> summarized the findings. A 30% increased risk was associated with a history of respiratory tract cancer in parents or sibs after adjustment for exposure to environmental tobacco smoke in adult life. Lung cancer, which represented approximately two-thirds of the respiratory tract cancers, occurred more frequently in first-degree relatives of lung cancer patients than in comparable relatives of population controls. A significant 3-fold increased risk for lung cancer was associated with lung cancer diagnosed in mothers and sisters. <a href="#52" class="mim-tip-reference" title="Wu, A. H., Fontham, E. T. H., Reynolds, P., Greenberg, R. S., Buffler, P., Liff, J., Boyd, P., Correa, P. <strong>Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States.</strong> Am. J. Epidemiol. 143: 535-542, 1996.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8610670/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8610670</a>] [<a href="https://doi.org/10.1093/oxfordjournals.aje.a008783" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="8610670">Wu et al. (1996)</a> also observed the increased risk in relation to family history of lung cancer among parents and sibs who were smokers as well as in those who were nonsmokers. The association with family history of lung cancer was strengthened when the analysis was restricted to adenocarcinoma of the lung. However, the authors pointed out that there was no association between family history of other cancers and risk of lung cancer in nonsmokers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8610670" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="populationGenetics" class="mim-anchor"></a>
|
|
<h4 href="#mimPopulationGeneticsFold" id="mimPopulationGeneticsToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimPopulationGeneticsToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Population Genetics</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimPopulationGeneticsFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p><a href="#19" class="mim-tip-reference" title="Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E., Le Marchand, L. <strong>Ethnic and racial differences in the smoking-related risk of lung cancer.</strong> New Eng. J. Med. 354: 333-342, 2006.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16436765/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16436765</a>] [<a href="https://doi.org/10.1056/NEJMoa033250" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="16436765">Haiman et al. (2006)</a> investigated differences in the risk of lung cancer associated with cigarette smoking in 183,813 African American, Japanese American, Latino, Native Hawaiian, and white men and women. Their analysis included 1,979 cases of incident lung cancer identified prospectively over an 8-year period. They found that among cigarette smokers, African Americans and Native Hawaiians are more susceptible to lung cancer than whites, Japanese Americans, and Latinos. <a href="#39" class="mim-tip-reference" title="Risch, N. <strong>Dissecting racial and ethnic differences. (Editorial)</strong> New Eng. J. Med. 354: 408-411, 2006.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16436773/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16436773</a>] [<a href="https://doi.org/10.1056/NEJMe058265" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="16436773">Risch (2006)</a> discussed the problems of dissecting racial and ethnic differences in relation to the frequency of disease. He stated that it is 'difficult to discuss the role of genetics in differences among groups, because of the fear that such discourse may reinforce notions of biologic determinism. Some insist that racial and ethnic categories are purely social and devoid of genetic content, or at least of minimal relevance.' <a href="https://pubmed.ncbi.nlm.nih.gov/?term=16436765+16436773" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="pathogenesis" class="mim-anchor"></a>
|
|
<h4 href="#mimPathogenesisFold" id="mimPathogenesisToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimPathogenesisToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Pathogenesis</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimPathogenesisFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p>In the DNA from 1 colon and 2 lung carcinoma cell lines, <a href="#35" class="mim-tip-reference" title="Perucho, M., Goldfarb, M., Shimizu, K., Lama, C., Fogh, J., Wigler, M. <strong>Human-tumor-derived cell lines contain common and different transforming genes.</strong> Cell 27: 467-476, 1981.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6101201/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6101201</a>] [<a href="https://doi.org/10.1016/0092-8674(81)90388-3" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="6101201">Perucho et al. (1981)</a> demonstrated the same or closely related transforming elements. By DNA-mediated gene transfer, mouse fibroblasts could be morphologically transformed and rendered tumorigenic in nude mice. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6101201" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>Starting from studies of lung adenocarcinomas, <a href="#38" class="mim-tip-reference" title="Ramaswamy, S., Ross, K. N., Lander, E. S., Golub, T. R. <strong>A molecular signature of metastasis in primary solid tumors.</strong> Nature Genet. 33: 49-54, 2003.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12469122/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12469122</a>] [<a href="https://doi.org/10.1038/ng1060" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="12469122">Ramaswamy et al. (2003)</a> explored the molecular differences between human primary tumors and metastases by comparing their gene expression profiles. They found a 17-gene-expression signature that distinguished primary from metastatic adenocarcinomas. Notably, they found that a subset of primary tumors resembled metastatic tumors with respect to this gene-expression signature. They confirmed their findings by applying the expression signature to data on 279 primary solid tumors of diverse types. They found that solid tumors carrying the gene-expression signature were most likely to be associated with metastasis and poor clinical outcome (P less than 0.03). These results suggested that the metastatic potential of human tumors is encoded in the bulk of a primary tumor, thus challenging the notion that metastases arise from rare cells within a primary tumor that have the ability to metastasize. The results supported the idea that some primary tumors are preconfigured to metastasize, and that this propensity is detectable at the time of initial diagnosis. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12469122" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>A considerable proportion of the refined gene-expression signature that <a href="#38" class="mim-tip-reference" title="Ramaswamy, S., Ross, K. N., Lander, E. S., Golub, T. R. <strong>A molecular signature of metastasis in primary solid tumors.</strong> Nature Genet. 33: 49-54, 2003.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12469122/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12469122</a>] [<a href="https://doi.org/10.1038/ng1060" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="12469122">Ramaswamy et al. (2003)</a> found to be associated with metastasis seemed to be derived from nonepithelial components of the tumor. Specifically, these included genes encoding the type 1 collagens (COL1A1, <a href="/entry/120150">120150</a>; COL1A2, <a href="/entry/120160">120160</a>) whose expression is restricted to fibroblasts. Some of the 17 genes constituting the signature were upregulated in metastases, others were downregulated. The upregulation of collagen genes in primary tumors with metastatic potential is consistent with observations that epithelial-mesenchymal interactions are critical determinants of tumor cell behavior. High levels of type 1 collagen in metastatic lesions and in the serum of individuals with metastatic disease have been reported. In general, the findings were consistent with the existence of a molecular program of metastasis that is shared by multiple solid-tumor types, suggesting the possible existence of therapeutic targets common to different cancers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12469122" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#9" class="mim-tip-reference" title="Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glockner, S., Piantadosi, S., Gabrielson, E., Pridham, G., Pelosky, K., Belinsky, S. A., Yang, S. C., Baylin, S. B., Herman, J. G. <strong>DNA methylation markers and early recurrence in stage I lung cancer.</strong> New Eng. J. Med. 358: 1118-1128, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18337602/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18337602</a>] [<a href="https://doi.org/10.1056/NEJMoa0706550" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18337602">Brock et al. (2008)</a> analyzed methylation of 7 genes in tumor tissue and lymph nodes from 51 patients with stage I nonsmall cell lung cancer (NSCLC) who underwent curative resection but had a recurrence within 40 months and from 116 age-, sex-, NSCLC stage-, and date of surgery-matched patients who underwent curative resection and did not have a recurrence within 40 months. In a multivariate model, the authors found that promoter methylation of the CDKN2A (<a href="/entry/600160">600160</a>), CDH13 (<a href="/entry/601364">601364</a>), RASSF1A (<a href="/entry/605082">605082</a>), and APC (<a href="/entry/611731">611731</a>) genes in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor. Methylation of the promoter regions of CDKN2A and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an OR of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18337602" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#51" class="mim-tip-reference" title="Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., Yoon, S., Crowley, D., Bronson, R. T., Chiang, D. Y., Meyerson, M., Jacks, T. <strong>Suppression of lung adenocarcinoma progression by Nkx2-1.</strong> Nature 473: 101-104, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21471965/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21471965</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21471965[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature09881" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21471965">Winslow et al. (2011)</a> modeled human lung adenocarcinoma, which frequently harbors activating point mutations in KRAS (<a href="/entry/190070">190070</a>) and inactivation of the p53 (<a href="/entry/191170">191170</a>) pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development. Although tumors are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed <a href="#51" class="mim-tip-reference" title="Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., Yoon, S., Crowley, D., Bronson, R. T., Chiang, D. Y., Meyerson, M., Jacks, T. <strong>Suppression of lung adenocarcinoma progression by Nkx2-1.</strong> Nature 473: 101-104, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21471965/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21471965</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21471965[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature09881" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21471965">Winslow et al. (2011)</a> to distinguish metastatic from nonmetastatic tumors and determine the gene expression alterations that distinguish these tumor types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (<a href="/entry/600635">600635</a>) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumors. Gain- and loss-of-function experiments in cells derived from metastatic and nonmetastatic tumors demonstrated that Nkx2-1 controls tumor differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumors at defined developmental stages, and functional complementation experiments indicated that Nkx2-1 constrains tumors in part by repressing the embryonically restricted chromatin regulator Hmga2 (<a href="/entry/600698">600698</a>). Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas had focused attention on its oncogenic function, <a href="#51" class="mim-tip-reference" title="Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., Yoon, S., Crowley, D., Bronson, R. T., Chiang, D. Y., Meyerson, M., Jacks, T. <strong>Suppression of lung adenocarcinoma progression by Nkx2-1.</strong> Nature 473: 101-104, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21471965/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21471965</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21471965[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature09881" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21471965">Winslow et al. (2011)</a> stated that their data specifically linked Nkx2-1 downregulation to loss of differentiation, enhanced tumor seeding ability, and increased metastatic proclivity. <a href="#51" class="mim-tip-reference" title="Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., Yoon, S., Crowley, D., Bronson, R. T., Chiang, D. Y., Meyerson, M., Jacks, T. <strong>Suppression of lung adenocarcinoma progression by Nkx2-1.</strong> Nature 473: 101-104, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21471965/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21471965</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21471965[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature09881" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21471965">Winslow et al. (2011)</a> concluded that the oncogenic and suppressive functions of Nkx2-1 in the same tumor type substantiate its role as a dual function lineage factor. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21471965" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#14" class="mim-tip-reference" title="de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., Gronroos, E., Muhammad, M. A., and 31 others. <strong>Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.</strong> Science 346: 251-256, 2014.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25301630/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25301630</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=25301630[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1126/science.1253462" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="25301630">De Bruin et al. (2014)</a> sequenced 25 spatially distinct regions from 7 operable NSCLCs and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC (see <a href="/entry/600130">600130</a>) cytidine deaminase activity. Despite maintained carcinogen exposure, tumors from smokers showed a relative decrease in smoking-related mutations over time, accompanied by an increase in APOBEC-associated mutations. In tumors from former smokers, genome doubling occurred within a smoking-signature context before subclonal diversification, which suggested that a long period of tumor latency had preceded clinical detection. <a href="#14" class="mim-tip-reference" title="de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., Gronroos, E., Muhammad, M. A., and 31 others. <strong>Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.</strong> Science 346: 251-256, 2014.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25301630/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25301630</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=25301630[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1126/science.1253462" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="25301630">De Bruin et al. (2014)</a> concluded that regionally separated driver mutations, coupled with the relentless and heterogeneous nature of the genome instability processes, are likely to confound treatment success in NSCLC. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=25301630" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#53" class="mim-tip-reference" title="Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., Gold, K. A., Kalhor, N., and 15 others. <strong>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.</strong> Science 346: 256-259, 2014.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25301631/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25301631</a>] [<a href="https://doi.org/10.1126/science.1256930" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="25301631">Zhang et al. (2014)</a> applied multiregion whole-exome sequencing to 11 localized lung adenocarcinomas. All tumors showed clear evidence of intratumor heterogeneity. On average, 76% of all mutations and 20 out of 21 known cancer gene mutations were identified in all regions of individual tumors, which suggested that single-region sequencing may be adequate to identify the majority of known cancer gene mutations in localized lung adenocarcinomas. With a median follow-up of 21 months after surgery, 3 patients had relapsed, and all 3 had significantly larger fractions of subclonal mutations in their primary tumors than patients without relapse. <a href="#53" class="mim-tip-reference" title="Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., Gold, K. A., Kalhor, N., and 15 others. <strong>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.</strong> Science 346: 256-259, 2014.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25301631/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25301631</a>] [<a href="https://doi.org/10.1126/science.1256930" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="25301631">Zhang et al. (2014)</a> concluded that a larger subclonal mutation fraction may be associated with increased likelihood of postsurgical relapse in patients with localized lung adenocarcinomas. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=25301631" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>Reviews of Lung Cancer Pathogenesis</em></strong></p><p>
|
|
<a href="#20" class="mim-tip-reference" title="Herbst, R. S., Heymach, J. V., Lippman, S. M. <strong>Lung cancer.</strong> New Eng. J. Med. 359: 1367-1380, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18815398/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18815398</a>] [<a href="https://doi.org/10.1056/NEJMra0802714" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18815398">Herbst et al. (2008)</a> reviewed lung cancer with a focus on the origins and biology of squamous cell carcinoma and adenocarcinoma, which constitute the majority of diagnosed lung cancers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18815398" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="clinicalManagement" class="mim-anchor"></a>
|
|
<h4 href="#mimClinicalManagementFold" id="mimClinicalManagementToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimClinicalManagementToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Clinical Management</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimClinicalManagementFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p>In a multiinstitutional phase II trial, <a href="#17" class="mim-tip-reference" title="Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.-P., Baselga, J. <strong>Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial).</strong> J. Clin. Oncol. 21: 2237-2246, 2003. Note: Erratum: J. Clin. Oncol. 22: 4863 only, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12748244/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12748244</a>] [<a href="https://doi.org/10.1200/JCO.2003.10.038" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="12748244">Fukuoka et al. (2003)</a> found a higher rate of response to the tyrosine kinase inhibitor gefitinib (Iressa) in Japanese patients with nonsmall cell lung cancer (NSCLC) than in a predominantly European-derived population (27.5% vs 10.4%). See 'EGFR Mutations and Lung Cancer' in MOLECULAR GENETICS for information on EGFR (<a href="/entry/131550">131550</a>) mutations associated with gefitinib-responsive lung cancer. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12748244" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In a randomized control trial of 1,217 East Asian patients with nonsmall cell lung cancer, <a href="#30" class="mim-tip-reference" title="Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., Fukuoka, M. <strong>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</strong> New Eng. J. Med. 361: 947-957, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19692680/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19692680</a>] [<a href="https://doi.org/10.1056/NEJMoa0810699" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19692680">Mok et al. (2009)</a> found that the 12-month rate of progression-free survival was 24.9% in patients treated with gefitinib and 6.7% in those treated with carboplatin-paclitaxel. In the subgroup of 261 patients who were positive for an EGFR mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel, whereas in the subgroup of 176 patients who were negative for a mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel. The findings indicated that gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia, and showed that the presence in the tumor of an EGFR mutation is a strong predictor of a better outcome with gefitinib. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19692680" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#40" class="mim-tip-reference" title="Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., and 16 others. <strong>Screening for epidermal growth factor receptor mutations in lung cancer.</strong> New Eng. J. Med. 361: 958-967, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19692684/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19692684</a>] [<a href="https://doi.org/10.1056/NEJMoa0904554" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19692684">Rosell et al. (2009)</a> concluded that large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in treatment decisions. EGFR mutations were identified in tumor tissue of 350 (16.6%) of 2,105 Spanish patients with nonsmall cell lung cancer. Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%). The mutations were deletions in exon 19 (62.2%) and L858R (<a href="/entry/131550#0002">131550.0002</a>) (37.8%). Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 months and 27 months, respectively. Multivariate analysis showed an association between poor progression-free survival and male sex (hazard ratio of 2.94), and the presence of the L858R mutation (hazard ratio of 1.92) as compared with a deletion in exon 19. The most common adverse events were mild rashes and diarrhea. The results suggested that EGFR-mutant lung cancer is a distinct class of nonsmall cell lung cancer. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19692684" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#6" class="mim-tip-reference" title="Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., Sawyers, C. L. <strong>FAS and NF-kappa-B signalling modulate dependence of lung cancers on mutant EGFR.</strong> Nature 471: 523-526, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21430781/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21430781</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21430781[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature09870" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21430781">Bivona et al. (2011)</a> used a pooled RNAi screen to show that knockdown of FAS (<a href="/entry/134637">134637</a>) and several components of the NF-kappa-B pathway (see <a href="/entry/164011">164011</a>) specifically enhanced cell death induced by the EGFR (<a href="/entry/131550">131550</a>) tyrosine kinase inhibitor (TKI) erlotinib in EGFR-mutant lung cancer cells. Activation of NF-kappa-B through overexpression of c-FLIP (<a href="/entry/603599">603599</a>) or IKK (<a href="/entry/603258">603258</a>), or silencing of I-kappa-B (see <a href="/entry/164008">164008</a>), rescued EGFR-mutant lung cancer cells from EGFR TKI treatment. Genetic or pharmacologic inhibition of NF-kappa-B enhanced erlotinib-induced apoptosis in erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models. Increased expression of the NF-kappa-B inhibitor I-kappa-B predicted improved response and survival in EGFR-mutant lung cancer patients treated with EGFR TKI. <a href="#6" class="mim-tip-reference" title="Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., Sawyers, C. L. <strong>FAS and NF-kappa-B signalling modulate dependence of lung cancers on mutant EGFR.</strong> Nature 471: 523-526, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21430781/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21430781</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21430781[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature09870" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21430781">Bivona et al. (2011)</a> concluded that their data identified NF-kappa-B as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provided insight into the mechanisms by which tumor cells escape from oncogene dependence. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21430781" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#55" class="mim-tip-reference" title="Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., Choi, Y. J., Choi, C.-M., and 18 others. <strong>Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.</strong> Nature Genet. 44: 852-860, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22751098/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22751098</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22751098[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.2330" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22751098">Zhang et al. (2012)</a> reported increased activation of AXL (<a href="/entry/109135">109135</a>) and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR T790M alteration (<a href="/entry/131550#0006">131550.0006</a>) or MET activation. Genetic or pharmacologic inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 (<a href="/entry/600441">600441</a>) was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to tyrosine kinase inhibitors. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=22751098" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="mapping" class="mim-anchor"></a>
|
|
<h4 href="#mimMappingFold" id="mimMappingToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimMappingToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Mapping</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimMappingFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p>In 3 varieties of nonsmall cell cancer of the lung, <a href="#49" class="mim-tip-reference" title="Weston, A., Willey, J. C., Modali, R., Sugimura, H., McDowell, E. M., Resau, J., Light, B., Haugen, A., Mann, D. L., Trump, B. F., Harris, C. C. <strong>Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung.</strong> Proc. Nat. Acad. Sci. 86: 5099-5103, 1989.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2567993/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2567993</a>] [<a href="https://doi.org/10.1073/pnas.86.13.5099" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="2567993">Weston et al. (1989)</a> found evidence of loss of heterozygosity in chromosome 17p and chromosome 11. Only a minority had loss of heterozygosity involving a chromosomal locus on 3p previously shown to be lost consistently in small cell cancer of the lung (SCLC1; <a href="/entry/182280">182280</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2567993" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#13" class="mim-tip-reference" title="Dai, Z., Zhu, W.-G., Morrison, C. D., Brena, R. M., Smiraglia, D. J., Raval, A., Wu, Y.-Z., Rush, L. J., Ross, P., Molina, J. R., Otterson, G. A., Plass, C. <strong>A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes.</strong> Hum. Molec. Genet. 12: 791-801, 2003.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12651874/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12651874</a>] [<a href="https://doi.org/10.1093/hmg/ddg083" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="12651874">Dai et al. (2003)</a> used restriction landmark genomic scanning (RLGS) to identify novel amplified sequences in primary lung carcinomas and lung cancer cell lines. Enhanced RLGS fragments indicative of gene amplification were observed in tumors and cell lines of both nonsmall cell lung cancer and small cell lung cancer. The authors identified a novel amplicon on chromosome 11q22, in addition to previously reported amplicons that include oncogenes MYC (<a href="/entry/190080">190080</a>), MYCL1 (<a href="/entry/164850">164850</a>), and previously identified amplification of chromosomal regions 6q21 and 3q26-27. The amplified region of 11q22 was refined to 0.92 Mb in 1 patient sample. Immunohistochemistry and Western blot analysis identified CIAP1 (BIRC2; <a href="/entry/601712">601712</a>) and CIAP2 (BIRC3; <a href="/entry/601721">601721</a>) as potential oncogenes in this region, since both are overexpressed in multiple lung cancers with or without higher copy numbers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12651874" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#2" class="mim-tip-reference" title="Bailey-Wilson, J. E., Amos, C. I., Pinney, S. M., Petersen, G. M., de Andrade, M., Wiest, J. S., Fain, P., Schwartz, A. G., You, M., Franklin, W., Klein, C., Gazdar, A., and 15 others. <strong>A major lung cancer susceptibility locus maps to chromosome 6q23-25.</strong> Am. J. Hum. Genet. 75: 460-474, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15272417/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15272417</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15272417[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1086/423857" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15272417">Bailey-Wilson et al. (2004)</a> mapped a major lung cancer susceptibility locus to chromosome 6q23-q25 (LNCR1; <a href="/entry/608935">608935</a>). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15272417" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="molecularGenetics" class="mim-anchor"></a>
|
|
<h4 href="#mimMolecularGeneticsFold" id="mimMolecularGeneticsToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimMolecularGeneticsToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Molecular Genetics</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimMolecularGeneticsFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p><a href="#15" class="mim-tip-reference" title="Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., and 78 others. <strong>Somatic mutations affect key pathways in lung adenocarcinoma.</strong> Nature 455: 1069-1075, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18948947/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18948947</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=18948947[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature07423" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18948947">Ding et al. (2008)</a> sequenced 623 genes with known or potential relationship to cancer in 188 human lung adenocarcinomas. Their analysis identified 26 genes that are mutated at significantly high frequencies and are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homolog ERBB4 (<a href="/entry/600543">600543</a>); multiple ephrin receptor genes, notably EPHA3 (<a href="/entry/179611">179611</a>); KDR (<a href="/entry/191306">191306</a>); and NTRK (<a href="/entry/191315">191315</a>). Their data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumor suppressor genes involved in other cancers, including NF1 (<a href="/entry/613113">613113</a>), APC (<a href="/entry/611731">611731</a>), RB1 (<a href="/entry/614041">614041</a>), and ATM (<a href="/entry/607585">607585</a>), and for sequence changes in PTPRD (<a href="/entry/601598">601598</a>) as well as the frequently deleted gene LRP1B (<a href="/entry/608766">608766</a>). The observed mutational profiles correlate with clinical features, smoking status, and DNA repair defects. In general, <a href="#15" class="mim-tip-reference" title="Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., and 78 others. <strong>Somatic mutations affect key pathways in lung adenocarcinoma.</strong> Nature 455: 1069-1075, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18948947/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18948947</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=18948947[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature07423" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18948947">Ding et al. (2008)</a> found that genetic alterations in lung adenocarcinoma frequently occur in genes of the MAPK (see <a href="/entry/176948">176948</a>), p53 (<a href="/entry/191170">191170</a>), WNT (see <a href="/entry/164820">164820</a>), cell cycle, and mTOR (<a href="/entry/601231">601231</a>) signaling pathways. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18948947" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>In affected members of 2 families with idiopathic pulmonary fibrosis (<a href="/entry/178500">178500</a>), some of whom also had lung cancer, <a href="#47" class="mim-tip-reference" title="Wang, Y., Kuan, P. J., Xing, C., Cronkhite, J. T., Torres, F., Rosenblatt, R. L., DiMaio, J. M., Kinch, L. N., Grishin, N. V., Garcia, C. K. <strong>Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.</strong> Am. J. Hum. Genet. 84: 52-59, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19100526/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19100526</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19100526[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1016/j.ajhg.2008.11.010" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19100526">Wang et al. (2009)</a> identified 2 heterozygous missense mutations in the SFTPA2 gene (see <a href="/entry/178642#0001">178642.0001</a> and <a href="/entry/178642#0002">178642.0002</a>, respectively). <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19100526" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#24" class="mim-tip-reference" title="Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., and 20 others. <strong>Diverse somatic mutation patterns and pathway alterations in human cancers.</strong> Nature 466: 869-873, 2010.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/20668451/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">20668451</a>] [<a href="https://doi.org/10.1038/nature09208" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="20668451">Kan et al. (2010)</a> reported the identification of 2,576 somatic mutations across approximately 1,800 megabases of DNA representing 1,507 coding genes from 441 tumors comprising breast, lung, ovarian, and prostate cancer types and subtypes. <a href="#24" class="mim-tip-reference" title="Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., and 20 others. <strong>Diverse somatic mutation patterns and pathway alterations in human cancers.</strong> Nature 466: 869-873, 2010.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/20668451/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">20668451</a>] [<a href="https://doi.org/10.1038/nature09208" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="20668451">Kan et al. (2010)</a> found that mutation rates and the sets of mutated genes varied substantially across tumor types and subtypes. Statistical analysis identified 77 significantly mutated genes including protein kinases, G protein-coupled receptors such as GRM8 (<a href="/entry/601116">601116</a>), BAI3 (<a href="/entry/602684">602684</a>), AGTRL1 (<a href="/entry/600052">600052</a>), and LPHN3, and other druggable targets. Integrated analysis of somatic mutations and copy number alterations identified another 35 significantly altered genes including GNAS (see <a href="/entry/139320">139320</a>), indicating an expanded role for G-alpha subunits in multiple cancer types. Experimental analyses demonstrated the functional roles of mutant GNAO1 (<a href="/entry/139311">139311</a>) and mutant MAP2K4 (<a href="/entry/601335">601335</a>) in oncogenesis. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=20668451" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>The <a href="#10" class="mim-tip-reference" title="Cancer Genome Atlas Research Network. <strong>Comprehensive genomic characterization of squamous cell lung cancers.</strong> Nature 489: 519-525, 2012. Note: Erratum: Nature 491: 288 only, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22960745/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22960745</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22960745[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature11404" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22960745">Cancer Genome Atlas Research Network (2012)</a> profiled 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations, and showed that the tumor type is characterized by complex genomic alterations with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumor. The <a href="#10" class="mim-tip-reference" title="Cancer Genome Atlas Research Network. <strong>Comprehensive genomic characterization of squamous cell lung cancers.</strong> Nature 489: 519-525, 2012. Note: Erratum: Nature 491: 288 only, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22960745/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22960745</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22960745[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature11404" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22960745">Cancer Genome Atlas Research Network (2012)</a> found statistically recurrent mutations in 11 genes, including mutations in TP53 in nearly all specimens. Previously unreported loss-of-function mutations were seen in the HLA-A class I major histocompatibility gene (<a href="/entry/142800">142800</a>). Significantly altered pathways included NFE2L2 (<a href="/entry/600492">600492</a>) and KEAP1 (<a href="/entry/606016">606016</a>) in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A (<a href="/entry/600160">600160</a>) and RB1 (<a href="/entry/614041">614041</a>) in 72% of tumors. The <a href="#10" class="mim-tip-reference" title="Cancer Genome Atlas Research Network. <strong>Comprehensive genomic characterization of squamous cell lung cancers.</strong> Nature 489: 519-525, 2012. Note: Erratum: Nature 491: 288 only, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22960745/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22960745</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22960745[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature11404" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22960745">Cancer Genome Atlas Research Network (2012)</a> identified a potential therapeutic target in most tumors, offering new avenues of investigation for the treatment of squamous cell lung cancers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=22960745" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p>The <a href="#11" class="mim-tip-reference" title="Cancer Genome Atlas Research Network. <strong>Comprehensive molecular profiling of lung adenocarcinoma.</strong> Nature 511: 543-550, 2014. Note: Erratum: Nature 514: 262 only, 2014. Erratum: Nature 559: E12, 2018.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25079552/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25079552</a>] [<a href="https://doi.org/10.1038/nature13385" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="25079552">Cancer Genome Atlas Research Network (2014)</a> reported molecular profiling of 230 resected lung adenocarcinomas using mRNA, microRNA, and DNA sequencing integrated with copy number, methylation, and proteomic analyses. High rates of somatic mutation were observed (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 (<a href="/entry/609591">609591</a>) with activating mutations and MGA (<a href="/entry/616061">616061</a>) with loss-of-function mutations that were mutually exclusive with focal MYC amplification. EGFR (<a href="/entry/131550">131550</a>) mutations were more frequent in female patients, whereas mutations in RBM10 (<a href="/entry/300080">300080</a>) were more common in males. Aberrations in NF1 (<a href="/entry/613113">613113</a>), MET (<a href="/entry/164860">164860</a>), ERBB2 (<a href="/entry/164870">164870</a>), and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumors. DNA and mRNA sequences from the same tumor highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK (see <a href="/entry/176948">176948</a>) and PI3K (see <a href="/entry/601232">601232</a>) pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=25079552" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>p53 Mutations and Lung Cancer</em></strong></p><p>
|
|
Among members of 97 families enrolled in a cohort study of families ascertained through childhood soft tissue sarcoma patients, <a href="#21" class="mim-tip-reference" title="Hwang, S.-J., Cheng, L. S.-C., Lozano, G., Amos, C. I., Gu, X., Strong, L. C. <strong>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk.</strong> Hum. Genet. 113: 238-243, 2003.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12802680/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12802680</a>] [<a href="https://doi.org/10.1007/s00439-003-0968-7" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="12802680">Hwang et al. (2003)</a> studied the role of cigarette smoking and lung cancer risk in people with a genetic susceptibility based on a p53 germline mutation. They assessed the incidence of lung and smoking-related cancers in 33 carriers of germline p53 mutations and in 1,230 noncarriers from the same families. They observed an increased risk of a variety of histologic types of lung cancer in the carriers of the p53 mutations. Mutation carriers who smoked had a 3.16-fold (95% CI = 1.48-6.78) higher risk for lung cancer than the mutation carriers who did not smoke. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12802680" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>EGFR Mutations and Lung Cancer</em></strong></p><p>
|
|
In tumors from patients with NSCLC responsive to the tyrosine kinase inhibitor gefitinib, <a href="#27" class="mim-tip-reference" title="Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., Haber, D. A. <strong>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</strong> New Eng. J. Med. 350: 2129-2139, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15118073/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15118073</a>] [<a href="https://doi.org/10.1056/NEJMoa040938" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15118073">Lynch et al. (2004)</a> and <a href="#33" class="mim-tip-reference" title="Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., Meyerson, M. <strong>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.</strong> Science 304: 1497-1500, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15118125/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15118125</a>] [<a href="https://doi.org/10.1126/science.1099314" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15118125">Paez et al. (2004)</a> identified mutations in the EGFR gene (<a href="/entry/131550#0001">131550.0001</a>-<a href="/entry/131550#0005">131550.0005</a>). <a href="#33" class="mim-tip-reference" title="Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., Meyerson, M. <strong>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.</strong> Science 304: 1497-1500, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15118125/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15118125</a>] [<a href="https://doi.org/10.1126/science.1099314" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15118125">Paez et al. (2004)</a> found somatic mutations in EGFR in 15 of 58 unselected NSCLC tumors from Japan and 1 of 61 from the United States. EGFR mutations showed a striking correlation with patient characteristics. Mutations were more frequent in adenocarcinomas than in other NSCLCs, being present in 15 (21%) of 70 and 1 (2%) of 49, respectively; more frequent in women than in men, being present in 9 (20%) of 45 and 7 (9%) of 74, respectively; and more frequent in patients from Japan than in those from the United States, being present in 15 (26%) of 58 and 14 (32%) of 41 adenocarcinomas versus 1 (2%) of 61 and 1 (3%) of 29 adenocarcinomas, respectively. The patient characteristics that correlated with the presence of EGFR mutations were those that correlated with clinical response to gefitinib treatment. The striking difference in the frequency of EGFR mutation and response to gefitinib between Japanese and U.S. patients raised general questions regarding variation in the molecular pathogenesis of cancer in different ethnic, cultural, and geographic groups and argued for the benefit of population diversity in cancer clinical trials. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=15118073+15118125" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#34" class="mim-tip-reference" title="Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. <strong>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.</strong> Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15329413/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15329413</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15329413[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1073/pnas.0405220101" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15329413">Pao et al. (2004)</a> found that in-frame deletions in exon 19 of the EGFR gene and somatic point mutations in codon 858 (exon 21) were common particularly in lung cancers from 'never smokers' and were associated, as found by others, with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. <a href="#34" class="mim-tip-reference" title="Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. <strong>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.</strong> Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15329413/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15329413</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15329413[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1073/pnas.0405220101" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15329413">Pao et al. (2004)</a> found EGFR tyrosine kinase domain mutations in 7 of 10 gefitinib-sensitive tumors and 5 of 7 erlotinib-sensitive tumors. No mutations were found in 8 gefitinib-refractory tumors and 10 erlotinib-refractory tumors. Because most of the mutation-positive tumors were adenocarcinomas from 'never smokers' (defined as patients who smoked less than 100 cigarettes in a lifetime), <a href="#34" class="mim-tip-reference" title="Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. <strong>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.</strong> Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15329413/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15329413</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15329413[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1073/pnas.0405220101" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15329413">Pao et al. (2004)</a> screened EGFR exons 2 through 28 for mutations in 15 adenocarcinomas resected from untreated 'never smokers.' Seven tumors had tyrosine kinase domain mutations, in contrast to 4 of 81 nonsmall cell lung cancers resected from untreated former or current smokers. Collectively the data showed that adenocarcinomas from 'never smokers' comprise a distinct subset of lung cancers, frequently containing mutations within the tyrosine kinase domain of EGFR that are associated with kinase inhibitor sensitivity. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15329413" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><a href="#28" class="mim-tip-reference" title="Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., Digumarthy, S., Muzikansky, A., Irimia, D., Settleman, J., Tompkins, R. G., Lynch, T. J., Toner, M., Haber, D. A. <strong>Detection of mutations in EGFR in circulating lung-cancer cells.</strong> New Eng. J. Med. 359: 366-377, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18596266/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18596266</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=18596266[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1056/NEJMoa0800668" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18596266">Maheswaran et al. (2008)</a> identified the EGFR T790M (<a href="/entry/131550#0006">131550.0006</a>) mutation in pretreatment tumor samples from 10 (38%) of 26 patients with nonsmall cell lung cancer. Although low levels of the drug-resistant mutation did not preclude response to treatment, it was highly correlated with reduced progression-free survival. Use of a microfluidic-based isolation device and sequence amplification technology allowed for detection of EGFR mutations in circulating tumor cells from 11 (92%) of 12 patients. Serial analysis of circulating tumor cells showed that a reduction in the number of captured cells was associated with a radiographic tumor response; an increase in the number of cells was associated with tumor progression, with the emergence of additional EGFR mutations in some cases. <a href="#28" class="mim-tip-reference" title="Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., Digumarthy, S., Muzikansky, A., Irimia, D., Settleman, J., Tompkins, R. G., Lynch, T. J., Toner, M., Haber, D. A. <strong>Detection of mutations in EGFR in circulating lung-cancer cells.</strong> New Eng. J. Med. 359: 366-377, 2008.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18596266/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18596266</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=18596266[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1056/NEJMoa0800668" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="18596266">Maheswaran et al. (2008)</a> concluded that molecular analysis of circulating tumor cells from the blood of patients with EGFR-related nonsmall cell lung cancer could offer the possibility of monitoring changes in tumor genotype. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18596266" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>MET Amplification and Drug Resistance in Lung Cancer</em></strong></p><p>
|
|
The EGFR kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. <a href="#16" class="mim-tip-reference" title="Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., Janne, P. A. <strong>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</strong> Science 316: 1039-1043, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17463250/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17463250</a>] [<a href="https://doi.org/10.1126/science.1141478" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17463250">Engelman et al. (2007)</a> described a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET (<a href="/entry/164860">164860</a>) protooncogene. Inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 (22%) of 18 lung cancer specimens that had developed resistance to gefitinib or erlotinib. <a href="#16" class="mim-tip-reference" title="Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., Janne, P. A. <strong>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</strong> Science 316: 1039-1043, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17463250/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17463250</a>] [<a href="https://doi.org/10.1126/science.1141478" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17463250">Engelman et al. (2007)</a> found that amplification of MET caused gefitinib resistance by driving ERBB3 (<a href="/entry/190151">190151</a>)-dependent activation of phosphoinositide 3-kinase, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, <a href="#16" class="mim-tip-reference" title="Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., Janne, P. A. <strong>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</strong> Science 316: 1039-1043, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17463250/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17463250</a>] [<a href="https://doi.org/10.1126/science.1141478" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17463250">Engelman et al. (2007)</a> proposed that MET amplification may promote drug resistance in other ERBB-driven cancers as well. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17463250" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>KRAS Mutations and Lung Adenocarcinoma</em></strong></p><p>
|
|
In a study of 106 prospectively enrolled patients with primary adenocarcinoma of the lung, <a href="#1" class="mim-tip-reference" title="Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Y., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J., Sidransky, D. <strong>Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.</strong> Cancer 92: 1525-1530, 2001.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/11745231/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">11745231</a>] [<a href="https://doi.org/10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="11745231">Ahrendt et al. (2001)</a> found that 92 (87%) were smokers. KRAS mutations were detected in 40 (38%) of 106 tumors and were significantly more common in smokers compared with nonsmokers (43% vs 0%; P = 0.001). Thirty-nine of the 40 tumors with KRAS mutations had 1 of 4 changes in codon 12, the most common being gly12 to cys (<a href="/entry/190070#0001">190070.0001</a>), which was present in 25. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=11745231" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>BRAF Mutations and Lung Adenocarcinoma</em></strong></p><p>
|
|
Mutations of the BRAF protein serine/threonine kinase gene (<a href="/entry/164757">164757</a>) have been identified in a variety of human cancers, most notably melanomas. <a href="#31" class="mim-tip-reference" title="Naoki, K., Chen, T.-H., Richards, W. G., Sugarbaker, D. J., Meyerson, M. <strong>Missense mutations of the BRAF gene in human lung adenocarcinoma.</strong> Cancer Res. 62: 7001-7003, 2002.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12460919/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12460919</a>]" pmid="12460919">Naoki et al. (2002)</a> analyzed the BRAF sequence in 127 primary human lung adenocarcinomas and found mutations in 2 tumor specimens, one in exon 11 (<a href="/entry/164757#0006">164757.0006</a>) and another in exon 15 (<a href="/entry/164757#0007">164757.0007</a>). The specimens belonged to the same adenocarcinoma subgroup as defined by clustering of gene expression data. The authors proposed that BRAF may provide a target for anticancer chemotherapy in a subset of lung adenocarcinoma patients. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12460919" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>ERBB2 Mutations and Lung Cancer</em></strong></p><p>
|
|
The <a href="#12" class="mim-tip-reference" title="Cancer Genome Project and Collaborative Group. <strong>Intragenic ERBB2 kinase mutations in tumours.</strong> Nature 431: 525-526, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15457249/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15457249</a>] [<a href="https://doi.org/10.1038/431525b" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15457249">Cancer Genome Project and Collaborative Group (2004)</a> sequenced the ERBB2 gene from 120 primary lung tumors and identified 4% that had mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. In-frame deletions within the kinase domain of EGFR (e.g., <a href="/entry/131550#0001">131550.0001</a>) are associated with lung tumors that respond to therapy with gefitinib, an EGFR inhibitor. The <a href="#12" class="mim-tip-reference" title="Cancer Genome Project and Collaborative Group. <strong>Intragenic ERBB2 kinase mutations in tumours.</strong> Nature 431: 525-526, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15457249/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15457249</a>] [<a href="https://doi.org/10.1038/431525b" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15457249">Cancer Genome Project and Collaborative Group (2004)</a> suggested that ERBB2 inhibitors, which had to that time proved to be ineffective in treating lung cancer, should be clinically reevaluated in the specific subset of patients with lung cancer whose tumors carry ERBB2 mutations. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15457249" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>STK11 Mutations and Lung Cancer</em></strong></p><p>
|
|
<a href="#22" class="mim-tip-reference" title="Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., and 22 others. <strong>LKB1 modulates lung cancer differentiation and metastasis.</strong> Nature 448: 807-810, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17676035/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17676035</a>] [<a href="https://doi.org/10.1038/nature06030" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17676035">Ji et al. (2007)</a> used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 (STK11; <a href="/entry/602216">602216</a>) to other tumor suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (CDKN2A; <a href="/entry/600160">600160</a>), in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumors demonstrated shorter latency, an expanded histologic spectrum (adeno-, squamous, and large-cell carcinoma), and more frequent metastasis compared to tumors lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analyzed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumors identified a variety of metastasis-promoting genes, such as NEDD9 (<a href="/entry/602265">602265</a>), VEGFC (<a href="/entry/601528">601528</a>), and CD24 (<a href="/entry/600074">600074</a>), as targets of LKB1 repression in lung cancer. <a href="#22" class="mim-tip-reference" title="Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., and 22 others. <strong>LKB1 modulates lung cancer differentiation and metastasis.</strong> Nature 448: 807-810, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17676035/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17676035</a>] [<a href="https://doi.org/10.1038/nature06030" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17676035">Ji et al. (2007)</a> concluded that their studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation, and metastasis. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17676035" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>PIK3CA Mutations and Lung Cancer</em></strong></p><p>
|
|
<a href="#41" class="mim-tip-reference" title="Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K. V., Markowitz, S., Kinzler, K. W., Vogelstein, B., Velculescu, V. E. <strong>High frequency of mutations of the PIK3CA gene in human cancers.</strong> Science 304: 554 only, 2004.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15016963/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15016963</a>] [<a href="https://doi.org/10.1126/science.1096502" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15016963">Samuels et al. (2004)</a> identified a somatic mutation in the PIK3CA gene (<a href="/entry/171834">171834</a>) in 1 (4%) of 24 lung cancers examined. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15016963" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>NKX2-1 Amplification and Lung Adenocarcinoma</em></strong></p><p>
|
|
<a href="#48" class="mim-tip-reference" title="Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., and 58 others. <strong>Characterizing the cancer genome in lung adenocarcinoma.</strong> Nature 450: 893-898, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17982442/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17982442</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17982442[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature06358" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17982442">Weir et al. (2007)</a> reported a large-scale project to characterize copy number alterations in primary lung adenocarcinomas. By analysis of 371 tumors using dense single-nucleotide polymorphism arrays, <a href="#48" class="mim-tip-reference" title="Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., and 58 others. <strong>Characterizing the cancer genome in lung adenocarcinoma.</strong> Nature 450: 893-898, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17982442/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17982442</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17982442[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature06358" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17982442">Weir et al. (2007)</a> identified 57 significantly recurrent events. <a href="#48" class="mim-tip-reference" title="Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., and 58 others. <strong>Characterizing the cancer genome in lung adenocarcinoma.</strong> Nature 450: 893-898, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17982442/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17982442</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17982442[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature06358" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17982442">Weir et al. (2007)</a> found that 26 of 39 autosomal chromosome arms showed consistent large-scale copy number gain or loss, of which only a handful had been linked to a specific gene. They also identified 31 recurrent focal events, including 24 amplifications and 7 homozygous deletions. Only 6 of these focal events were associated with mutations in lung carcinomas. The most common event, amplification of chromosome 14q13.3, was found in about 12% of samples. On the basis of genomic and functional analyses, <a href="#48" class="mim-tip-reference" title="Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., and 58 others. <strong>Characterizing the cancer genome in lung adenocarcinoma.</strong> Nature 450: 893-898, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17982442/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17982442</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17982442[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/nature06358" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17982442">Weir et al. (2007)</a> identified NKX2-1 (<a href="/entry/600635">600635</a>), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate protooncogene involved in a significant fraction of lung adenocarcinomas. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17982442" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>HMOX1 Polymorphism and Susceptibility to Lung Adenocarcinoma</em></strong></p><p>
|
|
<a href="#25" class="mim-tip-reference" title="Kikuchi, A., Yamaya, M., Suzuki, S., Yasuda, H., Kubo, H., Nakayama, K., Handa, M., Sasaki, T., Shibahara, S., Sekizawa, K., Sasaki, H. <strong>Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism.</strong> Hum. Genet. 116: 354-360, 2005.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15688187/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15688187</a>] [<a href="https://doi.org/10.1007/s00439-004-1162-2" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15688187">Kikuchi et al. (2005)</a> screened the heme oxygenase-1 gene (HMOX1; <a href="/entry/141250">141250</a>) for (GT)n repeat length in 151 Japanese patients with lung adenocarcinoma and 153 controls. The proportion of L allele carriers was significantly higher among patients than controls (p = 0.02); the adjusted odds ratio for lung adenocarcinoma for L allele carriers was 1.8 (95% CI, 1.1-3.0) compared with non-L allele carriers. The risk of lung adenocarcinoma for L allele carriers versus non-L allele carriers was greatly increased in the group of male smokers (OR = 3.3; 95% CI, 1.5-7.4; p = 0.004); however, in female nonsmokers, the proportion of L allele carriers did not differ between patients and controls, nor did it differ between 108 patients with lung squamous cell carcinoma and 100 controls. <a href="#25" class="mim-tip-reference" title="Kikuchi, A., Yamaya, M., Suzuki, S., Yasuda, H., Kubo, H., Nakayama, K., Handa, M., Sasaki, T., Shibahara, S., Sekizawa, K., Sasaki, H. <strong>Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism.</strong> Hum. Genet. 116: 354-360, 2005.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15688187/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15688187</a>] [<a href="https://doi.org/10.1007/s00439-004-1162-2" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15688187">Kikuchi et al. (2005)</a> suggested that a large (GT)n repeat in the HMOX1 gene promoter may be associated with the development of lung adenocarcinoma in Japanese male smokers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15688187" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>CDKN1A Polymorphism and Susceptibility to Lung Cancer</em></strong></p><p>
|
|
<a href="#43" class="mim-tip-reference" title="Sjalander, A., Birgander, R., Rannug, A., Alexandrie, A.-K., Tornling, G., Beckman, G. <strong>Association between the p21 codon 31A1 (arg) allele and lung cancer.</strong> Hum. Hered. 46: 221-225, 1996.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8807325/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8807325</a>] [<a href="https://doi.org/10.1159/000154357" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="8807325">Sjalander et al. (1996)</a> found an increased frequency of the p21 arg31 allele (<a href="/entry/116899#0001">116899.0001</a>) in lung cancer patients, especially in comparison with patients with chronic obstructive pulmonary disease (COPD); p = 0.004. Thus allelic variants of both p53 and its effector protein p21 may have an influence on lung cancer. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8807325" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>GSTM1 Polymorphism and Susceptibility to Lung Cancer</em></strong></p><p>
|
|
<a href="#4" class="mim-tip-reference" title="Bennett, W. P., Alavanja, M. C. R., Blomeke, B., Vahakangas, K. H., Castren, K., Welsh, J. A., Bowman, E. D., Khan, M. A., Flieder, D. B., Harris, C. C. <strong>Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women.</strong> J. Nat. Cancer Inst. 91: 2009-2014, 1999.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10580025/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10580025</a>] [<a href="https://doi.org/10.1093/jnci/91.23.2009" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="10580025">Bennett et al. (1999)</a> studied genes whose products activate (CYP1A1; <a href="/entry/108330">108330</a>) or detoxify (GSTM1, <a href="/entry/138350">138350</a>; GSTT1, <a href="/entry/600436">600436</a>) chemical carcinogens found in tobacco smoke in never-smoking women who were exposed to environmental tobacco smoke (ETS) and developed lung cancer. Archival, paraffin-embedded, and DNA yielding, surgically resected lung cancer tissues were obtained from 106 white women who never smoked and developed lung cancer. When compared with 55 never smokers who developed lung cancer without ETS exposure, 51 never smokers who developed lung cancer with ETS exposure were more likely to be GSTM1-null homozygotes (OR, 2.6; 95% CI, 1.1-6.1). No evidence was found of associations between lung cancer risk due to ETS exposure and GSTT1 deficiency or the CYP1A1 valine variant. The authors concluded that white women who never smoke and are homozygous for the GSTM1 null allele, which occurs in about 50% of the white population, have a statistically significant greater risk of developing lung cancer from ETS. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10580025" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>FAS and FASL Polymorphisms and Susceptibility to Lung Cancer</em></strong></p><p>
|
|
<a href="#54" class="mim-tip-reference" title="Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y., Lin, D. <strong>Functional polymorphisms in cell death pathway genes FAS and FASL contribute to the risk of lung cancer.</strong> J. Med. Genet. 42: 479-484, 2005.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15937082/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15937082</a>] [<a href="https://doi.org/10.1136/jmg.2004.030106" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15937082">Zhang et al. (2005)</a> genotyped 1,000 Han Chinese lung cancer patients and 1,270 controls for 2 functional polymorphisms in the promoter regions of the FAS and FASL genes, -1377G-A (TNFRSF6; <a href="/entry/134637#0021">134637.0021</a>) and -844T-C (TNFSF6; <a href="/entry/134638#0002">134638.0002</a>), respectively. Compared to noncarriers, there was a 1.6-fold increased risk of developing lung cancer for carriers of the FAS -1377AA genotype and a 1.8-fold increased risk for carriers of the FASL -844CC genotype. Carriers of both homozygous genotypes had a more than 4-fold increased risk, indicative of multiplicative gene-gene interaction; the increased risk was consistently observed in all subtypes of lung cancer. <a href="#54" class="mim-tip-reference" title="Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y., Lin, D. <strong>Functional polymorphisms in cell death pathway genes FAS and FASL contribute to the risk of lung cancer.</strong> J. Med. Genet. 42: 479-484, 2005.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15937082/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15937082</a>] [<a href="https://doi.org/10.1136/jmg.2004.030106" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="15937082">Zhang et al. (2005)</a> stated that these results support the hypothesis that the FAS- and FASL-triggered apoptosis pathway plays an important role in human carcinogenesis. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15937082" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>CASP8 Polymorphism and Protection Against Lung Cancer</em></strong></p><p>
|
|
Caspases are important in the life and death of immune cells and therefore influence immune surveillance of malignancies. Using a haplotype-tagging SNP approach, <a href="#45" class="mim-tip-reference" title="Sun, T., Gao, Y., Tan, W., Ma, S., Shi, Y., Yao, J., Guo, Y., Yang, M., Zhang, X., Zhang, Q., Zeng, C., Lin, D. <strong>A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.</strong> Nature Genet. 39: 605-613, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17450141/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17450141</a>] [<a href="https://doi.org/10.1038/ng2030" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17450141">Sun et al. (2007)</a> identified a 6-nucleotide deletion (-652 6N del) variant in the CASP8 promoter (<a href="/entry/601763#0004">601763.0004</a>) associated with decreased risk of lung cancer in a population of Han Chinese subjects. The deletion destroyed a binding site for stimulatory protein-1 (SP1; <a href="/entry/189906">189906</a>) and decreased transcription. Biochemical analyses showed that T lymphocytes with the deletion variant had lower caspase-8 activity and activation-induced cell death upon stimulation with cancer cell antigens. Case-control analyses of 4,995 individuals with cancer and 4,972 controls in a Chinese population showed that this genetic variant is associated with reduced susceptibility to multiple cancers, including lung, esophageal, gastric, colorectal, cervical, and breast cancers, acting in an allele dose-dependent manner. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17450141" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>CYP2A6 Polymorphism and Protection Against Lung Cancer</em></strong></p><p>
|
|
<a href="#29" class="mim-tip-reference" title="Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N., Kamataki, T. <strong>CYP2A6 gene deletion reduces susceptibility to lung cancer.</strong> Biochem. Biophys. Res. Commun. 261: 658-660, 1999.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10441482/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10441482</a>] [<a href="https://doi.org/10.1006/bbrc.1999.1089" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="10441482">Miyamoto et al. (1999)</a> studied the relationship between genetic polymorphism of the CYP2A6 gene (<a href="/entry/122720">122720</a>) and lung cancer risk in a case-control study of Japanese. They found that the frequency of subjects homozygous for the CYP2A6 gene deletion (<a href="/entry/122720#0002">122720.0002</a>), which causes lack of the enzyme activity, was lower in the lung cancer patients than in the healthy control subjects. These findings suggested that deficient CYP2A6 activity due to genetic polymorphism reduces lung cancer risk. <a href="#32" class="mim-tip-reference" title="Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q.-Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O., Ingelman-Sundberg, M. <strong>Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.</strong> FEBS Lett. 448: 105-110, 1999.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10217419/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10217419</a>] [<a href="https://doi.org/10.1016/s0014-5793(99)00359-2" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="10217419">Oscarson et al. (1999)</a> found that this deletion allele was rare in Europeans but had a frequency of 15.1% among 96 Chinese subjects. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=10441482+10217419" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>MPO Polymorphism and Protection Against Lung Cancer in Smokers</em></strong></p><p>
|
|
<a href="#46" class="mim-tip-reference" title="Taioli, E., Benhamou, S., Bouchardy, C., Cascorbi, I., Cajas-Salazar, N., Dally, H., Fong, K. M., Larsen, J. E., Le Marchand, L., London, S. J., Risch, A., Spitz, M. R., Stucker, I., Weinshenker, B., Wu, X., Yang, P. <strong>Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis.</strong> Genet. Med. 9: 67-73, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17304047/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17304047</a>] [<a href="https://doi.org/10.1097/gim.0b013e31803068b1" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17304047">Taioli et al. (2007)</a> found that the -463G/A polymorphism in the MPO gene (<a href="/entry/606989#0008">606989.0008</a>) conferred resistance to lung cancer among smokers. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17304047" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>SOX2 Amplification in Lung Cancer</em></strong></p><p>
|
|
<a href="#3" class="mim-tip-reference" title="Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., Ramos, A. H., Woo, M. S., and 36 others. <strong>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</strong> Nature Genet. 41: 1238-1242, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19801978/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19801978</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19801978[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.465" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19801978">Bass et al. (2009)</a> showed that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas of the lung and esophagus contains the transcription factor gene SOX2 (<a href="/entry/184429">184429</a>), which is necessary for normal esophageal squamous development (<a href="#37" class="mim-tip-reference" title="Que, J., Okubo, T., Goldenring, J. R., Nam, K.-T., Kurotani, R., Morrisey, E. E., Taranova, O., Pevny, L. H., Hogan, B. L. M. <strong>Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm.</strong> Development 134: 2521-2531, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17522155/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17522155</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17522155[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1242/dev.003855" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17522155">Que et al., 2007</a>) and differentiation and proliferation of basal tracheal cells (<a href="#36" class="mim-tip-reference" title="Que, J., Luo, X., Schwartz, R. J., Hogan, B. L. M. <strong>Multiple roles for Sox2 in the developing and adult mouse trachea.</strong> Development 136: 1899-1907, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19403656/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19403656</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19403656[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1242/dev.034629" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19403656">Que et al., 2009</a>), and cooperates in induction of pluripotent stem cells, as summarized by <a href="#3" class="mim-tip-reference" title="Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., Ramos, A. H., Woo, M. S., and 36 others. <strong>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</strong> Nature Genet. 41: 1238-1242, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19801978/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19801978</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19801978[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.465" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19801978">Bass et al. (2009)</a>. <a href="#3" class="mim-tip-reference" title="Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., Ramos, A. H., Woo, M. S., and 36 others. <strong>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</strong> Nature Genet. 41: 1238-1242, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19801978/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19801978</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19801978[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.465" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19801978">Bass et al. (2009)</a> found that SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 in this study cooperated with FOXE1 (<a href="/entry/602617">602617</a>) or FGFR2 (<a href="/entry/176943">176943</a>) to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors showed expression of markers of both squamous differentiation and pluripotency. <a href="#3" class="mim-tip-reference" title="Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., Ramos, A. H., Woo, M. S., and 36 others. <strong>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</strong> Nature Genet. 41: 1238-1242, 2009.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19801978/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19801978</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19801978[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.465" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="19801978">Bass et al. (2009)</a> concluded that these characteristics identified SOX2 as a lineage-survival oncogene in lung and esophageal squamous cell carcinoma. <a href="https://pubmed.ncbi.nlm.nih.gov/?term=17522155+19403656+19801978" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>DOK2 Deletion in Lung Cancer</em></strong></p><p>
|
|
<a href="#5" class="mim-tip-reference" title="Berger, A. H., Niki, M., Morotti, A., Taylor, B. S., Socci, N. D., Viale, A., Brennan, C., Szoke, J., Motoi, N., Rothman, P. B., Teruya-Feldstein, J., Gerald, W. L., Ladanyi, M., Pandolfi, P. P. <strong>Identification of DOK genes as lung tumor suppressors.</strong> Nature Genet. 42: 216-223, 2010.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/20139980/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">20139980</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=20139980[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.527" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="20139980">Berger et al. (2010)</a> showed that, of 199 primary human lung adenocarcinoma samples, 37% showed a deletion of 1 copy of the DOK2 gene (<a href="/entry/604997">604997</a>) , which maps to chromosome 8p21.3, one of the regions most frequently deleted in human lung cancer. The deletion correlated with loss of DOK2 protein expression. Loss of the DOK1 gene (<a href="/entry/602919">602919</a>), which maps to chromosome 2p13.1, occurred in 1.5% of samples, and loss of the DOK3 gene (<a href="/entry/611435">611435</a>), which maps to chromosome 5q35.3, occurred in 7.0% of samples. Further studies in mice showed that haploinsufficiency of Dok2 was sufficient for tumor formation, as the wildtype allele was retained in most tumor samples. <a href="#5" class="mim-tip-reference" title="Berger, A. H., Niki, M., Morotti, A., Taylor, B. S., Socci, N. D., Viale, A., Brennan, C., Szoke, J., Motoi, N., Rothman, P. B., Teruya-Feldstein, J., Gerald, W. L., Ladanyi, M., Pandolfi, P. P. <strong>Identification of DOK genes as lung tumor suppressors.</strong> Nature Genet. 42: 216-223, 2010.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/20139980/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">20139980</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=20139980[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1038/ng.527" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="20139980">Berger et al. (2010)</a> suggested a tumor-suppressor role for DOK2 in human lung cancer. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=20139980" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>C10ORF97 Polymorphism and Susceptibility to Nonsmall Cell Lung Cancer</em></strong></p><p>
|
|
<a href="#42" class="mim-tip-reference" title="Shi, Y., Chen, J., Li, Z., Zhang, Z., Yu, H., Sun, K., Wang, X., Song, X., Wang, Y., Zhen, Y., Yang, T., Lou, K., Zhang, Y., Zhang, G., Hu, Y., Ji, J., Hui, R. <strong>C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.</strong> Oncogene 30: 4107-4117, 2011.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21499297/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21499297</a>] [<a href="https://doi.org/10.1038/onc.2011.116" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="21499297">Shi et al. (2011)</a> identified a 216C-T SNP (<a href="https://www.ensembl.org/Homo_sapiens/Variation/Summary?v=rs2297882;toggle_HGVS_names=open" target="_blank" onclick="gtag(\'event\', \'mim_outbound\', {\'name\': \'dbSNP\', \'domain\': \'ensembl.org\'})">rs2297882</a>) in the promoter region of the C10ORF97 gene (<a href="/entry/611649">611649</a>) that affected the efficiency of translation. The T allele was associated with lower protein levels than the C allele. Genotyping of 418 Chinese patients with nonsmall cell lung cancer and 743 controls showed an association between the TT genotype and lung cancer compared to the TC or CC genotype (odds ratio of 1.73, p = 4.6 x 10(-5)). The findings suggested that C10ORF97 may act as a tumor suppressor gene, and that low levels of it may be associated with tumorigenesis. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21499297" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<a id="cytogenetics" class="mim-anchor"></a>
|
|
<h4 href="#mimCytogeneticsFold" id="mimCytogeneticsToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span id="mimCytogeneticsToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<span class="mim-font">
|
|
<strong>Cytogenetics</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<div id="mimCytogeneticsFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<p><strong><em>ALK/EML4 Fusion Gene</em></strong></p><p>
|
|
<a href="#44" class="mim-tip-reference" title="Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H. <strong>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.</strong> Nature 448: 561-566, 2007.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17625570/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17625570</a>] [<a href="https://doi.org/10.1038/nature05945" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="17625570">Soda et al. (2007)</a> identified a fusion gene, ALK/EML4 (see <a href="/entry/105590">105590</a>), that was present in 5 of 75 Japanese nonsmall cell lung cancer patients examined. None of these patients had mutations in EGFR. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17625570" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p><p><strong><em>Copy Number Variation at the MAPKAPK2 Locus</em></strong></p><p>
|
|
<a href="#26" class="mim-tip-reference" title="Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Li, W., Zhou, Y., Lu, J. <strong>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.</strong> Am. J. Hum. Genet. 91: 384-390, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22883146/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22883146</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22883146[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1016/j.ajhg.2012.07.003" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22883146">Liu et al. (2012)</a> investigated the role in lung cancer of a copy number variant (CNV), g.CNV-30450, which spans the MAPKAPK2 (<a href="/entry/602006">602006</a>) promoter region and has 1.7-kb sequences from -1098 to approximately +664 nucleotides to the initiation transcription codon. This variant was found to have an allele frequency of 6/30 (0.20) in the Database of Genetic Variants. The authors detected 2, 3, or 4 copies of g.CNV-30450 among 4,789 Chinese individuals. <a href="#26" class="mim-tip-reference" title="Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Li, W., Zhou, Y., Lu, J. <strong>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.</strong> Am. J. Hum. Genet. 91: 384-390, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22883146/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22883146</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22883146[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1016/j.ajhg.2012.07.003" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22883146">Liu et al. (2012)</a> investigated the association between cancer risk and g.CNV-30450 in 3 independent case-control studies of 2,332 individuals with lung cancer and 2,457 controls, and also studied the effects of this CNV on cancer prognosis in 1,137 individuals with lung cancer with survival data in Southern and Eastern Chinese populations. <a href="#26" class="mim-tip-reference" title="Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Li, W., Zhou, Y., Lu, J. <strong>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.</strong> Am. J. Hum. Genet. 91: 384-390, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22883146/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22883146</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22883146[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1016/j.ajhg.2012.07.003" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22883146">Liu et al. (2012)</a> found that those subjects who had 4 copies of g.CNV-30450 had an increased cancer risk (OR = 1.94, 95% CI = 1.61-2.35) and, in individuals with lung cancer, a worse prognosis (with a median survival time of only 9 months) (hazard ratio = 1.47, 95% CI = 1.22-1.78) compared with those with 2 or 3 copies (with a median survival time of 14 months). <a href="#26" class="mim-tip-reference" title="Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Li, W., Zhou, Y., Lu, J. <strong>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.</strong> Am. J. Hum. Genet. 91: 384-390, 2012.[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22883146/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22883146</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22883146[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>] [<a href="https://doi.org/10.1016/j.ajhg.2012.07.003" target="_blank" onclick="gtag('event', 'mim_outbound', {'destination': 'Publisher'})">Full Text</a>]" pmid="22883146">Liu et al. (2012)</a> also showed that 4 copies of g.CNV-30450 significantly increased MAPKAPK2 expression, both in vitro and in vivo, compared with 2 or 3 copies. <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=22883146" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})"><span class="glyphicon glyphicon-plus-sign mim-tip-hint" title="Click this 'reference-plus' icon to see articles related to this paragraph in PubMed."></span></a></p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="seeAlso" class="mim-anchor"></a>
|
|
<h4 href="#mimSeeAlsoFold" id="mimSeeAlsoToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span class="mim-font">
|
|
<span id="mimSeeAlsoToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<strong>See Also:</strong>
|
|
</span>
|
|
</h4>
|
|
<div id="mimSeeAlsoFold" class="collapse in mimTextToggleFold">
|
|
<span class="mim-text-font">
|
|
<a href="#Brisman1967" class="mim-tip-reference" title="Brisman, R., Baker, R. R., Elkins, R., Hartmann, W. H. <strong>Carcinoma of lung in four siblings.</strong> Cancer 20: 2048-2053, 1967.">Brisman et al. (1967)</a>; <a href="#Goffman1982" class="mim-tip-reference" title="Goffman, T. E., Hassinger, D. D., Mulvihill, J. J. <strong>Familial respiratory tract cancer: opportunities for research and prevention.</strong> JAMA 247: 1020-1023, 1982.">Goffman et al. (1982)</a>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="references"class="mim-anchor"></a>
|
|
<h4 href="#mimReferencesFold" id="mimReferencesToggle" class="mimTriangleToggle" style="cursor: pointer;" data-toggle="collapse">
|
|
<span class="mim-font">
|
|
<span id="mimReferencesToggleTriangle" class="small mimTextToggleTriangle">▼</span>
|
|
<strong>REFERENCES</strong>
|
|
</span>
|
|
</h4>
|
|
<div>
|
|
<p />
|
|
</div>
|
|
|
|
<div id="mimReferencesFold" class="collapse in mimTextToggleFold">
|
|
<ol>
|
|
|
|
<li>
|
|
<a id="1" class="mim-anchor"></a>
|
|
<a id="Ahrendt2001" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Y., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J., Sidransky, D.
|
|
<strong>Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.</strong>
|
|
Cancer 92: 1525-1530, 2001.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/11745231/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">11745231</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=11745231" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="2" class="mim-anchor"></a>
|
|
<a id="Bailey-Wilson2004" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Bailey-Wilson, J. E., Amos, C. I., Pinney, S. M., Petersen, G. M., de Andrade, M., Wiest, J. S., Fain, P., Schwartz, A. G., You, M., Franklin, W., Klein, C., Gazdar, A., and 15 others.
|
|
<strong>A major lung cancer susceptibility locus maps to chromosome 6q23-25.</strong>
|
|
Am. J. Hum. Genet. 75: 460-474, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15272417/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15272417</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15272417[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15272417" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1086/423857" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="3" class="mim-anchor"></a>
|
|
<a id="Bass2009" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., Ramos, A. H., Woo, M. S., and 36 others.
|
|
<strong>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</strong>
|
|
Nature Genet. 41: 1238-1242, 2009.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19801978/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19801978</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19801978[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19801978" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/ng.465" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="4" class="mim-anchor"></a>
|
|
<a id="Bennett1999" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Bennett, W. P., Alavanja, M. C. R., Blomeke, B., Vahakangas, K. H., Castren, K., Welsh, J. A., Bowman, E. D., Khan, M. A., Flieder, D. B., Harris, C. C.
|
|
<strong>Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women.</strong>
|
|
J. Nat. Cancer Inst. 91: 2009-2014, 1999.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10580025/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10580025</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10580025" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1093/jnci/91.23.2009" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="5" class="mim-anchor"></a>
|
|
<a id="Berger2010" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Berger, A. H., Niki, M., Morotti, A., Taylor, B. S., Socci, N. D., Viale, A., Brennan, C., Szoke, J., Motoi, N., Rothman, P. B., Teruya-Feldstein, J., Gerald, W. L., Ladanyi, M., Pandolfi, P. P.
|
|
<strong>Identification of DOK genes as lung tumor suppressors.</strong>
|
|
Nature Genet. 42: 216-223, 2010.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/20139980/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">20139980</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=20139980[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=20139980" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/ng.527" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="6" class="mim-anchor"></a>
|
|
<a id="Bivona2011" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., Sawyers, C. L.
|
|
<strong>FAS and NF-kappa-B signalling modulate dependence of lung cancers on mutant EGFR.</strong>
|
|
Nature 471: 523-526, 2011.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21430781/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21430781</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21430781[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21430781" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature09870" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="7" class="mim-anchor"></a>
|
|
<a id="Braun1994" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Braun, M. M., Caporaso, N. E., Page, W. F., Hoover, R. N.
|
|
<strong>Genetic component of lung cancer: cohort study of twins.</strong>
|
|
Lancet 344: 440-443, 1994.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/7914565/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">7914565</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7914565" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1016/s0140-6736(94)91770-1" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="8" class="mim-anchor"></a>
|
|
<a id="Brisman1967" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Brisman, R., Baker, R. R., Elkins, R., Hartmann, W. H.
|
|
<strong>Carcinoma of lung in four siblings.</strong>
|
|
Cancer 20: 2048-2053, 1967.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6061638/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6061638</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6061638" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1002/1097-0142(196711)20:11<2048::aid-cncr2820201134>3.0.co;2-a" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="9" class="mim-anchor"></a>
|
|
<a id="Brock2008" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glockner, S., Piantadosi, S., Gabrielson, E., Pridham, G., Pelosky, K., Belinsky, S. A., Yang, S. C., Baylin, S. B., Herman, J. G.
|
|
<strong>DNA methylation markers and early recurrence in stage I lung cancer.</strong>
|
|
New Eng. J. Med. 358: 1118-1128, 2008.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18337602/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18337602</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18337602" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMoa0706550" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="10" class="mim-anchor"></a>
|
|
<a id="{Cancer Genome Atlas Research Network}2012" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Cancer Genome Atlas Research Network.
|
|
<strong>Comprehensive genomic characterization of squamous cell lung cancers.</strong>
|
|
Nature 489: 519-525, 2012. Note: Erratum: Nature 491: 288 only, 2012.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22960745/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22960745</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22960745[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=22960745" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature11404" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="11" class="mim-anchor"></a>
|
|
<a id="{Cancer Genome Atlas Research Network}2014" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Cancer Genome Atlas Research Network.
|
|
<strong>Comprehensive molecular profiling of lung adenocarcinoma.</strong>
|
|
Nature 511: 543-550, 2014. Note: Erratum: Nature 514: 262 only, 2014. Erratum: Nature 559: E12, 2018.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25079552/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25079552</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=25079552" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature13385" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="12" class="mim-anchor"></a>
|
|
<a id="{Cancer Genome Project and Collaborative Group}2004" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Cancer Genome Project and Collaborative Group.
|
|
<strong>Intragenic ERBB2 kinase mutations in tumours.</strong>
|
|
Nature 431: 525-526, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15457249/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15457249</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15457249" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/431525b" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="13" class="mim-anchor"></a>
|
|
<a id="Dai2003" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Dai, Z., Zhu, W.-G., Morrison, C. D., Brena, R. M., Smiraglia, D. J., Raval, A., Wu, Y.-Z., Rush, L. J., Ross, P., Molina, J. R., Otterson, G. A., Plass, C.
|
|
<strong>A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes.</strong>
|
|
Hum. Molec. Genet. 12: 791-801, 2003.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12651874/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12651874</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12651874" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1093/hmg/ddg083" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="14" class="mim-anchor"></a>
|
|
<a id="de Bruin2014" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., Gronroos, E., Muhammad, M. A., and 31 others.
|
|
<strong>Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.</strong>
|
|
Science 346: 251-256, 2014.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25301630/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25301630</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=25301630[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=25301630" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1126/science.1253462" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="15" class="mim-anchor"></a>
|
|
<a id="Ding2008" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., and 78 others.
|
|
<strong>Somatic mutations affect key pathways in lung adenocarcinoma.</strong>
|
|
Nature 455: 1069-1075, 2008.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18948947/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18948947</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=18948947[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18948947" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature07423" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="16" class="mim-anchor"></a>
|
|
<a id="Engelman2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., Janne, P. A.
|
|
<strong>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</strong>
|
|
Science 316: 1039-1043, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17463250/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17463250</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17463250" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1126/science.1141478" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="17" class="mim-anchor"></a>
|
|
<a id="Fukuoka2003" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.-P., Baselga, J.
|
|
<strong>Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial).</strong>
|
|
J. Clin. Oncol. 21: 2237-2246, 2003. Note: Erratum: J. Clin. Oncol. 22: 4863 only, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12748244/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12748244</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12748244" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1200/JCO.2003.10.038" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="18" class="mim-anchor"></a>
|
|
<a id="Goffman1982" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Goffman, T. E., Hassinger, D. D., Mulvihill, J. J.
|
|
<strong>Familial respiratory tract cancer: opportunities for research and prevention.</strong>
|
|
JAMA 247: 1020-1023, 1982.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/7057577/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">7057577</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=7057577" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="19" class="mim-anchor"></a>
|
|
<a id="Haiman2006" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E., Le Marchand, L.
|
|
<strong>Ethnic and racial differences in the smoking-related risk of lung cancer.</strong>
|
|
New Eng. J. Med. 354: 333-342, 2006.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16436765/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16436765</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16436765" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMoa033250" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="20" class="mim-anchor"></a>
|
|
<a id="Herbst2008" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Herbst, R. S., Heymach, J. V., Lippman, S. M.
|
|
<strong>Lung cancer.</strong>
|
|
New Eng. J. Med. 359: 1367-1380, 2008.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18815398/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18815398</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18815398" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMra0802714" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="21" class="mim-anchor"></a>
|
|
<a id="Hwang2003" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Hwang, S.-J., Cheng, L. S.-C., Lozano, G., Amos, C. I., Gu, X., Strong, L. C.
|
|
<strong>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk.</strong>
|
|
Hum. Genet. 113: 238-243, 2003.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12802680/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12802680</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12802680" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1007/s00439-003-0968-7" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="22" class="mim-anchor"></a>
|
|
<a id="Ji2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., and 22 others.
|
|
<strong>LKB1 modulates lung cancer differentiation and metastasis.</strong>
|
|
Nature 448: 807-810, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17676035/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17676035</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17676035" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature06030" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="23" class="mim-anchor"></a>
|
|
<a id="Joishy1977" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Joishy, S. K., Cooper, R. A., Rowley, P. T.
|
|
<strong>Alveolar cell carcinoma in identical twins: similarity in time of onset, histochemistry, and site of metastasis.</strong>
|
|
Ann. Intern. Med. 87: 447-450, 1977.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/199100/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">199100</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=199100" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.7326/0003-4819-87-4-447" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="24" class="mim-anchor"></a>
|
|
<a id="Kan2010" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., and 20 others.
|
|
<strong>Diverse somatic mutation patterns and pathway alterations in human cancers.</strong>
|
|
Nature 466: 869-873, 2010.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/20668451/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">20668451</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=20668451" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature09208" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="25" class="mim-anchor"></a>
|
|
<a id="Kikuchi2005" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Kikuchi, A., Yamaya, M., Suzuki, S., Yasuda, H., Kubo, H., Nakayama, K., Handa, M., Sasaki, T., Shibahara, S., Sekizawa, K., Sasaki, H.
|
|
<strong>Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism.</strong>
|
|
Hum. Genet. 116: 354-360, 2005.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15688187/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15688187</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15688187" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1007/s00439-004-1162-2" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="26" class="mim-anchor"></a>
|
|
<a id="Liu2012" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Li, W., Zhou, Y., Lu, J.
|
|
<strong>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.</strong>
|
|
Am. J. Hum. Genet. 91: 384-390, 2012.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22883146/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22883146</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22883146[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=22883146" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1016/j.ajhg.2012.07.003" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="27" class="mim-anchor"></a>
|
|
<a id="Lynch2004" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., Haber, D. A.
|
|
<strong>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</strong>
|
|
New Eng. J. Med. 350: 2129-2139, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15118073/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15118073</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15118073" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMoa040938" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="28" class="mim-anchor"></a>
|
|
<a id="Maheswaran2008" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., Digumarthy, S., Muzikansky, A., Irimia, D., Settleman, J., Tompkins, R. G., Lynch, T. J., Toner, M., Haber, D. A.
|
|
<strong>Detection of mutations in EGFR in circulating lung-cancer cells.</strong>
|
|
New Eng. J. Med. 359: 366-377, 2008.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/18596266/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">18596266</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=18596266[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=18596266" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMoa0800668" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="29" class="mim-anchor"></a>
|
|
<a id="Miyamoto1999" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N., Kamataki, T.
|
|
<strong>CYP2A6 gene deletion reduces susceptibility to lung cancer.</strong>
|
|
Biochem. Biophys. Res. Commun. 261: 658-660, 1999.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10441482/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10441482</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10441482" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1006/bbrc.1999.1089" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="30" class="mim-anchor"></a>
|
|
<a id="Mok2009" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., Fukuoka, M.
|
|
<strong>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</strong>
|
|
New Eng. J. Med. 361: 947-957, 2009.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19692680/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19692680</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19692680" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMoa0810699" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="31" class="mim-anchor"></a>
|
|
<a id="Naoki2002" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Naoki, K., Chen, T.-H., Richards, W. G., Sugarbaker, D. J., Meyerson, M.
|
|
<strong>Missense mutations of the BRAF gene in human lung adenocarcinoma.</strong>
|
|
Cancer Res. 62: 7001-7003, 2002.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12460919/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12460919</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12460919" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="32" class="mim-anchor"></a>
|
|
<a id="Oscarson1999" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q.-Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O., Ingelman-Sundberg, M.
|
|
<strong>Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.</strong>
|
|
FEBS Lett. 448: 105-110, 1999.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10217419/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10217419</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10217419" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1016/s0014-5793(99)00359-2" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="33" class="mim-anchor"></a>
|
|
<a id="Paez2004" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., Meyerson, M.
|
|
<strong>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.</strong>
|
|
Science 304: 1497-1500, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15118125/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15118125</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15118125" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1126/science.1099314" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="34" class="mim-anchor"></a>
|
|
<a id="Pao2004" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H.
|
|
<strong>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.</strong>
|
|
Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15329413/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15329413</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=15329413[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15329413" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1073/pnas.0405220101" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="35" class="mim-anchor"></a>
|
|
<a id="Perucho1981" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Perucho, M., Goldfarb, M., Shimizu, K., Lama, C., Fogh, J., Wigler, M.
|
|
<strong>Human-tumor-derived cell lines contain common and different transforming genes.</strong>
|
|
Cell 27: 467-476, 1981.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/6101201/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">6101201</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=6101201" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1016/0092-8674(81)90388-3" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="36" class="mim-anchor"></a>
|
|
<a id="Que2009" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Que, J., Luo, X., Schwartz, R. J., Hogan, B. L. M.
|
|
<strong>Multiple roles for Sox2 in the developing and adult mouse trachea.</strong>
|
|
Development 136: 1899-1907, 2009.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19403656/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19403656</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19403656[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19403656" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1242/dev.034629" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="37" class="mim-anchor"></a>
|
|
<a id="Que2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Que, J., Okubo, T., Goldenring, J. R., Nam, K.-T., Kurotani, R., Morrisey, E. E., Taranova, O., Pevny, L. H., Hogan, B. L. M.
|
|
<strong>Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm.</strong>
|
|
Development 134: 2521-2531, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17522155/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17522155</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17522155[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17522155" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1242/dev.003855" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="38" class="mim-anchor"></a>
|
|
<a id="Ramaswamy2003" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Ramaswamy, S., Ross, K. N., Lander, E. S., Golub, T. R.
|
|
<strong>A molecular signature of metastasis in primary solid tumors.</strong>
|
|
Nature Genet. 33: 49-54, 2003.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/12469122/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">12469122</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=12469122" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/ng1060" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="39" class="mim-anchor"></a>
|
|
<a id="Risch2006" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Risch, N.
|
|
<strong>Dissecting racial and ethnic differences. (Editorial)</strong>
|
|
New Eng. J. Med. 354: 408-411, 2006.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/16436773/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">16436773</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=16436773" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMe058265" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="40" class="mim-anchor"></a>
|
|
<a id="Rosell2009" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., and 16 others.
|
|
<strong>Screening for epidermal growth factor receptor mutations in lung cancer.</strong>
|
|
New Eng. J. Med. 361: 958-967, 2009.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19692684/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19692684</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19692684" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1056/NEJMoa0904554" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="41" class="mim-anchor"></a>
|
|
<a id="Samuels2004" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K. V., Markowitz, S., Kinzler, K. W., Vogelstein, B., Velculescu, V. E.
|
|
<strong>High frequency of mutations of the PIK3CA gene in human cancers.</strong>
|
|
Science 304: 554 only, 2004.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15016963/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15016963</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15016963" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1126/science.1096502" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="42" class="mim-anchor"></a>
|
|
<a id="Shi2011" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Shi, Y., Chen, J., Li, Z., Zhang, Z., Yu, H., Sun, K., Wang, X., Song, X., Wang, Y., Zhen, Y., Yang, T., Lou, K., Zhang, Y., Zhang, G., Hu, Y., Ji, J., Hui, R.
|
|
<strong>C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.</strong>
|
|
Oncogene 30: 4107-4117, 2011.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21499297/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21499297</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21499297" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/onc.2011.116" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="43" class="mim-anchor"></a>
|
|
<a id="Sjalander1996" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Sjalander, A., Birgander, R., Rannug, A., Alexandrie, A.-K., Tornling, G., Beckman, G.
|
|
<strong>Association between the p21 codon 31A1 (arg) allele and lung cancer.</strong>
|
|
Hum. Hered. 46: 221-225, 1996.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8807325/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8807325</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8807325" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1159/000154357" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="44" class="mim-anchor"></a>
|
|
<a id="Soda2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H.
|
|
<strong>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.</strong>
|
|
Nature 448: 561-566, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17625570/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17625570</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17625570" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature05945" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="45" class="mim-anchor"></a>
|
|
<a id="Sun2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Sun, T., Gao, Y., Tan, W., Ma, S., Shi, Y., Yao, J., Guo, Y., Yang, M., Zhang, X., Zhang, Q., Zeng, C., Lin, D.
|
|
<strong>A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.</strong>
|
|
Nature Genet. 39: 605-613, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17450141/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17450141</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17450141" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/ng2030" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="46" class="mim-anchor"></a>
|
|
<a id="Taioli2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Taioli, E., Benhamou, S., Bouchardy, C., Cascorbi, I., Cajas-Salazar, N., Dally, H., Fong, K. M., Larsen, J. E., Le Marchand, L., London, S. J., Risch, A., Spitz, M. R., Stucker, I., Weinshenker, B., Wu, X., Yang, P.
|
|
<strong>Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis.</strong>
|
|
Genet. Med. 9: 67-73, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17304047/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17304047</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17304047" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1097/gim.0b013e31803068b1" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="47" class="mim-anchor"></a>
|
|
<a id="Wang2009" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Wang, Y., Kuan, P. J., Xing, C., Cronkhite, J. T., Torres, F., Rosenblatt, R. L., DiMaio, J. M., Kinch, L. N., Grishin, N. V., Garcia, C. K.
|
|
<strong>Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.</strong>
|
|
Am. J. Hum. Genet. 84: 52-59, 2009.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/19100526/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">19100526</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=19100526[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=19100526" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1016/j.ajhg.2008.11.010" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="48" class="mim-anchor"></a>
|
|
<a id="Weir2007" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., and 58 others.
|
|
<strong>Characterizing the cancer genome in lung adenocarcinoma.</strong>
|
|
Nature 450: 893-898, 2007.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/17982442/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">17982442</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=17982442[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=17982442" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature06358" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="49" class="mim-anchor"></a>
|
|
<a id="Weston1989" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Weston, A., Willey, J. C., Modali, R., Sugimura, H., McDowell, E. M., Resau, J., Light, B., Haugen, A., Mann, D. L., Trump, B. F., Harris, C. C.
|
|
<strong>Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung.</strong>
|
|
Proc. Nat. Acad. Sci. 86: 5099-5103, 1989.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/2567993/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">2567993</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=2567993" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1073/pnas.86.13.5099" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="50" class="mim-anchor"></a>
|
|
<a id="Wingo1999" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Wingo, P. A., Ries, L. A. G., Giovino, G. A., Miller, D. S., Rosenberg, H. M., Shopland, D. R., Thun, M. J., Edwards, B. K.
|
|
<strong>Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking.</strong>
|
|
J. Nat. Cancer Inst. 91: 675-690, 1999.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/10218505/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">10218505</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=10218505" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1093/jnci/91.8.675" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="51" class="mim-anchor"></a>
|
|
<a id="Winslow2011" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., Yoon, S., Crowley, D., Bronson, R. T., Chiang, D. Y., Meyerson, M., Jacks, T.
|
|
<strong>Suppression of lung adenocarcinoma progression by Nkx2-1.</strong>
|
|
Nature 473: 101-104, 2011.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/21471965/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">21471965</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=21471965[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=21471965" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/nature09881" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="52" class="mim-anchor"></a>
|
|
<a id="Wu1996" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Wu, A. H., Fontham, E. T. H., Reynolds, P., Greenberg, R. S., Buffler, P., Liff, J., Boyd, P., Correa, P.
|
|
<strong>Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States.</strong>
|
|
Am. J. Epidemiol. 143: 535-542, 1996.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/8610670/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">8610670</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=8610670" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1093/oxfordjournals.aje.a008783" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="53" class="mim-anchor"></a>
|
|
<a id="Zhang2014" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., Gold, K. A., Kalhor, N., and 15 others.
|
|
<strong>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.</strong>
|
|
Science 346: 256-259, 2014.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/25301631/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">25301631</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=25301631" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1126/science.1256930" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="54" class="mim-anchor"></a>
|
|
<a id="Zhang2005" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y., Lin, D.
|
|
<strong>Functional polymorphisms in cell death pathway genes FAS and FASL contribute to the risk of lung cancer.</strong>
|
|
J. Med. Genet. 42: 479-484, 2005.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/15937082/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">15937082</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=15937082" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1136/jmg.2004.030106" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
<li>
|
|
<a id="55" class="mim-anchor"></a>
|
|
<a id="Zhang2012" class="mim-anchor"></a>
|
|
<div class="">
|
|
<p class="mim-text-font">
|
|
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., Choi, Y. J., Choi, C.-M., and 18 others.
|
|
<strong>Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.</strong>
|
|
Nature Genet. 44: 852-860, 2012.
|
|
|
|
|
|
[PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/22751098/" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">22751098</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/?term=22751098[PMID]&report=imagesdocsum" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Image', 'domain': 'ncbi.nlm.nih.gov'})">images</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?cmd=link&linkname=pubmed_pubmed&from_uid=22751098" target="_blank" onclick="gtag('event', 'mim_outbound', {'name': 'PubMed Related', 'domain': 'pubmed.ncbi.nlm.nih.gov'})">related citations</a>]
|
|
|
|
|
|
[<a href="https://doi.org/10.1038/ng.2330" target="_blank">Full Text</a>]
|
|
|
|
|
|
</p>
|
|
</div>
|
|
</li>
|
|
|
|
</ol>
|
|
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="contributors" class="mim-anchor"></a>
|
|
|
|
<div class="row">
|
|
<div class="col-lg-2 col-md-2 col-sm-4 col-xs-4">
|
|
<span class="mim-text-font">
|
|
<a href="#mimCollapseContributors" role="button" data-toggle="collapse"> Contributors: </a>
|
|
</span>
|
|
</div>
|
|
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
Ada Hamosh - updated : 11/17/2014
|
|
</span>
|
|
</div>
|
|
</div>
|
|
<div class="row collapse" id="mimCollapseContributors">
|
|
<div class="col-lg-offset-2 col-md-offset-4 col-sm-offset-4 col-xs-offset-2 col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
Ada Hamosh - updated : 9/19/2014<br>Ada Hamosh - updated : 10/15/2013<br>Ada Hamosh - updated : 2/26/2013<br>Ada Hamosh - updated : 10/9/2012<br>Cassandra L. Kniffin - updated : 6/19/2012<br>Ada Hamosh - updated : 7/8/2011<br>Ada Hamosh - updated : 5/9/2011<br>Ada Hamosh - updated : 9/21/2010<br>Cassandra L. Kniffin - updated : 5/14/2010<br>Ada Hamosh - updated : 2/16/2010<br>Cassandra L. Kniffin - updated : 9/3/2009<br>Marla J. F. O'Neill - updated : 2/19/2009<br>Ada Hamosh - updated : 11/26/2008<br>Matthew B. Gross - reorganized : 10/2/2008<br>Matthew B. Gross - updated : 10/2/2008<br>Cassandra L. Kniffin - updated : 8/20/2008<br>Ada Hamosh - updated : 7/29/2008<br>Ada Hamosh - updated : 5/21/2008<br>Ada Hamosh - updated : 4/16/2008<br>Marla J. F. O'Neill - updated : 3/24/2008<br>Cassandra L. Kniffin - updated : 3/20/2008<br>Ada Hamosh - updated : 8/13/2007<br>Ada Hamosh - updated : 6/14/2007<br>Victor A. McKusick - updated : 2/9/2006<br>Marla J. F. O'Neill - updated : 7/21/2005<br>Marla J. F. O'Neill - updated : 6/21/2005<br>George E. Tiller - updated : 2/28/2005<br>Victor A. McKusick - updated : 2/7/2005<br>Victor A. McKusick - updated : 9/8/2004<br>Victor A. McKusick - updated : 7/15/2004<br>Victor A. McKusick - updated : 8/13/2003<br>Victor A. McKusick - updated : 3/3/2003<br>Victor A. McKusick - updated : 12/10/2002<br>Wilson H. Y. Lo - updated : 4/7/2000
|
|
</span>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="creationDate" class="mim-anchor"></a>
|
|
<div class="row">
|
|
<div class="col-lg-2 col-md-2 col-sm-4 col-xs-4">
|
|
<span class="text-nowrap mim-text-font">
|
|
Creation Date:
|
|
</span>
|
|
</div>
|
|
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
Victor A. McKusick : 6/3/1986
|
|
</span>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<a id="editHistory" class="mim-anchor"></a>
|
|
|
|
<div class="row">
|
|
<div class="col-lg-2 col-md-2 col-sm-4 col-xs-4">
|
|
<span class="text-nowrap mim-text-font">
|
|
<a href="#mimCollapseEditHistory" role="button" data-toggle="collapse"> Edit History: </a>
|
|
</span>
|
|
</div>
|
|
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
alopez : 05/16/2019
|
|
</span>
|
|
</div>
|
|
</div>
|
|
<div class="row collapse" id="mimCollapseEditHistory">
|
|
<div class="col-lg-offset-2 col-md-offset-2 col-sm-offset-4 col-xs-offset-4 col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
carol : 06/23/2016<br>carol : 3/31/2016<br>carol : 1/29/2015<br>alopez : 11/17/2014<br>mgross : 10/24/2014<br>alopez : 9/19/2014<br>carol : 4/10/2014<br>alopez : 10/15/2013<br>tpirozzi : 9/30/2013<br>tpirozzi : 9/30/2013<br>alopez : 3/4/2013<br>terry : 2/26/2013<br>alopez : 10/24/2012<br>terry : 10/9/2012<br>alopez : 8/8/2012<br>carol : 6/21/2012<br>carol : 6/21/2012<br>ckniffin : 6/19/2012<br>alopez : 9/2/2011<br>alopez : 7/8/2011<br>terry : 7/8/2011<br>carol : 6/17/2011<br>alopez : 5/11/2011<br>terry : 5/9/2011<br>alopez : 9/23/2010<br>terry : 9/21/2010<br>wwang : 5/21/2010<br>ckniffin : 5/14/2010<br>terry : 4/2/2010<br>alopez : 3/2/2010<br>terry : 2/16/2010<br>ckniffin : 1/15/2010<br>carol : 11/23/2009<br>wwang : 9/22/2009<br>ckniffin : 9/3/2009<br>wwang : 6/12/2009<br>terry : 6/3/2009<br>terry : 2/19/2009<br>wwang : 2/12/2009<br>ckniffin : 2/9/2009<br>alopez : 12/5/2008<br>terry : 11/26/2008<br>mgross : 10/3/2008<br>mgross : 10/2/2008<br>mgross : 10/2/2008<br>mgross : 10/2/2008<br>wwang : 8/26/2008<br>ckniffin : 8/20/2008<br>alopez : 8/19/2008<br>terry : 7/29/2008<br>alopez : 5/21/2008<br>alopez : 5/16/2008<br>terry : 4/16/2008<br>terry : 4/16/2008<br>wwang : 3/25/2008<br>terry : 3/24/2008<br>wwang : 3/20/2008<br>alopez : 1/24/2008<br>ckniffin : 1/16/2008<br>carol : 8/14/2007<br>terry : 8/13/2007<br>alopez : 7/31/2007<br>alopez : 6/28/2007<br>terry : 6/14/2007<br>alopez : 6/6/2007<br>alopez : 10/25/2006<br>alopez : 2/14/2006<br>terry : 2/9/2006<br>wwang : 7/25/2005<br>terry : 7/21/2005<br>wwang : 6/29/2005<br>terry : 6/21/2005<br>wwang : 2/28/2005<br>carol : 2/28/2005<br>wwang : 2/7/2005<br>alopez : 9/21/2004<br>terry : 9/8/2004<br>tkritzer : 7/15/2004<br>tkritzer : 7/15/2004<br>tkritzer : 8/19/2003<br>terry : 8/13/2003<br>carol : 3/11/2003<br>tkritzer : 3/10/2003<br>terry : 3/3/2003<br>alopez : 1/2/2003<br>alopez : 12/11/2002<br>terry : 12/10/2002<br>terry : 3/5/2002<br>carol : 1/3/2002<br>carol : 9/18/2001<br>carol : 7/6/2000<br>terry : 4/7/2000<br>mgross : 2/2/2000<br>mark : 12/9/1996<br>mark : 4/30/1996<br>carol : 12/30/1994<br>terry : 12/22/1994<br>mimadm : 2/19/1994<br>supermim : 3/16/1992<br>carol : 2/11/1992<br>supermim : 3/20/1990
|
|
</span>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
<div class="container visible-print-block">
|
|
|
|
<div class="row">
|
|
|
|
|
|
|
|
<div class="col-md-8 col-md-offset-1">
|
|
|
|
<div>
|
|
<div>
|
|
<h3>
|
|
<span class="mim-font">
|
|
<strong>#</strong> 211980
|
|
</span>
|
|
</h3>
|
|
</div>
|
|
|
|
<div>
|
|
<h3>
|
|
<span class="mim-font">
|
|
|
|
LUNG CANCER
|
|
|
|
</span>
|
|
</h3>
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div>
|
|
<p>
|
|
<span class="mim-font">
|
|
Other entities represented in this entry:
|
|
</span>
|
|
</p>
|
|
</div>
|
|
<div>
|
|
<span class="h3 mim-font">
|
|
ALVEOLAR CELL CARCINOMA, INCLUDED
|
|
</span>
|
|
</div>
|
|
|
|
<div>
|
|
<span class="h4 mim-font">
|
|
|
|
ADENOCARCINOMA OF LUNG, INCLUDED<br />
|
|
NONSMALL CELL LUNG CANCER, INCLUDED<br />
|
|
LUNG CANCER, PROTECTION AGAINST, INCLUDED
|
|
</span>
|
|
</div>
|
|
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<p>
|
|
<span class="mim-text-font">
|
|
|
|
<strong>SNOMEDCT:</strong> 363358000;
|
|
|
|
|
|
<strong>ICD10CM:</strong> C34.90;
|
|
|
|
|
|
|
|
|
|
<strong>DO:</strong> 1324;
|
|
|
|
|
|
</span>
|
|
</p>
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Phenotype-Gene Relationships</strong>
|
|
</span>
|
|
</h4>
|
|
<div>
|
|
<table class="table table-bordered table-condensed small mim-table-padding">
|
|
<thead>
|
|
<tr class="active">
|
|
<th>
|
|
Location
|
|
</th>
|
|
<th>
|
|
Phenotype
|
|
</th>
|
|
<th>
|
|
Phenotype <br /> MIM number
|
|
</th>
|
|
<th>
|
|
Inheritance
|
|
</th>
|
|
<th>
|
|
Phenotype <br /> mapping key
|
|
</th>
|
|
<th>
|
|
Gene/Locus
|
|
</th>
|
|
<th>
|
|
Gene/Locus <br /> MIM number
|
|
</th>
|
|
</tr>
|
|
</thead>
|
|
<tbody>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
1q24.3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, susceptibility to}
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
FASLG
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
134638
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
2q33.1
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, protection against}
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
CASP8
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
601763
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
3q26.32
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
PIK3CA
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
171834
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
5q31.1
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
IRF1
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
147575
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
6q26
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
PRKN
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
602544
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
7p11.2
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
EGFR
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
131550
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
7p11.2
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Nonsmall cell lung cancer, susceptibility to}
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
EGFR
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
131550
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
7p11.2
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, response to tyrosine kinase inhibitor in
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
EGFR
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
131550
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
7q34
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
BRAF
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
164757
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
7q34
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Nonsmall cell lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
BRAF
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
164757
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
10p11.23
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
MAP3K8
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
191195
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
10q11.23
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, susceptibility to}
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
ERCC6
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
609413
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
11p15.4
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
SLC22A1L
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
602631
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
11q23.1
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
PPP2R1B
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
603113
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
12p12.1
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Lung cancer, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
KRAS
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
190070
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
17q12
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Adenocarcinoma of lung, somatic
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
ERBB2
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
164870
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
<tr>
|
|
<td>
|
|
<span class="mim-font">
|
|
19q13.2
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
{Lung cancer, resistance to}
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
211980
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
Autosomal dominant; Somatic mutation
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
3
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
CYP2A6
|
|
</span>
|
|
</td>
|
|
<td>
|
|
<span class="mim-font">
|
|
122720
|
|
</span>
|
|
</td>
|
|
</tr>
|
|
|
|
</tbody>
|
|
</table>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>TEXT</strong>
|
|
</span>
|
|
</h4>
|
|
|
|
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>A number sign (#) is used with this entry because mutations in several genes are associated with lung cancer. Both germline and somatic mutations have been identified in the EGFR (131550) and p53 (TP53; 191170) genes, and somatic mutations have been identified in the KRAS (190070), BRAF (164757), ERBB2 (164870), MET (164860), STK11 (602216), PIK3CA (171834), and PARK2 (602544) genes. Amplification of several genes, including EGFR, ERBB2, MET, PIK3CA, and NKX2-1 (600635), is also associated with lung cancer. Deletion of several genes, including DOK2 (604977), is also associated with lung cancer. An ALK/EML4 fusion gene (see 105590) has been identified in lung cancer. Several polymorphisms are associated with lung cancer susceptibility, including a 5-prime SNP in the ERCC6 gene (609413) and SNPs in the nicotinic acetylcholine receptor gene cluster on chromosome 15q25.1 (see LNCR2; 612052). Lung cancer susceptibility loci have been mapped to chromosome 6q23-q25 (LNCR1; 608935), 5p15 (LNCR3; 612571), 6p21 (LNCR4; 612593), and 3q28 (LNCR5; 614210). Deletion alleles in the CYP2A6 (122720) and CASP8 (601763) genes are associated with a reduced risk of lung cancer in Japanese and Han Chinese individuals, respectively. A SNP in the MPO gene (606989) is associated with reduced risk of lung cancer in smokers.</p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Description</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Clinical Features</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>Joishy et al. (1977) described identical twins who developed symptoms of alveolar cell carcinoma almost simultaneously. </p><p>Ahrendt et al. (2001) noted that incidence rates for squamous cell and small cell lung carcinoma began falling among males in the mid-1980s, but a decline in the incidence of primary adenocarcinoma of the lung among males was not observed until 5 to 10 years later. Similarly, although the incidence rates of squamous cell, large cell, and small cell lung carcinoma among women leveled off or started to decrease, the incidence of adenocarcinoma continued to increase. With these changes in the incidence among the different histologic types of lung carcinoma over the 1990s, adenocarcinoma of the lung became the most common type of lung carcinoma in the U.S. (Wingo et al., 1999). </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Inheritance</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>Braun et al. (1994) conducted a genetic analysis of lung cancer mortality in the National Academy of Sciences/National Research Council Twin Registry. The registry is composed of 15,924 male twin pairs who were born in the U.S. between 1917 and 1927 and who served in the armed forces during World War II. As evidence for a genetic effect on lung cancer, they required concordance for lung cancer death to be greater among monozygotic than among dizygotic twin pairs. No genetic effect on lung cancer mortality was observed. The ratio of observed to expected concordance among monozygotic twins did not exceed that among dizygotic twins, even though monozygotic twin pairs were more likely to be concordant for smoking than dizygotic twin pairs in this population. A cohort analysis (accounting for age, sex, race, and smoking intensity) of lung cancer mortality found no lung cancer deaths during the 300 person-years of follow-up among 47 monozygotic twins smokers whose smoking twin died of lung cancer, even though smoking histories were very similar within twin pairs. </p><p>In a multicenter study of lung cancer in lifetime nonsmokers in the United States, 646 female lung cancer patients and 1,252 population controls were interviewed regarding history of cancer in their first-degree relatives. Wu et al. (1996) summarized the findings. A 30% increased risk was associated with a history of respiratory tract cancer in parents or sibs after adjustment for exposure to environmental tobacco smoke in adult life. Lung cancer, which represented approximately two-thirds of the respiratory tract cancers, occurred more frequently in first-degree relatives of lung cancer patients than in comparable relatives of population controls. A significant 3-fold increased risk for lung cancer was associated with lung cancer diagnosed in mothers and sisters. Wu et al. (1996) also observed the increased risk in relation to family history of lung cancer among parents and sibs who were smokers as well as in those who were nonsmokers. The association with family history of lung cancer was strengthened when the analysis was restricted to adenocarcinoma of the lung. However, the authors pointed out that there was no association between family history of other cancers and risk of lung cancer in nonsmokers. </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Population Genetics</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>Haiman et al. (2006) investigated differences in the risk of lung cancer associated with cigarette smoking in 183,813 African American, Japanese American, Latino, Native Hawaiian, and white men and women. Their analysis included 1,979 cases of incident lung cancer identified prospectively over an 8-year period. They found that among cigarette smokers, African Americans and Native Hawaiians are more susceptible to lung cancer than whites, Japanese Americans, and Latinos. Risch (2006) discussed the problems of dissecting racial and ethnic differences in relation to the frequency of disease. He stated that it is 'difficult to discuss the role of genetics in differences among groups, because of the fear that such discourse may reinforce notions of biologic determinism. Some insist that racial and ethnic categories are purely social and devoid of genetic content, or at least of minimal relevance.' </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Pathogenesis</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>In the DNA from 1 colon and 2 lung carcinoma cell lines, Perucho et al. (1981) demonstrated the same or closely related transforming elements. By DNA-mediated gene transfer, mouse fibroblasts could be morphologically transformed and rendered tumorigenic in nude mice. </p><p>Starting from studies of lung adenocarcinomas, Ramaswamy et al. (2003) explored the molecular differences between human primary tumors and metastases by comparing their gene expression profiles. They found a 17-gene-expression signature that distinguished primary from metastatic adenocarcinomas. Notably, they found that a subset of primary tumors resembled metastatic tumors with respect to this gene-expression signature. They confirmed their findings by applying the expression signature to data on 279 primary solid tumors of diverse types. They found that solid tumors carrying the gene-expression signature were most likely to be associated with metastasis and poor clinical outcome (P less than 0.03). These results suggested that the metastatic potential of human tumors is encoded in the bulk of a primary tumor, thus challenging the notion that metastases arise from rare cells within a primary tumor that have the ability to metastasize. The results supported the idea that some primary tumors are preconfigured to metastasize, and that this propensity is detectable at the time of initial diagnosis. </p><p>A considerable proportion of the refined gene-expression signature that Ramaswamy et al. (2003) found to be associated with metastasis seemed to be derived from nonepithelial components of the tumor. Specifically, these included genes encoding the type 1 collagens (COL1A1, 120150; COL1A2, 120160) whose expression is restricted to fibroblasts. Some of the 17 genes constituting the signature were upregulated in metastases, others were downregulated. The upregulation of collagen genes in primary tumors with metastatic potential is consistent with observations that epithelial-mesenchymal interactions are critical determinants of tumor cell behavior. High levels of type 1 collagen in metastatic lesions and in the serum of individuals with metastatic disease have been reported. In general, the findings were consistent with the existence of a molecular program of metastasis that is shared by multiple solid-tumor types, suggesting the possible existence of therapeutic targets common to different cancers. </p><p>Brock et al. (2008) analyzed methylation of 7 genes in tumor tissue and lymph nodes from 51 patients with stage I nonsmall cell lung cancer (NSCLC) who underwent curative resection but had a recurrence within 40 months and from 116 age-, sex-, NSCLC stage-, and date of surgery-matched patients who underwent curative resection and did not have a recurrence within 40 months. In a multivariate model, the authors found that promoter methylation of the CDKN2A (600160), CDH13 (601364), RASSF1A (605082), and APC (611731) genes in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor. Methylation of the promoter regions of CDKN2A and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an OR of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC. </p><p>Winslow et al. (2011) modeled human lung adenocarcinoma, which frequently harbors activating point mutations in KRAS (190070) and inactivation of the p53 (191170) pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development. Although tumors are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed Winslow et al. (2011) to distinguish metastatic from nonmetastatic tumors and determine the gene expression alterations that distinguish these tumor types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (600635) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumors. Gain- and loss-of-function experiments in cells derived from metastatic and nonmetastatic tumors demonstrated that Nkx2-1 controls tumor differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumors at defined developmental stages, and functional complementation experiments indicated that Nkx2-1 constrains tumors in part by repressing the embryonically restricted chromatin regulator Hmga2 (600698). Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas had focused attention on its oncogenic function, Winslow et al. (2011) stated that their data specifically linked Nkx2-1 downregulation to loss of differentiation, enhanced tumor seeding ability, and increased metastatic proclivity. Winslow et al. (2011) concluded that the oncogenic and suppressive functions of Nkx2-1 in the same tumor type substantiate its role as a dual function lineage factor. </p><p>De Bruin et al. (2014) sequenced 25 spatially distinct regions from 7 operable NSCLCs and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC (see 600130) cytidine deaminase activity. Despite maintained carcinogen exposure, tumors from smokers showed a relative decrease in smoking-related mutations over time, accompanied by an increase in APOBEC-associated mutations. In tumors from former smokers, genome doubling occurred within a smoking-signature context before subclonal diversification, which suggested that a long period of tumor latency had preceded clinical detection. De Bruin et al. (2014) concluded that regionally separated driver mutations, coupled with the relentless and heterogeneous nature of the genome instability processes, are likely to confound treatment success in NSCLC. </p><p>Zhang et al. (2014) applied multiregion whole-exome sequencing to 11 localized lung adenocarcinomas. All tumors showed clear evidence of intratumor heterogeneity. On average, 76% of all mutations and 20 out of 21 known cancer gene mutations were identified in all regions of individual tumors, which suggested that single-region sequencing may be adequate to identify the majority of known cancer gene mutations in localized lung adenocarcinomas. With a median follow-up of 21 months after surgery, 3 patients had relapsed, and all 3 had significantly larger fractions of subclonal mutations in their primary tumors than patients without relapse. Zhang et al. (2014) concluded that a larger subclonal mutation fraction may be associated with increased likelihood of postsurgical relapse in patients with localized lung adenocarcinomas. </p><p><strong><em>Reviews of Lung Cancer Pathogenesis</em></strong></p><p>
|
|
Herbst et al. (2008) reviewed lung cancer with a focus on the origins and biology of squamous cell carcinoma and adenocarcinoma, which constitute the majority of diagnosed lung cancers. </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Clinical Management</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>In a multiinstitutional phase II trial, Fukuoka et al. (2003) found a higher rate of response to the tyrosine kinase inhibitor gefitinib (Iressa) in Japanese patients with nonsmall cell lung cancer (NSCLC) than in a predominantly European-derived population (27.5% vs 10.4%). See 'EGFR Mutations and Lung Cancer' in MOLECULAR GENETICS for information on EGFR (131550) mutations associated with gefitinib-responsive lung cancer. </p><p>In a randomized control trial of 1,217 East Asian patients with nonsmall cell lung cancer, Mok et al. (2009) found that the 12-month rate of progression-free survival was 24.9% in patients treated with gefitinib and 6.7% in those treated with carboplatin-paclitaxel. In the subgroup of 261 patients who were positive for an EGFR mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel, whereas in the subgroup of 176 patients who were negative for a mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel. The findings indicated that gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia, and showed that the presence in the tumor of an EGFR mutation is a strong predictor of a better outcome with gefitinib. </p><p>Rosell et al. (2009) concluded that large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in treatment decisions. EGFR mutations were identified in tumor tissue of 350 (16.6%) of 2,105 Spanish patients with nonsmall cell lung cancer. Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%). The mutations were deletions in exon 19 (62.2%) and L858R (131550.0002) (37.8%). Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 months and 27 months, respectively. Multivariate analysis showed an association between poor progression-free survival and male sex (hazard ratio of 2.94), and the presence of the L858R mutation (hazard ratio of 1.92) as compared with a deletion in exon 19. The most common adverse events were mild rashes and diarrhea. The results suggested that EGFR-mutant lung cancer is a distinct class of nonsmall cell lung cancer. </p><p>Bivona et al. (2011) used a pooled RNAi screen to show that knockdown of FAS (134637) and several components of the NF-kappa-B pathway (see 164011) specifically enhanced cell death induced by the EGFR (131550) tyrosine kinase inhibitor (TKI) erlotinib in EGFR-mutant lung cancer cells. Activation of NF-kappa-B through overexpression of c-FLIP (603599) or IKK (603258), or silencing of I-kappa-B (see 164008), rescued EGFR-mutant lung cancer cells from EGFR TKI treatment. Genetic or pharmacologic inhibition of NF-kappa-B enhanced erlotinib-induced apoptosis in erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models. Increased expression of the NF-kappa-B inhibitor I-kappa-B predicted improved response and survival in EGFR-mutant lung cancer patients treated with EGFR TKI. Bivona et al. (2011) concluded that their data identified NF-kappa-B as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provided insight into the mechanisms by which tumor cells escape from oncogene dependence. </p><p>Zhang et al. (2012) reported increased activation of AXL (109135) and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR T790M alteration (131550.0006) or MET activation. Genetic or pharmacologic inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 (600441) was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to tyrosine kinase inhibitors. </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Mapping</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>In 3 varieties of nonsmall cell cancer of the lung, Weston et al. (1989) found evidence of loss of heterozygosity in chromosome 17p and chromosome 11. Only a minority had loss of heterozygosity involving a chromosomal locus on 3p previously shown to be lost consistently in small cell cancer of the lung (SCLC1; 182280). </p><p>Dai et al. (2003) used restriction landmark genomic scanning (RLGS) to identify novel amplified sequences in primary lung carcinomas and lung cancer cell lines. Enhanced RLGS fragments indicative of gene amplification were observed in tumors and cell lines of both nonsmall cell lung cancer and small cell lung cancer. The authors identified a novel amplicon on chromosome 11q22, in addition to previously reported amplicons that include oncogenes MYC (190080), MYCL1 (164850), and previously identified amplification of chromosomal regions 6q21 and 3q26-27. The amplified region of 11q22 was refined to 0.92 Mb in 1 patient sample. Immunohistochemistry and Western blot analysis identified CIAP1 (BIRC2; 601712) and CIAP2 (BIRC3; 601721) as potential oncogenes in this region, since both are overexpressed in multiple lung cancers with or without higher copy numbers. </p><p>Bailey-Wilson et al. (2004) mapped a major lung cancer susceptibility locus to chromosome 6q23-q25 (LNCR1; 608935). </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Molecular Genetics</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p>Ding et al. (2008) sequenced 623 genes with known or potential relationship to cancer in 188 human lung adenocarcinomas. Their analysis identified 26 genes that are mutated at significantly high frequencies and are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homolog ERBB4 (600543); multiple ephrin receptor genes, notably EPHA3 (179611); KDR (191306); and NTRK (191315). Their data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumor suppressor genes involved in other cancers, including NF1 (613113), APC (611731), RB1 (614041), and ATM (607585), and for sequence changes in PTPRD (601598) as well as the frequently deleted gene LRP1B (608766). The observed mutational profiles correlate with clinical features, smoking status, and DNA repair defects. In general, Ding et al. (2008) found that genetic alterations in lung adenocarcinoma frequently occur in genes of the MAPK (see 176948), p53 (191170), WNT (see 164820), cell cycle, and mTOR (601231) signaling pathways. </p><p>In affected members of 2 families with idiopathic pulmonary fibrosis (178500), some of whom also had lung cancer, Wang et al. (2009) identified 2 heterozygous missense mutations in the SFTPA2 gene (see 178642.0001 and 178642.0002, respectively). </p><p>Kan et al. (2010) reported the identification of 2,576 somatic mutations across approximately 1,800 megabases of DNA representing 1,507 coding genes from 441 tumors comprising breast, lung, ovarian, and prostate cancer types and subtypes. Kan et al. (2010) found that mutation rates and the sets of mutated genes varied substantially across tumor types and subtypes. Statistical analysis identified 77 significantly mutated genes including protein kinases, G protein-coupled receptors such as GRM8 (601116), BAI3 (602684), AGTRL1 (600052), and LPHN3, and other druggable targets. Integrated analysis of somatic mutations and copy number alterations identified another 35 significantly altered genes including GNAS (see 139320), indicating an expanded role for G-alpha subunits in multiple cancer types. Experimental analyses demonstrated the functional roles of mutant GNAO1 (139311) and mutant MAP2K4 (601335) in oncogenesis. </p><p>The Cancer Genome Atlas Research Network (2012) profiled 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations, and showed that the tumor type is characterized by complex genomic alterations with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumor. The Cancer Genome Atlas Research Network (2012) found statistically recurrent mutations in 11 genes, including mutations in TP53 in nearly all specimens. Previously unreported loss-of-function mutations were seen in the HLA-A class I major histocompatibility gene (142800). Significantly altered pathways included NFE2L2 (600492) and KEAP1 (606016) in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A (600160) and RB1 (614041) in 72% of tumors. The Cancer Genome Atlas Research Network (2012) identified a potential therapeutic target in most tumors, offering new avenues of investigation for the treatment of squamous cell lung cancers. </p><p>The Cancer Genome Atlas Research Network (2014) reported molecular profiling of 230 resected lung adenocarcinomas using mRNA, microRNA, and DNA sequencing integrated with copy number, methylation, and proteomic analyses. High rates of somatic mutation were observed (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 (609591) with activating mutations and MGA (616061) with loss-of-function mutations that were mutually exclusive with focal MYC amplification. EGFR (131550) mutations were more frequent in female patients, whereas mutations in RBM10 (300080) were more common in males. Aberrations in NF1 (613113), MET (164860), ERBB2 (164870), and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumors. DNA and mRNA sequences from the same tumor highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK (see 176948) and PI3K (see 601232) pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. </p><p><strong><em>p53 Mutations and Lung Cancer</em></strong></p><p>
|
|
Among members of 97 families enrolled in a cohort study of families ascertained through childhood soft tissue sarcoma patients, Hwang et al. (2003) studied the role of cigarette smoking and lung cancer risk in people with a genetic susceptibility based on a p53 germline mutation. They assessed the incidence of lung and smoking-related cancers in 33 carriers of germline p53 mutations and in 1,230 noncarriers from the same families. They observed an increased risk of a variety of histologic types of lung cancer in the carriers of the p53 mutations. Mutation carriers who smoked had a 3.16-fold (95% CI = 1.48-6.78) higher risk for lung cancer than the mutation carriers who did not smoke. </p><p><strong><em>EGFR Mutations and Lung Cancer</em></strong></p><p>
|
|
In tumors from patients with NSCLC responsive to the tyrosine kinase inhibitor gefitinib, Lynch et al. (2004) and Paez et al. (2004) identified mutations in the EGFR gene (131550.0001-131550.0005). Paez et al. (2004) found somatic mutations in EGFR in 15 of 58 unselected NSCLC tumors from Japan and 1 of 61 from the United States. EGFR mutations showed a striking correlation with patient characteristics. Mutations were more frequent in adenocarcinomas than in other NSCLCs, being present in 15 (21%) of 70 and 1 (2%) of 49, respectively; more frequent in women than in men, being present in 9 (20%) of 45 and 7 (9%) of 74, respectively; and more frequent in patients from Japan than in those from the United States, being present in 15 (26%) of 58 and 14 (32%) of 41 adenocarcinomas versus 1 (2%) of 61 and 1 (3%) of 29 adenocarcinomas, respectively. The patient characteristics that correlated with the presence of EGFR mutations were those that correlated with clinical response to gefitinib treatment. The striking difference in the frequency of EGFR mutation and response to gefitinib between Japanese and U.S. patients raised general questions regarding variation in the molecular pathogenesis of cancer in different ethnic, cultural, and geographic groups and argued for the benefit of population diversity in cancer clinical trials. </p><p>Pao et al. (2004) found that in-frame deletions in exon 19 of the EGFR gene and somatic point mutations in codon 858 (exon 21) were common particularly in lung cancers from 'never smokers' and were associated, as found by others, with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Pao et al. (2004) found EGFR tyrosine kinase domain mutations in 7 of 10 gefitinib-sensitive tumors and 5 of 7 erlotinib-sensitive tumors. No mutations were found in 8 gefitinib-refractory tumors and 10 erlotinib-refractory tumors. Because most of the mutation-positive tumors were adenocarcinomas from 'never smokers' (defined as patients who smoked less than 100 cigarettes in a lifetime), Pao et al. (2004) screened EGFR exons 2 through 28 for mutations in 15 adenocarcinomas resected from untreated 'never smokers.' Seven tumors had tyrosine kinase domain mutations, in contrast to 4 of 81 nonsmall cell lung cancers resected from untreated former or current smokers. Collectively the data showed that adenocarcinomas from 'never smokers' comprise a distinct subset of lung cancers, frequently containing mutations within the tyrosine kinase domain of EGFR that are associated with kinase inhibitor sensitivity. </p><p>Maheswaran et al. (2008) identified the EGFR T790M (131550.0006) mutation in pretreatment tumor samples from 10 (38%) of 26 patients with nonsmall cell lung cancer. Although low levels of the drug-resistant mutation did not preclude response to treatment, it was highly correlated with reduced progression-free survival. Use of a microfluidic-based isolation device and sequence amplification technology allowed for detection of EGFR mutations in circulating tumor cells from 11 (92%) of 12 patients. Serial analysis of circulating tumor cells showed that a reduction in the number of captured cells was associated with a radiographic tumor response; an increase in the number of cells was associated with tumor progression, with the emergence of additional EGFR mutations in some cases. Maheswaran et al. (2008) concluded that molecular analysis of circulating tumor cells from the blood of patients with EGFR-related nonsmall cell lung cancer could offer the possibility of monitoring changes in tumor genotype. </p><p><strong><em>MET Amplification and Drug Resistance in Lung Cancer</em></strong></p><p>
|
|
The EGFR kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Engelman et al. (2007) described a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET (164860) protooncogene. Inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 (22%) of 18 lung cancer specimens that had developed resistance to gefitinib or erlotinib. Engelman et al. (2007) found that amplification of MET caused gefitinib resistance by driving ERBB3 (190151)-dependent activation of phosphoinositide 3-kinase, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, Engelman et al. (2007) proposed that MET amplification may promote drug resistance in other ERBB-driven cancers as well. </p><p><strong><em>KRAS Mutations and Lung Adenocarcinoma</em></strong></p><p>
|
|
In a study of 106 prospectively enrolled patients with primary adenocarcinoma of the lung, Ahrendt et al. (2001) found that 92 (87%) were smokers. KRAS mutations were detected in 40 (38%) of 106 tumors and were significantly more common in smokers compared with nonsmokers (43% vs 0%; P = 0.001). Thirty-nine of the 40 tumors with KRAS mutations had 1 of 4 changes in codon 12, the most common being gly12 to cys (190070.0001), which was present in 25. </p><p><strong><em>BRAF Mutations and Lung Adenocarcinoma</em></strong></p><p>
|
|
Mutations of the BRAF protein serine/threonine kinase gene (164757) have been identified in a variety of human cancers, most notably melanomas. Naoki et al. (2002) analyzed the BRAF sequence in 127 primary human lung adenocarcinomas and found mutations in 2 tumor specimens, one in exon 11 (164757.0006) and another in exon 15 (164757.0007). The specimens belonged to the same adenocarcinoma subgroup as defined by clustering of gene expression data. The authors proposed that BRAF may provide a target for anticancer chemotherapy in a subset of lung adenocarcinoma patients. </p><p><strong><em>ERBB2 Mutations and Lung Cancer</em></strong></p><p>
|
|
The Cancer Genome Project and Collaborative Group (2004) sequenced the ERBB2 gene from 120 primary lung tumors and identified 4% that had mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. In-frame deletions within the kinase domain of EGFR (e.g., 131550.0001) are associated with lung tumors that respond to therapy with gefitinib, an EGFR inhibitor. The Cancer Genome Project and Collaborative Group (2004) suggested that ERBB2 inhibitors, which had to that time proved to be ineffective in treating lung cancer, should be clinically reevaluated in the specific subset of patients with lung cancer whose tumors carry ERBB2 mutations. </p><p><strong><em>STK11 Mutations and Lung Cancer</em></strong></p><p>
|
|
Ji et al. (2007) used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 (STK11; 602216) to other tumor suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (CDKN2A; 600160), in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumors demonstrated shorter latency, an expanded histologic spectrum (adeno-, squamous, and large-cell carcinoma), and more frequent metastasis compared to tumors lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analyzed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumors identified a variety of metastasis-promoting genes, such as NEDD9 (602265), VEGFC (601528), and CD24 (600074), as targets of LKB1 repression in lung cancer. Ji et al. (2007) concluded that their studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation, and metastasis. </p><p><strong><em>PIK3CA Mutations and Lung Cancer</em></strong></p><p>
|
|
Samuels et al. (2004) identified a somatic mutation in the PIK3CA gene (171834) in 1 (4%) of 24 lung cancers examined. </p><p><strong><em>NKX2-1 Amplification and Lung Adenocarcinoma</em></strong></p><p>
|
|
Weir et al. (2007) reported a large-scale project to characterize copy number alterations in primary lung adenocarcinomas. By analysis of 371 tumors using dense single-nucleotide polymorphism arrays, Weir et al. (2007) identified 57 significantly recurrent events. Weir et al. (2007) found that 26 of 39 autosomal chromosome arms showed consistent large-scale copy number gain or loss, of which only a handful had been linked to a specific gene. They also identified 31 recurrent focal events, including 24 amplifications and 7 homozygous deletions. Only 6 of these focal events were associated with mutations in lung carcinomas. The most common event, amplification of chromosome 14q13.3, was found in about 12% of samples. On the basis of genomic and functional analyses, Weir et al. (2007) identified NKX2-1 (600635), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate protooncogene involved in a significant fraction of lung adenocarcinomas. </p><p><strong><em>HMOX1 Polymorphism and Susceptibility to Lung Adenocarcinoma</em></strong></p><p>
|
|
Kikuchi et al. (2005) screened the heme oxygenase-1 gene (HMOX1; 141250) for (GT)n repeat length in 151 Japanese patients with lung adenocarcinoma and 153 controls. The proportion of L allele carriers was significantly higher among patients than controls (p = 0.02); the adjusted odds ratio for lung adenocarcinoma for L allele carriers was 1.8 (95% CI, 1.1-3.0) compared with non-L allele carriers. The risk of lung adenocarcinoma for L allele carriers versus non-L allele carriers was greatly increased in the group of male smokers (OR = 3.3; 95% CI, 1.5-7.4; p = 0.004); however, in female nonsmokers, the proportion of L allele carriers did not differ between patients and controls, nor did it differ between 108 patients with lung squamous cell carcinoma and 100 controls. Kikuchi et al. (2005) suggested that a large (GT)n repeat in the HMOX1 gene promoter may be associated with the development of lung adenocarcinoma in Japanese male smokers. </p><p><strong><em>CDKN1A Polymorphism and Susceptibility to Lung Cancer</em></strong></p><p>
|
|
Sjalander et al. (1996) found an increased frequency of the p21 arg31 allele (116899.0001) in lung cancer patients, especially in comparison with patients with chronic obstructive pulmonary disease (COPD); p = 0.004. Thus allelic variants of both p53 and its effector protein p21 may have an influence on lung cancer. </p><p><strong><em>GSTM1 Polymorphism and Susceptibility to Lung Cancer</em></strong></p><p>
|
|
Bennett et al. (1999) studied genes whose products activate (CYP1A1; 108330) or detoxify (GSTM1, 138350; GSTT1, 600436) chemical carcinogens found in tobacco smoke in never-smoking women who were exposed to environmental tobacco smoke (ETS) and developed lung cancer. Archival, paraffin-embedded, and DNA yielding, surgically resected lung cancer tissues were obtained from 106 white women who never smoked and developed lung cancer. When compared with 55 never smokers who developed lung cancer without ETS exposure, 51 never smokers who developed lung cancer with ETS exposure were more likely to be GSTM1-null homozygotes (OR, 2.6; 95% CI, 1.1-6.1). No evidence was found of associations between lung cancer risk due to ETS exposure and GSTT1 deficiency or the CYP1A1 valine variant. The authors concluded that white women who never smoke and are homozygous for the GSTM1 null allele, which occurs in about 50% of the white population, have a statistically significant greater risk of developing lung cancer from ETS. </p><p><strong><em>FAS and FASL Polymorphisms and Susceptibility to Lung Cancer</em></strong></p><p>
|
|
Zhang et al. (2005) genotyped 1,000 Han Chinese lung cancer patients and 1,270 controls for 2 functional polymorphisms in the promoter regions of the FAS and FASL genes, -1377G-A (TNFRSF6; 134637.0021) and -844T-C (TNFSF6; 134638.0002), respectively. Compared to noncarriers, there was a 1.6-fold increased risk of developing lung cancer for carriers of the FAS -1377AA genotype and a 1.8-fold increased risk for carriers of the FASL -844CC genotype. Carriers of both homozygous genotypes had a more than 4-fold increased risk, indicative of multiplicative gene-gene interaction; the increased risk was consistently observed in all subtypes of lung cancer. Zhang et al. (2005) stated that these results support the hypothesis that the FAS- and FASL-triggered apoptosis pathway plays an important role in human carcinogenesis. </p><p><strong><em>CASP8 Polymorphism and Protection Against Lung Cancer</em></strong></p><p>
|
|
Caspases are important in the life and death of immune cells and therefore influence immune surveillance of malignancies. Using a haplotype-tagging SNP approach, Sun et al. (2007) identified a 6-nucleotide deletion (-652 6N del) variant in the CASP8 promoter (601763.0004) associated with decreased risk of lung cancer in a population of Han Chinese subjects. The deletion destroyed a binding site for stimulatory protein-1 (SP1; 189906) and decreased transcription. Biochemical analyses showed that T lymphocytes with the deletion variant had lower caspase-8 activity and activation-induced cell death upon stimulation with cancer cell antigens. Case-control analyses of 4,995 individuals with cancer and 4,972 controls in a Chinese population showed that this genetic variant is associated with reduced susceptibility to multiple cancers, including lung, esophageal, gastric, colorectal, cervical, and breast cancers, acting in an allele dose-dependent manner. </p><p><strong><em>CYP2A6 Polymorphism and Protection Against Lung Cancer</em></strong></p><p>
|
|
Miyamoto et al. (1999) studied the relationship between genetic polymorphism of the CYP2A6 gene (122720) and lung cancer risk in a case-control study of Japanese. They found that the frequency of subjects homozygous for the CYP2A6 gene deletion (122720.0002), which causes lack of the enzyme activity, was lower in the lung cancer patients than in the healthy control subjects. These findings suggested that deficient CYP2A6 activity due to genetic polymorphism reduces lung cancer risk. Oscarson et al. (1999) found that this deletion allele was rare in Europeans but had a frequency of 15.1% among 96 Chinese subjects. </p><p><strong><em>MPO Polymorphism and Protection Against Lung Cancer in Smokers</em></strong></p><p>
|
|
Taioli et al. (2007) found that the -463G/A polymorphism in the MPO gene (606989.0008) conferred resistance to lung cancer among smokers. </p><p><strong><em>SOX2 Amplification in Lung Cancer</em></strong></p><p>
|
|
Bass et al. (2009) showed that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas of the lung and esophagus contains the transcription factor gene SOX2 (184429), which is necessary for normal esophageal squamous development (Que et al., 2007) and differentiation and proliferation of basal tracheal cells (Que et al., 2009), and cooperates in induction of pluripotent stem cells, as summarized by Bass et al. (2009). Bass et al. (2009) found that SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 in this study cooperated with FOXE1 (602617) or FGFR2 (176943) to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors showed expression of markers of both squamous differentiation and pluripotency. Bass et al. (2009) concluded that these characteristics identified SOX2 as a lineage-survival oncogene in lung and esophageal squamous cell carcinoma. </p><p><strong><em>DOK2 Deletion in Lung Cancer</em></strong></p><p>
|
|
Berger et al. (2010) showed that, of 199 primary human lung adenocarcinoma samples, 37% showed a deletion of 1 copy of the DOK2 gene (604997) , which maps to chromosome 8p21.3, one of the regions most frequently deleted in human lung cancer. The deletion correlated with loss of DOK2 protein expression. Loss of the DOK1 gene (602919), which maps to chromosome 2p13.1, occurred in 1.5% of samples, and loss of the DOK3 gene (611435), which maps to chromosome 5q35.3, occurred in 7.0% of samples. Further studies in mice showed that haploinsufficiency of Dok2 was sufficient for tumor formation, as the wildtype allele was retained in most tumor samples. Berger et al. (2010) suggested a tumor-suppressor role for DOK2 in human lung cancer. </p><p><strong><em>C10ORF97 Polymorphism and Susceptibility to Nonsmall Cell Lung Cancer</em></strong></p><p>
|
|
Shi et al. (2011) identified a 216C-T SNP (rs2297882) in the promoter region of the C10ORF97 gene (611649) that affected the efficiency of translation. The T allele was associated with lower protein levels than the C allele. Genotyping of 418 Chinese patients with nonsmall cell lung cancer and 743 controls showed an association between the TT genotype and lung cancer compared to the TC or CC genotype (odds ratio of 1.73, p = 4.6 x 10(-5)). The findings suggested that C10ORF97 may act as a tumor suppressor gene, and that low levels of it may be associated with tumorigenesis. </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>Cytogenetics</strong>
|
|
</span>
|
|
</h4>
|
|
</div>
|
|
|
|
|
|
|
|
<span class="mim-text-font">
|
|
<p><strong><em>ALK/EML4 Fusion Gene</em></strong></p><p>
|
|
Soda et al. (2007) identified a fusion gene, ALK/EML4 (see 105590), that was present in 5 of 75 Japanese nonsmall cell lung cancer patients examined. None of these patients had mutations in EGFR. </p><p><strong><em>Copy Number Variation at the MAPKAPK2 Locus</em></strong></p><p>
|
|
Liu et al. (2012) investigated the role in lung cancer of a copy number variant (CNV), g.CNV-30450, which spans the MAPKAPK2 (602006) promoter region and has 1.7-kb sequences from -1098 to approximately +664 nucleotides to the initiation transcription codon. This variant was found to have an allele frequency of 6/30 (0.20) in the Database of Genetic Variants. The authors detected 2, 3, or 4 copies of g.CNV-30450 among 4,789 Chinese individuals. Liu et al. (2012) investigated the association between cancer risk and g.CNV-30450 in 3 independent case-control studies of 2,332 individuals with lung cancer and 2,457 controls, and also studied the effects of this CNV on cancer prognosis in 1,137 individuals with lung cancer with survival data in Southern and Eastern Chinese populations. Liu et al. (2012) found that those subjects who had 4 copies of g.CNV-30450 had an increased cancer risk (OR = 1.94, 95% CI = 1.61-2.35) and, in individuals with lung cancer, a worse prognosis (with a median survival time of only 9 months) (hazard ratio = 1.47, 95% CI = 1.22-1.78) compared with those with 2 or 3 copies (with a median survival time of 14 months). Liu et al. (2012) also showed that 4 copies of g.CNV-30450 significantly increased MAPKAPK2 expression, both in vitro and in vivo, compared with 2 or 3 copies. </p>
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>See Also:</strong>
|
|
</span>
|
|
</h4>
|
|
<span class="mim-text-font">
|
|
Brisman et al. (1967); Goffman et al. (1982)
|
|
</span>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<h4>
|
|
<span class="mim-font">
|
|
<strong>REFERENCES</strong>
|
|
</span>
|
|
</h4>
|
|
<div>
|
|
<p />
|
|
</div>
|
|
|
|
<div>
|
|
<ol>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Y., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J., Sidransky, D.
|
|
<strong>Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.</strong>
|
|
Cancer 92: 1525-1530, 2001.
|
|
|
|
|
|
[PubMed: 11745231]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Bailey-Wilson, J. E., Amos, C. I., Pinney, S. M., Petersen, G. M., de Andrade, M., Wiest, J. S., Fain, P., Schwartz, A. G., You, M., Franklin, W., Klein, C., Gazdar, A., and 15 others.
|
|
<strong>A major lung cancer susceptibility locus maps to chromosome 6q23-25.</strong>
|
|
Am. J. Hum. Genet. 75: 460-474, 2004.
|
|
|
|
|
|
[PubMed: 15272417]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1086/423857]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., Ramos, A. H., Woo, M. S., and 36 others.
|
|
<strong>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</strong>
|
|
Nature Genet. 41: 1238-1242, 2009.
|
|
|
|
|
|
[PubMed: 19801978]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/ng.465]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Bennett, W. P., Alavanja, M. C. R., Blomeke, B., Vahakangas, K. H., Castren, K., Welsh, J. A., Bowman, E. D., Khan, M. A., Flieder, D. B., Harris, C. C.
|
|
<strong>Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women.</strong>
|
|
J. Nat. Cancer Inst. 91: 2009-2014, 1999.
|
|
|
|
|
|
[PubMed: 10580025]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1093/jnci/91.23.2009]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Berger, A. H., Niki, M., Morotti, A., Taylor, B. S., Socci, N. D., Viale, A., Brennan, C., Szoke, J., Motoi, N., Rothman, P. B., Teruya-Feldstein, J., Gerald, W. L., Ladanyi, M., Pandolfi, P. P.
|
|
<strong>Identification of DOK genes as lung tumor suppressors.</strong>
|
|
Nature Genet. 42: 216-223, 2010.
|
|
|
|
|
|
[PubMed: 20139980]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/ng.527]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., Sawyers, C. L.
|
|
<strong>FAS and NF-kappa-B signalling modulate dependence of lung cancers on mutant EGFR.</strong>
|
|
Nature 471: 523-526, 2011.
|
|
|
|
|
|
[PubMed: 21430781]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature09870]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Braun, M. M., Caporaso, N. E., Page, W. F., Hoover, R. N.
|
|
<strong>Genetic component of lung cancer: cohort study of twins.</strong>
|
|
Lancet 344: 440-443, 1994.
|
|
|
|
|
|
[PubMed: 7914565]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1016/s0140-6736(94)91770-1]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Brisman, R., Baker, R. R., Elkins, R., Hartmann, W. H.
|
|
<strong>Carcinoma of lung in four siblings.</strong>
|
|
Cancer 20: 2048-2053, 1967.
|
|
|
|
|
|
[PubMed: 6061638]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1002/1097-0142(196711)20:11<2048::aid-cncr2820201134>3.0.co;2-a]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glockner, S., Piantadosi, S., Gabrielson, E., Pridham, G., Pelosky, K., Belinsky, S. A., Yang, S. C., Baylin, S. B., Herman, J. G.
|
|
<strong>DNA methylation markers and early recurrence in stage I lung cancer.</strong>
|
|
New Eng. J. Med. 358: 1118-1128, 2008.
|
|
|
|
|
|
[PubMed: 18337602]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMoa0706550]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Cancer Genome Atlas Research Network.
|
|
<strong>Comprehensive genomic characterization of squamous cell lung cancers.</strong>
|
|
Nature 489: 519-525, 2012. Note: Erratum: Nature 491: 288 only, 2012.
|
|
|
|
|
|
[PubMed: 22960745]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature11404]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Cancer Genome Atlas Research Network.
|
|
<strong>Comprehensive molecular profiling of lung adenocarcinoma.</strong>
|
|
Nature 511: 543-550, 2014. Note: Erratum: Nature 514: 262 only, 2014. Erratum: Nature 559: E12, 2018.
|
|
|
|
|
|
[PubMed: 25079552]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature13385]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Cancer Genome Project and Collaborative Group.
|
|
<strong>Intragenic ERBB2 kinase mutations in tumours.</strong>
|
|
Nature 431: 525-526, 2004.
|
|
|
|
|
|
[PubMed: 15457249]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/431525b]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Dai, Z., Zhu, W.-G., Morrison, C. D., Brena, R. M., Smiraglia, D. J., Raval, A., Wu, Y.-Z., Rush, L. J., Ross, P., Molina, J. R., Otterson, G. A., Plass, C.
|
|
<strong>A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes.</strong>
|
|
Hum. Molec. Genet. 12: 791-801, 2003.
|
|
|
|
|
|
[PubMed: 12651874]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1093/hmg/ddg083]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., Gronroos, E., Muhammad, M. A., and 31 others.
|
|
<strong>Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.</strong>
|
|
Science 346: 251-256, 2014.
|
|
|
|
|
|
[PubMed: 25301630]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1126/science.1253462]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., and 78 others.
|
|
<strong>Somatic mutations affect key pathways in lung adenocarcinoma.</strong>
|
|
Nature 455: 1069-1075, 2008.
|
|
|
|
|
|
[PubMed: 18948947]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature07423]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., Janne, P. A.
|
|
<strong>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</strong>
|
|
Science 316: 1039-1043, 2007.
|
|
|
|
|
|
[PubMed: 17463250]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1126/science.1141478]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.-P., Baselga, J.
|
|
<strong>Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial).</strong>
|
|
J. Clin. Oncol. 21: 2237-2246, 2003. Note: Erratum: J. Clin. Oncol. 22: 4863 only, 2004.
|
|
|
|
|
|
[PubMed: 12748244]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1200/JCO.2003.10.038]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Goffman, T. E., Hassinger, D. D., Mulvihill, J. J.
|
|
<strong>Familial respiratory tract cancer: opportunities for research and prevention.</strong>
|
|
JAMA 247: 1020-1023, 1982.
|
|
|
|
|
|
[PubMed: 7057577]
|
|
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E., Le Marchand, L.
|
|
<strong>Ethnic and racial differences in the smoking-related risk of lung cancer.</strong>
|
|
New Eng. J. Med. 354: 333-342, 2006.
|
|
|
|
|
|
[PubMed: 16436765]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMoa033250]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Herbst, R. S., Heymach, J. V., Lippman, S. M.
|
|
<strong>Lung cancer.</strong>
|
|
New Eng. J. Med. 359: 1367-1380, 2008.
|
|
|
|
|
|
[PubMed: 18815398]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMra0802714]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Hwang, S.-J., Cheng, L. S.-C., Lozano, G., Amos, C. I., Gu, X., Strong, L. C.
|
|
<strong>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk.</strong>
|
|
Hum. Genet. 113: 238-243, 2003.
|
|
|
|
|
|
[PubMed: 12802680]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1007/s00439-003-0968-7]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., and 22 others.
|
|
<strong>LKB1 modulates lung cancer differentiation and metastasis.</strong>
|
|
Nature 448: 807-810, 2007.
|
|
|
|
|
|
[PubMed: 17676035]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature06030]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Joishy, S. K., Cooper, R. A., Rowley, P. T.
|
|
<strong>Alveolar cell carcinoma in identical twins: similarity in time of onset, histochemistry, and site of metastasis.</strong>
|
|
Ann. Intern. Med. 87: 447-450, 1977.
|
|
|
|
|
|
[PubMed: 199100]
|
|
|
|
|
|
[Full Text: https://doi.org/10.7326/0003-4819-87-4-447]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., Moorhead, M., Chaudhuri, S., and 20 others.
|
|
<strong>Diverse somatic mutation patterns and pathway alterations in human cancers.</strong>
|
|
Nature 466: 869-873, 2010.
|
|
|
|
|
|
[PubMed: 20668451]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature09208]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Kikuchi, A., Yamaya, M., Suzuki, S., Yasuda, H., Kubo, H., Nakayama, K., Handa, M., Sasaki, T., Shibahara, S., Sekizawa, K., Sasaki, H.
|
|
<strong>Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism.</strong>
|
|
Hum. Genet. 116: 354-360, 2005.
|
|
|
|
|
|
[PubMed: 15688187]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1007/s00439-004-1162-2]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Liu, B., Yang, L., Huang, B., Cheng, M., Wang, H., Li, Y., Huang, D., Zheng, J., Li, Q., Zhang, X., Li, W., Zhou, Y., Lu, J.
|
|
<strong>A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.</strong>
|
|
Am. J. Hum. Genet. 91: 384-390, 2012.
|
|
|
|
|
|
[PubMed: 22883146]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1016/j.ajhg.2012.07.003]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., Haber, D. A.
|
|
<strong>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</strong>
|
|
New Eng. J. Med. 350: 2129-2139, 2004.
|
|
|
|
|
|
[PubMed: 15118073]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMoa040938]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., Digumarthy, S., Muzikansky, A., Irimia, D., Settleman, J., Tompkins, R. G., Lynch, T. J., Toner, M., Haber, D. A.
|
|
<strong>Detection of mutations in EGFR in circulating lung-cancer cells.</strong>
|
|
New Eng. J. Med. 359: 366-377, 2008.
|
|
|
|
|
|
[PubMed: 18596266]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMoa0800668]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N., Kamataki, T.
|
|
<strong>CYP2A6 gene deletion reduces susceptibility to lung cancer.</strong>
|
|
Biochem. Biophys. Res. Commun. 261: 658-660, 1999.
|
|
|
|
|
|
[PubMed: 10441482]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1006/bbrc.1999.1089]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., Fukuoka, M.
|
|
<strong>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</strong>
|
|
New Eng. J. Med. 361: 947-957, 2009.
|
|
|
|
|
|
[PubMed: 19692680]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMoa0810699]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Naoki, K., Chen, T.-H., Richards, W. G., Sugarbaker, D. J., Meyerson, M.
|
|
<strong>Missense mutations of the BRAF gene in human lung adenocarcinoma.</strong>
|
|
Cancer Res. 62: 7001-7003, 2002.
|
|
|
|
|
|
[PubMed: 12460919]
|
|
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q.-Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O., Ingelman-Sundberg, M.
|
|
<strong>Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.</strong>
|
|
FEBS Lett. 448: 105-110, 1999.
|
|
|
|
|
|
[PubMed: 10217419]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1016/s0014-5793(99)00359-2]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., Meyerson, M.
|
|
<strong>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.</strong>
|
|
Science 304: 1497-1500, 2004.
|
|
|
|
|
|
[PubMed: 15118125]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1126/science.1099314]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H.
|
|
<strong>EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.</strong>
|
|
Proc. Nat. Acad. Sci. 101: 13306-13311, 2004.
|
|
|
|
|
|
[PubMed: 15329413]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1073/pnas.0405220101]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Perucho, M., Goldfarb, M., Shimizu, K., Lama, C., Fogh, J., Wigler, M.
|
|
<strong>Human-tumor-derived cell lines contain common and different transforming genes.</strong>
|
|
Cell 27: 467-476, 1981.
|
|
|
|
|
|
[PubMed: 6101201]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1016/0092-8674(81)90388-3]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Que, J., Luo, X., Schwartz, R. J., Hogan, B. L. M.
|
|
<strong>Multiple roles for Sox2 in the developing and adult mouse trachea.</strong>
|
|
Development 136: 1899-1907, 2009.
|
|
|
|
|
|
[PubMed: 19403656]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1242/dev.034629]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Que, J., Okubo, T., Goldenring, J. R., Nam, K.-T., Kurotani, R., Morrisey, E. E., Taranova, O., Pevny, L. H., Hogan, B. L. M.
|
|
<strong>Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm.</strong>
|
|
Development 134: 2521-2531, 2007.
|
|
|
|
|
|
[PubMed: 17522155]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1242/dev.003855]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Ramaswamy, S., Ross, K. N., Lander, E. S., Golub, T. R.
|
|
<strong>A molecular signature of metastasis in primary solid tumors.</strong>
|
|
Nature Genet. 33: 49-54, 2003.
|
|
|
|
|
|
[PubMed: 12469122]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/ng1060]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Risch, N.
|
|
<strong>Dissecting racial and ethnic differences. (Editorial)</strong>
|
|
New Eng. J. Med. 354: 408-411, 2006.
|
|
|
|
|
|
[PubMed: 16436773]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMe058265]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., and 16 others.
|
|
<strong>Screening for epidermal growth factor receptor mutations in lung cancer.</strong>
|
|
New Eng. J. Med. 361: 958-967, 2009.
|
|
|
|
|
|
[PubMed: 19692684]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1056/NEJMoa0904554]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K. V., Markowitz, S., Kinzler, K. W., Vogelstein, B., Velculescu, V. E.
|
|
<strong>High frequency of mutations of the PIK3CA gene in human cancers.</strong>
|
|
Science 304: 554 only, 2004.
|
|
|
|
|
|
[PubMed: 15016963]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1126/science.1096502]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Shi, Y., Chen, J., Li, Z., Zhang, Z., Yu, H., Sun, K., Wang, X., Song, X., Wang, Y., Zhen, Y., Yang, T., Lou, K., Zhang, Y., Zhang, G., Hu, Y., Ji, J., Hui, R.
|
|
<strong>C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.</strong>
|
|
Oncogene 30: 4107-4117, 2011.
|
|
|
|
|
|
[PubMed: 21499297]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/onc.2011.116]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Sjalander, A., Birgander, R., Rannug, A., Alexandrie, A.-K., Tornling, G., Beckman, G.
|
|
<strong>Association between the p21 codon 31A1 (arg) allele and lung cancer.</strong>
|
|
Hum. Hered. 46: 221-225, 1996.
|
|
|
|
|
|
[PubMed: 8807325]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1159/000154357]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H.
|
|
<strong>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.</strong>
|
|
Nature 448: 561-566, 2007.
|
|
|
|
|
|
[PubMed: 17625570]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature05945]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Sun, T., Gao, Y., Tan, W., Ma, S., Shi, Y., Yao, J., Guo, Y., Yang, M., Zhang, X., Zhang, Q., Zeng, C., Lin, D.
|
|
<strong>A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.</strong>
|
|
Nature Genet. 39: 605-613, 2007.
|
|
|
|
|
|
[PubMed: 17450141]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/ng2030]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Taioli, E., Benhamou, S., Bouchardy, C., Cascorbi, I., Cajas-Salazar, N., Dally, H., Fong, K. M., Larsen, J. E., Le Marchand, L., London, S. J., Risch, A., Spitz, M. R., Stucker, I., Weinshenker, B., Wu, X., Yang, P.
|
|
<strong>Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis.</strong>
|
|
Genet. Med. 9: 67-73, 2007.
|
|
|
|
|
|
[PubMed: 17304047]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1097/gim.0b013e31803068b1]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Wang, Y., Kuan, P. J., Xing, C., Cronkhite, J. T., Torres, F., Rosenblatt, R. L., DiMaio, J. M., Kinch, L. N., Grishin, N. V., Garcia, C. K.
|
|
<strong>Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.</strong>
|
|
Am. J. Hum. Genet. 84: 52-59, 2009.
|
|
|
|
|
|
[PubMed: 19100526]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1016/j.ajhg.2008.11.010]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., Shah, K., Sato, M., and 58 others.
|
|
<strong>Characterizing the cancer genome in lung adenocarcinoma.</strong>
|
|
Nature 450: 893-898, 2007.
|
|
|
|
|
|
[PubMed: 17982442]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature06358]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Weston, A., Willey, J. C., Modali, R., Sugimura, H., McDowell, E. M., Resau, J., Light, B., Haugen, A., Mann, D. L., Trump, B. F., Harris, C. C.
|
|
<strong>Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung.</strong>
|
|
Proc. Nat. Acad. Sci. 86: 5099-5103, 1989.
|
|
|
|
|
|
[PubMed: 2567993]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1073/pnas.86.13.5099]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Wingo, P. A., Ries, L. A. G., Giovino, G. A., Miller, D. S., Rosenberg, H. M., Shopland, D. R., Thun, M. J., Edwards, B. K.
|
|
<strong>Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking.</strong>
|
|
J. Nat. Cancer Inst. 91: 675-690, 1999.
|
|
|
|
|
|
[PubMed: 10218505]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1093/jnci/91.8.675]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Winslow, M. M., Dayton, T. L., Verhaak, R. G. W., Kim-Kiselak, C., Snyder, E. L., Feldser, D. M., Hubbard, D. D., DuPage, M. J., Whittaker, C. A., Hoersch, S., Yoon, S., Crowley, D., Bronson, R. T., Chiang, D. Y., Meyerson, M., Jacks, T.
|
|
<strong>Suppression of lung adenocarcinoma progression by Nkx2-1.</strong>
|
|
Nature 473: 101-104, 2011.
|
|
|
|
|
|
[PubMed: 21471965]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/nature09881]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Wu, A. H., Fontham, E. T. H., Reynolds, P., Greenberg, R. S., Buffler, P., Liff, J., Boyd, P., Correa, P.
|
|
<strong>Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States.</strong>
|
|
Am. J. Epidemiol. 143: 535-542, 1996.
|
|
|
|
|
|
[PubMed: 8610670]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1093/oxfordjournals.aje.a008783]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., Gold, K. A., Kalhor, N., and 15 others.
|
|
<strong>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.</strong>
|
|
Science 346: 256-259, 2014.
|
|
|
|
|
|
[PubMed: 25301631]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1126/science.1256930]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y., Lin, D.
|
|
<strong>Functional polymorphisms in cell death pathway genes FAS and FASL contribute to the risk of lung cancer.</strong>
|
|
J. Med. Genet. 42: 479-484, 2005.
|
|
|
|
|
|
[PubMed: 15937082]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1136/jmg.2004.030106]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
<li>
|
|
<p class="mim-text-font">
|
|
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., Choi, Y. J., Choi, C.-M., and 18 others.
|
|
<strong>Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.</strong>
|
|
Nature Genet. 44: 852-860, 2012.
|
|
|
|
|
|
[PubMed: 22751098]
|
|
|
|
|
|
[Full Text: https://doi.org/10.1038/ng.2330]
|
|
|
|
|
|
</p>
|
|
</li>
|
|
|
|
</ol>
|
|
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div class="row">
|
|
<div class="col-lg-1 col-md-1 col-sm-2 col-xs-2">
|
|
<span class="text-nowrap mim-text-font">
|
|
Contributors:
|
|
</span>
|
|
</div>
|
|
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
Ada Hamosh - updated : 11/17/2014<br>Ada Hamosh - updated : 9/19/2014<br>Ada Hamosh - updated : 10/15/2013<br>Ada Hamosh - updated : 2/26/2013<br>Ada Hamosh - updated : 10/9/2012<br>Cassandra L. Kniffin - updated : 6/19/2012<br>Ada Hamosh - updated : 7/8/2011<br>Ada Hamosh - updated : 5/9/2011<br>Ada Hamosh - updated : 9/21/2010<br>Cassandra L. Kniffin - updated : 5/14/2010<br>Ada Hamosh - updated : 2/16/2010<br>Cassandra L. Kniffin - updated : 9/3/2009<br>Marla J. F. O'Neill - updated : 2/19/2009<br>Ada Hamosh - updated : 11/26/2008<br>Matthew B. Gross - reorganized : 10/2/2008<br>Matthew B. Gross - updated : 10/2/2008<br>Cassandra L. Kniffin - updated : 8/20/2008<br>Ada Hamosh - updated : 7/29/2008<br>Ada Hamosh - updated : 5/21/2008<br>Ada Hamosh - updated : 4/16/2008<br>Marla J. F. O'Neill - updated : 3/24/2008<br>Cassandra L. Kniffin - updated : 3/20/2008<br>Ada Hamosh - updated : 8/13/2007<br>Ada Hamosh - updated : 6/14/2007<br>Victor A. McKusick - updated : 2/9/2006<br>Marla J. F. O'Neill - updated : 7/21/2005<br>Marla J. F. O'Neill - updated : 6/21/2005<br>George E. Tiller - updated : 2/28/2005<br>Victor A. McKusick - updated : 2/7/2005<br>Victor A. McKusick - updated : 9/8/2004<br>Victor A. McKusick - updated : 7/15/2004<br>Victor A. McKusick - updated : 8/13/2003<br>Victor A. McKusick - updated : 3/3/2003<br>Victor A. McKusick - updated : 12/10/2002<br>Wilson H. Y. Lo - updated : 4/7/2000
|
|
</span>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div class="row">
|
|
<div class="col-lg-1 col-md-1 col-sm-2 col-xs-2">
|
|
<span class="text-nowrap mim-text-font">
|
|
Creation Date:
|
|
</span>
|
|
</div>
|
|
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
Victor A. McKusick : 6/3/1986
|
|
</span>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div>
|
|
<div class="row">
|
|
<div class="col-lg-1 col-md-1 col-sm-2 col-xs-2">
|
|
<span class="text-nowrap mim-text-font">
|
|
Edit History:
|
|
</span>
|
|
</div>
|
|
<div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
|
|
<span class="mim-text-font">
|
|
alopez : 05/16/2019<br>carol : 06/23/2016<br>carol : 3/31/2016<br>carol : 1/29/2015<br>alopez : 11/17/2014<br>mgross : 10/24/2014<br>alopez : 9/19/2014<br>carol : 4/10/2014<br>alopez : 10/15/2013<br>tpirozzi : 9/30/2013<br>tpirozzi : 9/30/2013<br>alopez : 3/4/2013<br>terry : 2/26/2013<br>alopez : 10/24/2012<br>terry : 10/9/2012<br>alopez : 8/8/2012<br>carol : 6/21/2012<br>carol : 6/21/2012<br>ckniffin : 6/19/2012<br>alopez : 9/2/2011<br>alopez : 7/8/2011<br>terry : 7/8/2011<br>carol : 6/17/2011<br>alopez : 5/11/2011<br>terry : 5/9/2011<br>alopez : 9/23/2010<br>terry : 9/21/2010<br>wwang : 5/21/2010<br>ckniffin : 5/14/2010<br>terry : 4/2/2010<br>alopez : 3/2/2010<br>terry : 2/16/2010<br>ckniffin : 1/15/2010<br>carol : 11/23/2009<br>wwang : 9/22/2009<br>ckniffin : 9/3/2009<br>wwang : 6/12/2009<br>terry : 6/3/2009<br>terry : 2/19/2009<br>wwang : 2/12/2009<br>ckniffin : 2/9/2009<br>alopez : 12/5/2008<br>terry : 11/26/2008<br>mgross : 10/3/2008<br>mgross : 10/2/2008<br>mgross : 10/2/2008<br>mgross : 10/2/2008<br>wwang : 8/26/2008<br>ckniffin : 8/20/2008<br>alopez : 8/19/2008<br>terry : 7/29/2008<br>alopez : 5/21/2008<br>alopez : 5/16/2008<br>terry : 4/16/2008<br>terry : 4/16/2008<br>wwang : 3/25/2008<br>terry : 3/24/2008<br>wwang : 3/20/2008<br>alopez : 1/24/2008<br>ckniffin : 1/16/2008<br>carol : 8/14/2007<br>terry : 8/13/2007<br>alopez : 7/31/2007<br>alopez : 6/28/2007<br>terry : 6/14/2007<br>alopez : 6/6/2007<br>alopez : 10/25/2006<br>alopez : 2/14/2006<br>terry : 2/9/2006<br>wwang : 7/25/2005<br>terry : 7/21/2005<br>wwang : 6/29/2005<br>terry : 6/21/2005<br>wwang : 2/28/2005<br>carol : 2/28/2005<br>wwang : 2/7/2005<br>alopez : 9/21/2004<br>terry : 9/8/2004<br>tkritzer : 7/15/2004<br>tkritzer : 7/15/2004<br>tkritzer : 8/19/2003<br>terry : 8/13/2003<br>carol : 3/11/2003<br>tkritzer : 3/10/2003<br>terry : 3/3/2003<br>alopez : 1/2/2003<br>alopez : 12/11/2002<br>terry : 12/10/2002<br>terry : 3/5/2002<br>carol : 1/3/2002<br>carol : 9/18/2001<br>carol : 7/6/2000<br>terry : 4/7/2000<br>mgross : 2/2/2000<br>mark : 12/9/1996<br>mark : 4/30/1996<br>carol : 12/30/1994<br>terry : 12/22/1994<br>mimadm : 2/19/1994<br>supermim : 3/16/1992<br>carol : 2/11/1992<br>supermim : 3/20/1990
|
|
</span>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div>
|
|
<br />
|
|
</div>
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
</div>
|
|
|
|
</div>
|
|
|
|
|
|
</div>
|
|
|
|
|
|
<div id="mimFooter">
|
|
|
|
|
|
<div class="container ">
|
|
<div class="row">
|
|
<br />
|
|
<br />
|
|
</div>
|
|
</div>
|
|
|
|
|
|
<div class="hidden-print mim-footer">
|
|
<div class="container">
|
|
<div class="row">
|
|
<p />
|
|
</div>
|
|
<div class="row text-center small">
|
|
NOTE: OMIM is intended for use primarily by physicians and other professionals concerned with genetic disorders, by genetics researchers,
|
|
and by advanced students in science and medicine. While the OMIM database is open to the public, users seeking information about a personal
|
|
medical or genetic condition are urged to consult with a qualified physician for diagnosis and for answers to personal questions.
|
|
<br />
|
|
OMIM<sup>®</sup> and Online Mendelian Inheritance in Man<sup>®</sup> are registered trademarks of the Johns Hopkins University.
|
|
<br />
|
|
Copyright<sup>®</sup> 1966-2025 Johns Hopkins University.
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
<div class="visible-print-block mim-footer" style="position: relative;">
|
|
<div class="container">
|
|
<div class="row">
|
|
<p />
|
|
</div>
|
|
<div class="row text-center small">
|
|
NOTE: OMIM is intended for use primarily by physicians and other professionals concerned with genetic disorders, by genetics researchers,
|
|
and by advanced students in science and medicine. While the OMIM database is open to the public, users seeking information about a personal
|
|
medical or genetic condition are urged to consult with a qualified physician for diagnosis and for answers to personal questions.
|
|
<br />
|
|
OMIM<sup>®</sup> and Online Mendelian Inheritance in Man<sup>®</sup> are registered trademarks of the Johns Hopkins University.
|
|
<br />
|
|
Copyright<sup>®</sup> 1966-2025 Johns Hopkins University.
|
|
<br />
|
|
Printed: March 13, 2025
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<div class="modal fade" id="mimDonationPopupModal" tabindex="-1" role="dialog" aria-labelledby="mimDonationPopupModalTitle">
|
|
<div class="modal-dialog" role="document">
|
|
<div class="modal-content">
|
|
<div class="modal-header">
|
|
<button type="button" id="mimDonationPopupCancel" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button>
|
|
<h4 class="modal-title" id="mimDonationPopupModalTitle">
|
|
OMIM Donation:
|
|
</h4>
|
|
</div>
|
|
<div class="modal-body">
|
|
<div class="row">
|
|
<div class="col-lg-offset-1 col-md-offset-1 col-sm-offset-1 col-xs-offset-1 col-lg-10 col-md-10 col-sm-10 col-xs-10">
|
|
<p>
|
|
Dear OMIM User,
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-offset-1 col-md-offset-1 col-sm-offset-1 col-xs-offset-1 col-lg-10 col-md-10 col-sm-10 col-xs-10">
|
|
<p>
|
|
To ensure long-term funding for the OMIM project, we have diversified
|
|
our revenue stream. We are determined to keep this website freely
|
|
accessible. Unfortunately, it is not free to produce. Expert curators
|
|
review the literature and organize it to facilitate your work. Over 90%
|
|
of the OMIM's operating expenses go to salary support for MD and PhD
|
|
science writers and biocurators. Please join your colleagues by making a
|
|
donation now and again in the future. Donations are an important
|
|
component of our efforts to ensure long-term funding to provide you the
|
|
information that you need at your fingertips.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-offset-1 col-md-offset-1 col-sm-offset-1 col-xs-offset-1 col-lg-10 col-md-10 col-sm-10 col-xs-10">
|
|
<p>
|
|
Thank you in advance for your generous support, <br />
|
|
Ada Hamosh, MD, MPH <br />
|
|
Scientific Director, OMIM <br />
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<div class="modal-footer">
|
|
<button type="button" id="mimDonationPopupDonate" class="btn btn-success btn-block" data-dismiss="modal"> Donate To OMIM! </button>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
|
|
</div>
|
|
</body>
|
|
|
|
</html>
|
|
|
|
|